Financial Review
26 Ten-Year Selected Financial Data
28 Consolidated Balance Sheets
29 Consolidated Statements of Operations
30 Consolidated Statements of Changes in Stockholders' Equity
31 Consolidated Statements of Cash Flows
32 Notes to Consolidated Financial Statements
56 Report of Independent Auditors
57 Management Report on Consolidated Financial Statements
58 Quarterly Financial Data (Unaudited)
58 Market Prices of Common Stock and Dividends
59 Management's Discussion and Analysis of Financial Condition and Results of
Operations
Ten-Year Selected Financial Data
(Dollar amounts in thousands except per share amounts)
Year Ended December 31, 2003 2002 2001 2000 1999
- ----------------------- ------------ ------------ ------------ ------------- -------------
Summary of Net Revenue and Earnings
Net revenue(1) $ 15,850,632 $ 14,584,035 $ 13,983,745 $ 13,081,334 $ 11,695,061
Income (loss) from continuing operations(1)(2)(3) 2,051,192 4,447,205 2,285,294 (901,040) (1,207,243)
Diluted earnings (loss) per share from
continuing operations(1)(2) 1.54 3.33 1.72 (0.69) (0.92)
Dividends per common share 0.9200 0.9200 0.9200 0.9200 0.9050
Year-End Financial Position
Current assets(1)(3) $ 14,962,242 $ 11,605,699 $ 9,766,753 $ 10,180,811 $ 12,384,778
Current liabilities(1)(3) 8,429,510 5,485,506 7,257,181 9,742,059 6,480,383
Ratio of current assets to current
liabilities(1)(3) 1.77 2.12 1.35 1.05 1.91
Total assets(1)(3) 31,031,922 26,042,592 22,967,922 21,092,466 23,123,756
Long-term debt(1)(4) 8,076,429 7,546,041 7,357,277 2,394,790 3,606,423
Average stockholders' equity 8,725,147 6,114,243 3,445,333 4,516,420 7,914,772
Stockholders -- Outstanding Shares
Number of common stockholders 59,181 61,668 64,698 58,355 62,482
Weighted average common shares
outstanding used for diluted earnings (loss)
per share calculation (in thousands) 1,335,910 1,334,127 1,330,809 1,306,474 1,308,876
Employment Data(1)
Number of employees at year-end 52,385 52,762 52,289 48,036 46,815
Wages and salaries $ 3,003,555 $ 2,792,379 $ 2,536,220 $ 2,264,258 $ 2,032,431
Benefits (including Social Security taxes) 933,448 842,177 691,018 602,816 593,222
</Table>
(1) As a result of the sale of the Cyanamid Agricultural Products business on
June 30, 2000, amounts for the years 1994 through 1999 were restated to
reflect this business as a discontinued operation with the net assets of
the discontinued business held for sale related to the Cyanamid
Agricultural Products business included in current assets.
(2) See "Management's Discussion and Analysis of Financial Condition and
Results of Operations" for discussion of the gains related to Immunex/Amgen
common stock transactions, diet drug litigation charges and special charges
for the years ended December 31, 2003, 2002 and 2001.
(3) As a result of charges of $2,000,000, $1,400,000, $950,000, $7,500,000 and
$4,750,000 in 2003, 2002, 2001, 2000 and 1999, respectively, related to the
litigation brought against the Company regarding the use of the diet drugs
Redux or Pondimin, current liabilities increased substantially beginning in
1999 compared with prior years and unfavorably impacted the ratio of
current assets to current liabilities in years subsequent to 1998.
In 2002, the Company sold 67,050,400 shares of Amgen Inc. (Amgen) common
stock received in connection with Amgen's acquisition of Immunex
Corporation (Immunex) for net proceeds of $3,250,753. The Company used a
portion of these proceeds to pay down commercial paper and substantially
reduce current liabilities. Additionally, the remaining 31,235,958 shares
of Amgen common stock owned by the Company as of December 31, 2002 had a
fair value of $1,509,947. The fair value of these shares as well as the
proceeds from the shares sold in 2002 substantially increased total assets.
In 2003, the Company completed the sales of the remaining 31,235,958 shares
of its Amgen common stock holdings for net proceeds of $1,579,917.
(4) In 2001, the Company issued $3,000,000 of Senior Notes. In 2003, the
Company issued $4,800,000 of Senior Notes and $1,020,000 of Convertible
Senior Debentures. A portion of the proceeds from the 2003 borrowings was
used to repurchase approximately $1,700,000 in previously issued Senior
Notes.
(5) The 1994 information reflects the acquisition of American Cyanamid Company
for the one-month period ended December 31, 1994.
26 Wyeth
<Table>
1998 1997 1996 1995 1994(5)
- ---------- ------------ ------------ ------------ ------------
$ 11,101,100 $ 11,916,623 $ 11,928,290 $ 11,274,927 $ 8,597,560
2,152,344 1,747,638 1,651,617 1,472,525 1,525,517
1.61 1.33 1.28 1.18 1.24
0.8700 0.8300 0.7825 0.7550 0.7350
$ 10,698,188 $ 10,025,512 $ 10,310,256 $ 11,084,841 $ 11,321,682
3,478,119 3,476,322 3,584,256 3,929,940 4,291,452
3.08 2.88 2.88 2.82 2.64
20,224,231 19,851,517 19,924,666 20,721,093 21,328,267
3,839,402 5,007,610 6,010,297 7,806,717 9,972,444
8,895,024 7,568,672 6,252,545 4,898,550 4,065,295
65,124 64,313 67,545 68,763 71,223
1,336,641 1,312,975 1,287,790 1,250,902 1,234,100
47,446 54,921 54,194 58,957 70,300
$ 2,175,517 $ 2,428,518 $ 2,439,604 $ 2,512,418 $ 1,811,402
577,930 619,528 614,179 641,169 439,572
Wyeth 27
Consolidated Balance Sheets
(In thousands except share and per share amounts)
December 31, 2003 2002
- -------------------------------------------------------------------------------------------------------------------
Assets
Cash and cash equivalents $ 6,069,794 $ 2,943,604
Marketable securities 1,110,297 1,003,275
Amgen investment -- 1,509,947
Accounts receivable less allowances (2003 - $149,795 and 2002 - $132,342) 2,529,613 2,379,819
Inventories 2,412,184 1,992,724
Other current assets including deferred taxes 2,840,354 1,776,330
- -------------------------------------------------------------------------------------------------------------------
Total Current Assets 14,962,242 11,605,699
Property, plant and equipment:
Land 182,849 173,743
Buildings 4,130,838 3,401,490
Machinery and equipment 4,184,292 3,782,533
Construction in progress 3,188,273 2,477,219
- -------------------------------------------------------------------------------------------------------------------
11,686,252 9,834,985
Less accumulated depreciation 3,025,201 2,599,293
- -------------------------------------------------------------------------------------------------------------------
8,661,051 7,235,692
Goodwill 3,817,993 3,745,749
Other intangibles, net of accumulated amortization
(2003 - $128,137 and 2002 - $95,223) 133,134 145,915
Other assets including deferred taxes 3,457,502 3,309,537
- -------------------------------------------------------------------------------------------------------------------
Total Assets $ 31,031,922 $ 26,042,592
===================================================================================================================
Liabilities
Loans payable $ 1,512,845 $ 804,894
Trade accounts payable 1,010,749 672,633
Accrued expenses 5,461,835 3,798,500
Accrued federal and foreign taxes 444,081 209,479
- -------------------------------------------------------------------------------------------------------------------
Total Current Liabilities 8,429,510 5,485,506
Long-term debt 8,076,429 7,546,041
Accrued postretirement benefit obligations other than pensions 1,007,540 965,081
Other noncurrent liabilities 4,224,062 3,890,052
Contingencies and commitments (Note 14)
- -------------------------------------------------------------------------------------------------------------------
Stockholders' Equity
$2.00 convertible preferred stock, par value $2.50 per share; 5,000,000
shares authorized 42 46
Common stock, par value $0.331/3 per share; 2,400,000,000 shares authorized
(1,332,451,733 and 1,326,055,415 issued and outstanding, net of 89,930,211 and
96,276,705 treasury shares at par, for 2003 and 2002, respectively) 444,151 442,019
Additional paid-in capital 4,764,390 4,582,773
Retained earnings 4,112,285 3,286,645
Accumulated other comprehensive loss (26,487) (155,571)
- -------------------------------------------------------------------------------------------------------------------
Total Stockholders' Equity 9,294,381 8,155,912
- -------------------------------------------------------------------------------------------------------------------
Total Liabilities and Stockholders' Equity $ 31,031,922 $ 26,042,592
===================================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
28 Wyeth
Consolidated Statements of Operations
(In thousands except per share amounts)
Year Ended December 31, 2003 2002 2001
- ----------------------------------------------------------------------------------------------------------
Net Revenue $ 15,850,632 $ 14,584,035 $ 13,983,745
- ----------------------------------------------------------------------------------------------------------
Cost of goods sold 4,377,086 3,918,387 3,388,776
Selling, general and administrative expenses 5,468,174 5,010,507 5,034,516
Research and development expenses 2,093,533 2,080,191 1,869,679
Interest expense, net 103,140 202,052 146,358
Other income, net (332,264) (382,931) (274,331)
Gains related to Immunex/Amgen common stock transactions (860,554) (4,082,216) --
Diet drug litigation charges 2,000,000 1,400,000 950,000
Special charges 639,905 340,800 --
- ----------------------------------------------------------------------------------------------------------
Income before federal and foreign taxes 2,361,612 6,097,245 2,868,747
Provision for federal and foreign taxes 310,420 1,650,040 583,453
- ----------------------------------------------------------------------------------------------------------
Net Income $ 2,051,192 $ 4,447,205 $ 2,285,294
==========================================================================================================
Basic Earnings per Share $ 1.54 $ 3.35 $ 1.74
==========================================================================================================
Diluted Earnings per Share $ 1.54 $ 3.33 $ 1.72
==========================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
Wyeth 29
Consolidated Statements of Changes in Stockholders' Equity
(In thousands except per share amounts)
$2.00 Retained Accumulated
Convertible Additional Earnings Other Total
Preferred Common Paid-in (Accumulated Comprehensive Stockholders'
Stock Stock Capital Deficit) Loss Equity
- -------------------------------------------------------------------------------------------------------------------------------
Balance at January 1, 2001 $ 55 $437,258 $3,952,457 $ (899,118) $ (672,559) $ 2,818,093
- --------------------------------------------------------------------------------------------------------------------------------
Net income 2,285,294 2,285,294
Currency translation adjustments (166,200) (166,200)
Unrealized gains on derivative contracts, net 7,865 7,865
Unrealized losses on marketable securities, net (2,134) (2,134)
---------
Comprehensive income, net of tax 2,124,825
Cash dividends declared: ---------
Preferred stock (per share: $2.00) (42) (42)
Common stock (per share: $0.92) (1,211,012) (1,211,012)
Common stock issued for stock options 2,774 221,857 224,631
Other exchanges (4) 158 120,737 (4,813) 116,078
- --------------------------------------------------------------------------------------------------------------------------------
Balance at December 31, 2001 51 440,190 4,295,051 170,309 (833,028) 4,072,573
================================================================================================================================
Net income 4,447,205 4,447,205
Currency translation adjustments 226,797 226,797
Unrealized losses on derivative contracts, net (22,132) (22,132)
Unrealized gains on marketable securities, net 520,483 520,483
Minimum pension liability adjustments (47,691) (47,691)
---------
Comprehensive income, net of tax 5,124,662
Cash dividends declared: ---------
Preferred stock (per share: $2.00) (38) (38)
Common stock (per share: $0.92) (1,219,135) (1,219,135)
Common stock acquired for treasury (667) (5,472) (107,788) (113,927)
Common stock issued for stock options 2,349 213,021 215,370
Other exchanges (5) 147 80,173 (3,908) 76,407
- --------------------------------------------------------------------------------------------------------------------------------
Balance at December 31, 2002 46 442,019 4,582,773 3,286,645 (155,571) 8,155,912
================================================================================================================================
Net income 2,051,192 2,051,192
Currency translation adjustments 691,362 691,362
Unrealized losses on derivative contracts, net (32,887) (32,887)
Unrealized gains on marketable securities, net 7,780 7,780
Realized gain on sales of Amgen stock
reclassified to net income (515,114) (515,114)
Minimum pension liability adjustments (22,057) (22,057)
---------
Comprehensive income, net of tax 2,180,276
Cash dividends declared: ---------
Preferred stock (per share: $2.00) (35) (35)
Common stock (per share: $0.92) (1,223,123) (1,223,123)
Common stock issued for stock options 2,058 124,837 126,895
Other exchanges (4) 74 56,780 (2,394) 54,456
- --------------------------------------------------------------------------------------------------------------------------------
Balance at December 31, 2003 $ 42 $444,151 $4,764,390 $ 4,112,285 $ (26,487) $ 9,294,381
================================================================================================================================
The accompanying notes are an integral part of these consolidated financial
statements.
30 Wyeth
Consolidated Statements of Cash Flows
(In thousands)
Year Ended December 31, 2003 2002 2001
- --------------------------------------------------------------------------------------------------------
Operating Activities
Net income $ 2,051,192 $ 4,447,205 $ 2,285,294
Adjustments to reconcile net income to net cash provided
by/(used for) operating activities:
Diet drug litigation charges 2,000,000 1,400,000 950,000
Gains related to Immunex/Amgen common stock transactions (860,554) (4,082,216) --
Special charges 639,905 340,800 --
Net gains on sales of assets (343,064) (329,364) (249,399)
Depreciation 505,702 461,554 426,590
Amortization 32,181 23,146 181,139
Change in deferred income taxes (433,994) 1,109,535 267,820
Diet drug litigation payments (434,167) (1,307,013) (7,257,882)
Security fund deposits (535,215) (405,000) --
Contributions to defined benefit pension plans (230,787) (909,602) (429,710)
Changes in working capital, net:
Accounts receivable 69,628 271,988 (68,984)
Inventories (245,453) (185,611) (273,063)
Other current assets 48,870 (124,738) (395,764)
Trade accounts payable and accrued expenses 469,661 (250,887) 277,009
Accrued federal and foreign taxes 115,990 (33,214) (14,654)
Other items, net 61,208 (240,853) (145,231)
- --------------------------------------------------------------------------------------------------------
Net Cash Provided by/(Used for) Operating Activities 2,911,103 185,730 (4,446,835)
========================================================================================================
- --------------------------------------------------------------------------------------------------------
Investing Activities
Purchases of property, plant and equipment (1,908,661) (1,931,879) (1,924,265)
Proceeds from Amgen acquisition of Immunex -- 1,005,201 --
Proceeds from sales of Amgen common stock 1,579,917 3,250,753 --
Proceeds from sales of assets 402,692 798,274 408,230
Purchases of marketable securities (1,272,995) (2,235,872) (2,703,252)
Proceeds from sales and maturities of marketable securities 1,217,114 2,532,538 1,762,295
- --------------------------------------------------------------------------------------------------------
Net Cash Provided by/(Used for) Investing Activities 18,067 3,419,015 (2,456,992)
========================================================================================================
- --------------------------------------------------------------------------------------------------------
Financing Activities
Proceeds from (repayments of) commercial paper, net (3,787,145) (1,030,060) 4,019,176
Proceeds from issuance of long-term debt 5,820,000 -- 3,000,000
Repayments of long-term debt (691,087) (250,000) --
Other borrowing transactions, net (76,522) (13,797) (12,020)
Dividends paid (1,223,158) (1,219,173) (1,211,054)
Purchases of common stock for treasury -- (113,927) --
Exercises of stock options 126,895 215,370 224,631
- --------------------------------------------------------------------------------------------------------
Net Cash Provided by/(Used for) Financing Activities 168,983 (2,411,587) 6,020,733
- --------------------------------------------------------------------------------------------------------
Effect of exchange rate changes on cash and cash equivalents 28,037 5,712 (16,478)
- --------------------------------------------------------------------------------------------------------
Increase (Decrease) in Cash and Cash Equivalents 3,126,190 1,198,870 (899,572)
Cash and Cash Equivalents, Beginning of Year 2,943,604 1,744,734 2,644,306
- --------------------------------------------------------------------------------------------------------
Cash and Cash Equivalents, End of Year $ 6,069,794 $ 2,943,604 $ 1,744,734
========================================================================================================
</Table>
The accompanying notes are an integral part of these consolidated financial
statements.
Wyeth 31
Notes to Consolidated Financial Statements
1. Summary of Significant Accounting Policies
Basis of Presentation: The accompanying consolidated financial statements
include the accounts of Wyeth and subsidiaries (the Company). All per share
amounts, unless otherwise noted in the footnotes and quarterly financial data,
are presented on a diluted basis; that is, based on the weighted average number
of outstanding common shares and the effect of all potentially dilutive common
shares (primarily unexercised stock options).
Use of Estimates: The financial statements have been prepared in
accordance with accounting principles generally accepted in the United States,
which require the use of judgments and estimates made by management. Actual
results may differ from those estimates.
Description of Business: The Company is a U.S.-based multi-national
corporation engaged in the discovery, development, manufacture, distribution and
sale of a diversified line of products in three primary businesses: Wyeth
Pharmaceuticals (Pharmaceuticals), Wyeth Consumer Healthcare (Consumer
Healthcare) and Fort Dodge Animal Health (Animal Health). Pharmaceuticals
include branded human ethical pharmaceuticals, biologicals and nutritionals.
Principal products include neuroscience therapies, cardiovascular products,
nutritionals, gastroenterology drugs, anti-infectives, vaccines, oncology
therapies, musculoskeletal therapies, hemophilia treatments, immunological
products and women's health care products. Consumer Healthcare products include
analgesics, cough/cold/allergy remedies, nutritional supplements, and
hemorrhoidal, asthma and other relief items sold over-the-counter. Principal
Animal Health products include vaccines, pharmaceuticals, parasite control and
growth implants. The Company sells its diversified line of products to
wholesalers, pharmacies, hospitals, physicians, retailers and other health care
institutions located in various markets in more than 140 countries throughout
the world.
Wholesale distributors and large retail establishments account for a
large portion of the Company's consolidated net revenue and trade receivables,
especially in the United States. The Company's top three customers accounted for
approximately 23% and 25% of the Company's consolidated net revenue in 2003 and
2002, respectively. The Company's largest customer accounted for 10% of
consolidated net revenue in 2003 and 2002. The Company continuously monitors the
creditworthiness of its customers and has established internal policies
regarding customer credit limits.
The Company is not dependent on any one product or line of products for
a substantial portion of its net revenue or results of operations other than
Effexor, Protonix and the Premarin family products, each of which had sales in
excess of $1,000.0 million, and comprised approximately 17%, 9% and 8%,
respectively, of the Company's consolidated net revenue in 2003.
Equity Method of Accounting: The Company accounts for investments in
20%- to 50%-owned companies using the equity method. Accordingly, the Company's
share of the earnings of these companies is included in Other income, net. The
related equity method investment is included in Other assets including deferred
taxes. In 2001, Immunex Corporation (Immunex) was the Company's only material
equity method investment. During 2002, Amgen Inc. (Amgen) completed its
acquisition of Immunex. As a result, the Company's investment in Immunex, which
was previously accounted for on the equity method, was exchanged for an
investment in Amgen and was accounted for on the cost method subsequent to July
15, 2002. The Company liquidated all of its Amgen common stock holdings by the
end of the 2003 first quarter. As of December 31, 2003, the Company no longer
holds an investment in Amgen. See Note 2 for further description of
Immunex/Amgen-related common stock transactions. At December 31, 2003 and 2002,
the Company did not have any material equity method investments.
Cash Equivalents consist primarily of commercial paper, fixed-term
deposits and other short-term, highly liquid securities with maturities of three
months or less when purchased and are stated at cost. The carrying value of cash
equivalents approximates fair value due to their short-term, highly liquid
nature.
Marketable Securities: The Company has marketable debt and equity
securities, which are classified as either available-for-sale or
held-to-maturity, depending on management's investment intentions relating to
these securities. Available-for-sale securities are marked-to-market based on
quoted market values of the securities, with the unrealized gains and losses,
net of tax, reported as a component of Accumulated other comprehensive loss.
Realized gains and losses on sales of available-for-sale securities are computed
based upon initial cost adjusted for any other-than-temporary declines in fair
value. Investments categorized as held-to-maturity are carried at amortized cost
because the Company has both the intent and ability to hold these investments
until they mature. Impairment losses are charged to income for
other-than-temporary declines in fair value. Premiums and discounts are
amortized or accreted into earnings over the life of the related
available-for-sale or held-to-maturity security. Dividend and interest income is
recognized when earned. The Company owns no investments that are considered to
be trading securities.
Inventories are valued at the lower of cost or market. Inventories
valued under the last-in, first-out (LIFO) method amounted to $429.5 million and
$360.3 million at December 31, 2003 and 2002, respectively. The current value
exceeded the LIFO value by $74.0 million and $90.0 million at December 31, 2003
and 2002, respectively. The remaining inventories are valued primarily under the
first-in, first-out (FIFO) method.
32 Wyeth
Inventories at December 31 consisted of:
(In thousands) 2003 2002
- -------------- ---------- ----------
Finished goods $ 821,637 $ 736,360
Work in progress 1,141,916 808,711
Materials and supplies 448,631 447,653
---------- ----------
$2,412,184 $1,992,724
========== ==========
Property, Plant and Equipment is carried at cost. Depreciation is
provided over the estimated useful lives of the related assets, principally on
the straight-line method, as follows:
Buildings 10 - 50 years
Machinery and equipment 3 - 20 years
Long-lived assets are reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount may not be
recoverable based on projected undiscounted cash flows associated with the
affected assets. A loss is recognized for the difference between the fair value
and carrying amount of the asset. Fair value is determined based on market
quotes, if available, or other valuation techniques.
Goodwill and Other Intangibles: Goodwill is defined as the excess of
cost over the fair value of net assets acquired. On January 1, 2002, the Company
adopted Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and
Other Intangible Assets. With the adoption of SFAS No. 142, goodwill and other
intangibles with indefinite lives no longer are amortized but are subject to at
least an annual assessment for impairment by applying a fair value-based test.
Other intangibles with finite lives continue to be amortized. See Note 5 for
further detail relating to the Company's goodwill and other intangibles
balances.
Derivative Financial Instruments: The Company currently manages its
exposure to certain market risks, including foreign exchange and interest rate
risks, through the use of derivative financial instruments and accounts for them
in accordance with SFAS Nos. 133, Accounting for Derivative Instruments and
Hedging Activities, 138, Accounting for Certain Derivative Instruments and
Certain Hedging Activities and 149, Amendment of Statement 133 on Derivative
Instruments and Hedging Activities.
On the date that the Company enters into a derivative contract, it
designates the derivative as: (1) a hedge of the fair value of a recognized
asset or liability (fair value hedge), (2) a hedge of a forecasted transaction
or the variability of cash flows that are to be received or paid in connection
with a recognized asset or liability (cash flow hedge), (3) a foreign currency
fair value or cash flow hedge (foreign currency hedge) or (4) a derivative
instrument that is not designated for hedge accounting treatment. For certain
derivative contracts that are designated and qualify as fair value hedges
(including foreign currency fair value hedges), the derivative instrument is
marked-to-market with gains and losses recognized in current period earnings to
offset the respective losses and gains recognized on the underlying exposure.
For derivative contracts that are designated and qualify as cash flow hedges
(including foreign currency cash flow hedges), the effective portion of gains
and losses on these contracts is reported as a component of Accumulated other
comprehensive loss and reclassified into earnings in the same period the hedged
transaction affects earnings. Any hedge ineffectiveness on cash flow hedges is
immediately recognized in earnings. The Company also enters into derivative
contracts that are not designated as hedging instruments. These derivative
contracts are recorded at fair value with the gain or loss recognized in current
period earnings. The cash flows from each of the Company's derivative contracts
are reflected as operating activities in the consolidated statements of cash
flows. The Company does not hold any derivative instruments for trading
purposes. See Note 9 for further description of the Company's specific programs
to manage risk using derivative financial instruments.
Currency Translation: The majority of the Company's international
operations are translated into U.S. dollars using current foreign currency
exchange rates with currency translation adjustments reflected in Accumulated
other comprehensive loss. Currency translation adjustments related to
international operations in highly inflationary economies are included in the
results of operations.
Revenue Recognition: Revenue from the sale of Company products is
recognized in Net revenue upon shipment to customers. Provisions for certain
rebates, chargebacks, product returns and discounts to customers are provided
for as deductions in determining Net revenue.
Revenue under co-promotion agreements from the sale of products
developed by other companies, such as the Company's arrangement with Amgen to
co-promote Enbrel and with King Pharmaceuticals, Inc. to co-promote Altace, is
recorded as alliance revenue, which is included in Net revenue. Such alliance
revenue is earned when the co-promoting company ships the product to a third
party. Additionally, alliance revenue includes revenue earned related to
Rapamune. Its active ingredient, sirolimus, coats the coronary stent made by a
subsidiary of Johnson & Johnson. Selling and marketing expenses related to
alliance revenue are included in Selling, general and administrative expenses.
Alliance revenue totaled $654.4 million, $418.8 million and $322.4 million for
2003, 2002 and 2001, respectively.
Shipping and Handling Costs, which include transportation to customers,
transportation to distribution points, warehousing and handling costs, are
included in Selling, general and administrative expenses. The Company typically
does not charge customers for shipping and handling costs. Shipping and handling
costs were $234.3 million, $227.5 million and $228.9 million in 2003, 2002 and
2001, respectively.
Rebates and Sales Incentives, which are deducted to arrive at Net
revenue, are offered to customers based upon volume purchases, the attainment of
market share levels, government mandates, coupons and consumer discounts. These
costs are recognized at the later of a) the date at which the related revenue is
recorded or b) the date at which the incentives are offered. Rebates and sales
incentives accruals included in Accrued expenses at December 31, 2003 and 2002
were $801.4 million and $722.5 million, respectively.
Stock-Based Compensation: As of December 31, 2003, the Company has
three Stock Incentive Plans, which are described more fully in Note 12. The
Company accounts for those plans using the intrinsic value method in accordance
with Accounting
Wyeth 33
Principles Board Opinion No. 25, Accounting for Stock Issued to
Employees. No stock-based employee compensation cost is reflected in net income,
other than for the Company's restricted stock awards, as options granted under
all other plans had an exercise price equal to the market value of the
underlying common stock on the date of grant. The Company's restricted stock
awards are issued under the Company's Stock Incentive Plans (see Note 12). The
following table illustrates the effect on net income and earnings per share if
the Company had applied the fair value recognition provisions of SFAS No. 123,
Accounting for Stock-Based Compensation, as amended by SFAS No. 148, Accounting
for Stock-Based Compensation - Transition and Disclosure, Amendment of SFAS No.
123, to stock-based employee compensation:
(In thousands except per share amounts)
Year Ended December 31, 2003 2002 2001
- ----------------------- ----------- ----------- -----------
Net income, as reported $2,051,192 $4,447,205 $2,285,294
Add: Stock-based employee
compensation expense
included in reported net
income, net of tax 13,396 3,999 8,009
Deduct: Total stock-based
employee compensation
expense determined under
fair value-based method for
all awards, net of tax (335,082) (301,964) (208,697)
---------- ---------- ----------
Adjusted net income $1,729,506 $4,149,240 $2,084,606
========== ========== ==========
Earnings per share:
Basic - as reported $ 1.54 $ 3.35 $ 1.74
Basic - adjusted $ 1.30 $ 3.13 $ 1.58
========== ========== ==========
Diluted - as reported $ 1.54 $ 3.33 $ 1.72
Diluted - adjusted $ 1.29 $ 3.11 $ 1.57
========== ========== ==========
The fair value of issued stock options is estimated on the date of
grant using the Black-Scholes option-pricing model incorporating the following
assumptions for stock options granted:
Year Ended December 31, 2003 2002 2001
- ----------------------- ------- ------- -------
Expected volatility of stock price 35.6% 33.7% 32.1%
Expected dividend yield 2.2% 1.9% 1.6%
Risk-free interest rate 3.0% 4.1% 4.8%
Expected life of options 5 years 5 years 5 years
The weighted average fair value of stock options granted during 2003,
2002 and 2001 was $11.86, $16.12 and $17.76 per option share, respectively.
Research and Development Expenses are expensed as incurred. Upfront and
milestone payments made to third parties in connection with research and
development collaborations are expensed as incurred up to the point of
regulatory approval. Payments made to third parties subsequent to regulatory
approval are capitalized and amortized over the remaining useful life of the
respective intangible asset. Amounts capitalized for such payments are included
in Other intangibles, net of accumulated amortization.
Earnings per Share: The following table sets forth the computations of
basic earnings per share and diluted earnings per share:
(In thousands except per share amounts)
Year Ended December 31, 2003 2002 2001
- ----------------------- ---------- ---------- ----------
Net income less
preferred dividends $2,051,157 $4,447,167 $2,285,252
Denominator:
Weighted average common
shares outstanding 1,330,276 1,325,577 1,317,102
---------- ---------- ----------
Basic earnings per share $ 1.54 $ 3.35 $ 1.74
========== ========== ==========
Net income $2,051,192 $4,447,205 $2,285,294
Denominator:
Weighted average common
shares outstanding 1,330,276 1,325,577 1,317,102
Common stock equivalents
of outstanding stock
options and deferred
contingent common
stock awards 5,634 8,550 13,707
---------- ---------- ----------
Total shares* 1,335,910 1,334,127 1,330,809
---------- ---------- ----------
Diluted earnings per share* $ 1.54 $ 3.33 $ 1.72
========== ========== ==========
* At December 31, 2003, 2002 and 2001, 106,967,641, 90,360,361 and 18,945,057,
respectively, of common shares related to options outstanding under the
Company's Stock Incentive Plans were excluded from the computation of diluted
earnings per share, as the effect would have been antidilutive.
Recently Issued Accounting Standards: The Financial Accounting
Standards Board (FASB) recently issued SFAS Nos. 149 and 150, revised SFAS No.
132 and FASB Interpretation No. 46, and issued Staff Position No. 106-1, which
are summarized below.
- SFAS No. 149, Amendment of Statement 133 on Derivative Instruments
and Hedging Activities, amends and clarifies the accounting guidance
on derivative instruments, including certain derivative instruments
embedded in other contracts, and hedging activities that fall within
the scope of SFAS No. 133. With certain exceptions, SFAS No. 149 is
effective for contracts entered into or modified after June 30, 2003
and for hedging relationships designated after June 30, 2003. The
adoption of SFAS No. 149 did not have a material impact on the
Company's consolidated financial position or results of operations.
- SFAS No. 150, Accounting for Certain Financial Instruments
with Characteristics of both Liabilities and Equity, establishes
standards for how an issuer classifies and measures certain
financial instruments with characteristics of both liabilities and
equity. Financial instruments within the scope of SFAS No. 150 will
now be required to be classified as liabilities. This Statement also
requires enhanced disclosures regarding alternative methods of
settling the instruments and the capital structure of entities. SFAS
No. 150 is effective for financial instruments entered into or
modified after May 31, 2003 and otherwise is effective at the
beginning of the first interim period beginning after June 15, 2003.
The adoption of SFAS No. 150 had no impact on the Company's
consolidated financial position or results of operations.
34 Wyeth
- SFAS No. 132 (revised 2003), Employers' Disclosures about Pensions
and Other Postretirement Benefits, an amendment of FASB Statement
Nos. 87, 88, and 106, revises employers' disclosures about pension
plans and other postretirement benefit plans but does not change the
measurement or recognition of those plans required by SFAS Nos. 87,
Employers' Accounting for Pensions, 88, Employers' Accounting for
Settlements and Curtailments of Defined Benefit Plans and for
Termination Benefits, and 106, Employers' Accounting for
Postretirement Benefits. This revised Statement retains the
disclosures required by SFAS No. 132 and requires additional
disclosures about the assets, obligations, cash flows and net
periodic benefit cost of defined benefit pension plans and other
defined postretirement plans. Companies are required to segregate
plan assets by category and to provide certain additional
informational disclosures. In addition, this Statement requires
companies to disclose various elements of pension and postretirement
costs in interim financial statements. With certain exceptions, this
Statement is effective for financial statements with fiscal quarters
and years ending after December 15, 2003. The Company has adopted
the effective disclosure requirements prescribed by SFAS No. 132
(revised 2003) as of December 31, 2003 (see Note 8).
- FASB Interpretation No. 46 (revised December 2003), Consolidation of
Variable Interest Entities, an interpretation of ARB No. 51 (FIN
46R), replaces FIN 46, Consolidation of Variable Interest Entities,
an interpretation of ARB No. 51, which had been issued in January
2003. FIN 46R clarifies some of the provisions of FIN 46 relating to
variable interest entities (VIE) and exempts certain entities from
its requirements. FIN 46R addresses consolidation of VIEs which have
one or more of the following characteristics: the equity investment
at risk is not sufficient to permit the entity to finance its
activities without additional subordinated financial support
provided by any parties, the equity investors lack some essential
characteristics of a controlling financial interest and the equity
investors have voting rights that are not proportionate to their
economic interests. Application of FIN 46R is required in financial
statements of companies that have interests in structures that are
commonly referred to as special-purpose entities for periods ending
after December 15, 2003. Application by public entities for all
other types of VIEs is required in financial statements for periods
ending after March 15, 2004; however, early adoption is allowed. The
Company has elected to early adopt the provisions of FIN 46R
effective December 31, 2003. The adoption of this Statement had no
impact on the Company's consolidated financial position or results
of operations.
- FASB Staff Position (FSP) No. 106-1, Accounting and Disclosure
Requirements Related to the Medicare Prescription Drug, Improvement
and Modernization Act of 2003, was issued to permit a sponsor of a
postretirement health care plan that provides prescription drug
benefits to make a one-time election to defer accounting for the
effects of the Medicare Prescription Drug, Improvement and
Modernization Act of 2003 (the Act). The Act introduces a
prescription drug benefit under Medicare Part D as well as a federal
subsidy to sponsors of retiree health care benefit plans that
provide a benefit that is at least actuarially equivalent to
Medicare Part D. The federal subsidy is based on 28% of an
individual beneficiary's annual prescription drug costs between $250
and $5,000 (subject to indexing and the provisions of the Act as to
"allowable retiree costs"). FSP No. 106-1 requires certain
disclosures effective for fiscal years ending after December 7, 2003
regardless of whether a sponsor elects to defer accounting for the
Act. In accordance with FSP No. 106-1, the Company has elected not
to reflect the effects of the Act on its accumulated postretirement
benefit obligation or net periodic postretirement benefit cost in
its 2003 consolidated financial statements or accompanying notes to
consolidated financial statements. The Company acknowledges that
specific authoritative guidance on the accounting for the federal
subsidy portion of the Act is pending and that guidance, when
issued, could require the Company to change certain previously
reported information.
Reclassifications: Certain reclassifications have been made to the
December 31, 2002 and 2001 consolidated financial statements and accompanying
notes to conform with the December 31, 2003 presentation.
2. Divestitures
Immunex/Amgen Transactions
Acquisition of Immunex by Amgen and Related Sales of Amgen Common Stock
During 2002, the Company recorded gains totaling $4,082.2 million ($2,628.1
million after-tax or $1.97 per share) relating to the acquisition of Immunex by
Amgen and the subsequent sales of Amgen common stock.
Prior to July 15, 2002, the Company was the beneficial owner of
223,378,088 shares of Immunex common stock. On July 15, 2002, Amgen completed
its acquisition of Immunex. Under the terms of the acquisition agreement, each
share of Immunex common stock was exchanged for 0.44 shares of Amgen common
stock and $4.50 in cash. Accordingly, the Company received 98,286,358 shares of
Amgen common stock (representing approximately 7.7% of Amgen's outstanding
common stock) and $1,005.2 million in cash in exchange for all of its shares of
Immunex common stock.
The pre-tax gains of $4,082.2 million recorded in 2002 consisted of
$2,627.6 million relating to the initial acquisition of Immunex by Amgen and
$1,454.6 million relating to the subsequent sales of Amgen common stock and were
determined as follows:
1. As of July 15, 2002, the Company had valued its shares of Amgen
common stock at $2,500.1 million based on the quoted market price in
effect as of July 15, 2002 reduced by an overall discount of
approximately 18%. The discount rate was based on valuations
provided by independent valuation consultants. The book value of the
Company's Immunex investment was $867.7 million at July 15, 2002. A
gain of $2,627.6 million ($1,684.7 million after-tax or
Wyeth 35
$1.26 per share) was recorded on the exchange during the 2002 third
quarter and was calculated as follows:
(In thousands)
- --------------
Value received:
Cash $1,005,201
Amgen common stock 2,500,100
----------
3,505,301
Less:
Equity investment in Immunex 867,701
Transaction costs 10,000
----------
877,701
----------
Gain before federal taxes 2,627,600
Provision for federal taxes 942,877
----------
Net gain $1,684,723
==========
2. As of December 31, 2002, the Company sold 67,050,400 shares of Amgen
common stock generating net proceeds of $3,250.8 million. The net
proceeds of $3,250.8 million resulted in a gain of $1,454.6 million
($943.4 million after-tax or $0.71 per share). The gain was
determined by comparing the basis of the shares sold of $1,782.7
million with the net proceeds received reduced by certain related
expenses.
The remaining 31,235,958 shares of Amgen common stock held by the
Company at December 31, 2002 had a fair value of $1,509.9 million, which
included a mark-to-market gain of $515.1 million, net of tax, recorded as a
component of Accumulated other comprehensive loss. The Company completed the
sales of its remaining Amgen shares in January 2003 and netted proceeds of
$1,579.9 million, which resulted in a gain of $860.6 million ($558.7 million
after-tax or $0.42 per share).
The Company and Amgen continue to co-promote Enbrel in the United
States and Canada with the Company having exclusive international rights to
Enbrel. The financial aspects of the existing licensing and marketing rights to
Enbrel remain unchanged.
Sale of Rhode Island Facility
During the first quarter of 2002, the Company completed the sale of a
manufacturing plant located in West Greenwich, Rhode Island to Immunex
(subsequently acquired by Amgen) for $487.8 million. The Company received $189.2
million of these proceeds in 2001 and the remaining $298.6 million during the
2002 first quarter. The Company did not recognize a gain on this transaction
because the facility was sold at net book value. In December 2002, the U.S. Food
and Drug Administration (FDA) approved the Rhode Island facility, which has been
dedicated to expanding the production capacity of Enbrel.
Net Gains on Sales of Assets
As of December 31, 2003, 2002 and 2001, net gains on sales of assets of $343.1
million, $329.4 million and $249.4 million, respectively, were included in Other
income, net. The gains recorded in 2003 included sales of product rights in some
or all territories to Ativan, Isordil, Diamox, Ziac, Zebeta, Aygestin, Anacin
and Sonata. These divestitures resulted in pre-tax gains of approximately $265.8
million. Gains recorded during 2002 primarily resulted from the sale of certain
assets related to the Company's generic human injectables product line to Baxter
Healthcare Corporation for $305.0 million in cash. This transaction resulted in
a pre-tax gain of $172.9 million. The net assets, sales and profits of these
divested assets, individually or in the aggregate, were not material to any
business segment or the Company's consolidated financial position or results of
operations as of December 31, 2003, 2002 and 2001.
3. Special Charges
2003 Special Charges
The Company recorded a special charge of $639.9 million ($466.4 million
after-tax or $0.35 per share) in the 2003 fourth quarter for manufacturing
restructurings, asset impairments and the cost of debt extinguishment.
2003 Restructuring Charge and Related Asset Impairments
In December 2003, the Company recorded a special charge for manufacturing
restructurings and related asset impairments of $487.9 million ($367.6 million
after-tax or $0.28 per share). The Company recorded its 2003 restructuring
charges, including personnel and other costs, in accordance with SFAS No. 146,
Accounting for Costs Associated with Exit or Disposal Activities, and its asset
impairments in accordance with SFAS No. 144, Accounting for the Impairment of
Long-Lived Assets. The Company expects total charges related to its 2003
restructuring program to approximate $493.9 million and plans to record the
majority of the remaining $6.0 million in personnel charges during 2004, in
accordance with SFAS No. 146. The restructuring and related asset impairments
impacted only the Pharmaceuticals segment and were recorded to recognize the
costs of closing certain manufacturing facilities, as well as the elimination of
certain positions at the Company's facilities.
Specifically, the Company has decided to close its pharmaceutical plant
in Singapore and rationalize its network of collection sites for
Premarin-related raw materials as a result of lower volume in the Premarin
family products. In addition, as a result of declining demand for ReFacto, the
Company's treatment for hemophilia A, manufacturing operations at its St. Louis,
Missouri biopharmaceutical facility will be discontinued. The Company also has
recorded fixed and intangible asset impairment charges related to rhBMP-2 and
FluMist as a result of reduced demand projections.
The following table summarizes the total charges for restructuring and
asset impairments discussed above, payments made and the reserve balance at
December 31, 2003:
Payments/ Reserve at
(In thousands) Total Non-cash December 31,
2003 Restructuring Charges Charges 2003
- ------------------ --------- --------- ------------
Personnel costs $ 3,400 $ -- $ 3,400
Asset impairments 419,400 (419,400) --
Contract settlement costs 47,900 (2,700) 45,200
Other closure/exit costs 17,200 -- 17,200
--------- --------- ---------
$ 487,900 $(422,100) $ 65,800
========= ========= =========
36 Wyeth
The personnel costs relate to the termination of approximately 190
employees primarily engaged in manufacturing activities in Singapore. The charge
for asset impairments includes $396.6 million for fixed asset impairments and
$22.8 million for the write-down of certain intangible assets. The asset
impairments were determined by comparing the carrying value of the long-lived
assets to the discounted cash flows that are expected to be generated by these
assets. The fixed assets for the St. Louis and Singapore facilities have been
categorized as held for sale. The contract settlement costs and other
closure/exit costs are a direct result of the restructuring plan and include
settlements of purchase commitments, other obligations with suppliers and other
related exit costs necessary to properly close the facilities. The personnel
costs, contract settlement costs and other closure/exit costs require the outlay
of cash, while the fixed and intangible asset impairments represent non-cash
items. The Company expects the majority of the remaining costs will be expended
in 2004.
Debt Extinguishment Costs
In December 2003, the Company recorded a special charge of $152.0 million ($98.8
million after-tax or $0.07 per share) related to the early extinguishment of
debt in connection with the repurchase of certain Senior Notes. The costs relate
primarily to the excess of prepayment premiums and principal over the carrying
value of the debt retired and the related write-off of debt issuance costs. See
Note 6 for further discussion of debt extinguishment.
2002 Special Charge
2002 Restructuring Charge and Related Asset Impairments
In December 2002, the Company recorded a special charge for restructuring and
related asset impairments of $340.8 million ($233.5 million after-tax or $0.18
per share). The Company recorded its asset impairments in accordance with SFAS
No. 144 and its restructuring charges, including personnel and other costs, in
accordance with Emerging Issues Task Force No. 94-3, Liability Recognition for
Certain Employee Termination Benefits and Other Costs to Exit an Activity
(including Certain Costs Incurred in a Restructuring).
The restructuring charge and related asset impairments were recorded to
recognize the costs of closing certain manufacturing facilities and two research
facilities, as well as the elimination of certain positions at the Company's
facilities. The related asset impairments of $68.7 million were determined by
comparing the carrying value of the long-lived assets to the discounted cash
flows that are expected to be generated by these assets. The fixed assets that
have remained in use have been categorized as held and used. Depreciation was
adjusted to reflect the reduced carrying values of the facilities, which will be
recognized over the closure period.
The closing of the manufacturing and research facilities and reduction
of sales and administrative-related positions covered approximately 3,150
employees worldwide. The reductions in workforce were permanent and affected all
of the Company's reportable segments, including Corporate. Approximately 1,200
of these positions were located at the manufacturing and research facilities
that were identified to be closed. Of the 3,150 positions to be eliminated,
2,230 were located in North America, 370 in Europe, 300 in Latin America and 250
in Asia-Pacific. At December 31, 2003, approximately 95 positions have yet to be
eliminated. During 2003 and 2002, approximately $126.9 million and $30.9
million, respectively, of these personnel costs were paid, leaving an accrual of
$36.8 million at December 31, 2003. The timing of the remaining costs to be paid
has been delayed since, in many instances, the terminated employees elected or
were required to receive their severance payments over an extended period of
time. However, substantially all of the payments are expected to be made during
2004.
Other closure/exit costs are a direct result of the restructuring plan.
The majority of the other closure/exit costs are anticipated to be paid after
the facilities cease production and prior to disposition. These costs include
non-cancelable operating leases, security, utilities, maintenance, property
taxes and other related costs that will be paid during the disposal period. The
Company estimated the cost of exiting and terminating the facility leases based
on the contractual terms of the agreements and real estate market conditions.
During 2003 and 2002, approximately $45.1 million and $4.5 million,
respectively, of these costs were paid, leaving an accrual of $27.9 million at
December 31, 2003. Most of the remaining other closure/exit costs reserve
represents long-term lease payments which will be paid over the remaining lease
terms through 2012, as well as certain facility closure and decommissioning
costs which have been delayed as the Company continued to produce certain
products due to manufacturing commitments and in response to a potential market
shortage and related medical necessity. The Company expects the majority of the
remaining facility costs will be expended in 2004.
The following table summarizes the total charges for restructuring and
asset impairments discussed above, payments made and the reserve balance at
December 31, 2003 and 2002:
Payments/ Reserve at Payments/ Reserve at
(In thousands) Total Non-cash December 31, Non-cash December 31,
2002 Restructuring Charges Charges in 2002 2002 Charges in 2003 2003
- ------------------ --------- --------------- ------------ --------------- ------------
Personnel costs $ 194,600 $ (30,900) $ 163,700 $(126,900) $ 36,800
Asset impairments 68,700 (68,700) -- -- --
Other closure/exit costs 77,500 (4,500) 73,000 (45,100) 27,900
--------- ---------- ---------- --------- ---------
$ 340,800 $ (104,100) $ 236,700 $(172,000) $ 64,700
========= ========== ========== ========= =========
Wyeth 37
4. Marketable Securities
The cost, gross unrealized gains (losses) and fair value of available-for-sale
and held-to-maturity securities by major security type at December 31, 2003 and
2002 were as follows:
Gross Gross
(In thousands) Unrealized Unrealized Fair
At December 31, 2003 Cost Gains (Losses) Value
- -------------------- ---------- ---------- ---------- -----------
Available-for-sale:
U.S. Treasury securities $ 152,851 $ 44 $ (23) $ 152,872
Commercial paper 42,964 4 (4) 42,964
Certificates of deposit 63,643 22 (27) 63,638
Corporate debt securities 212,198 252 (32) 212,418
Other debt securities 4,296 -- (11) 4,285
Equity securities 21,078 13,158 (188) 34,048
Institutional fixed income fund 522,847 16,868 -- 539,715
---------- ---------- --------- -----------
Total available-for-sale 1,019,877 30,348 (285) 1,049,940
---------- ---------- --------- -----------
Held-to-maturity:
Commercial paper 60,107 -- -- 60,107
Certificates of deposit 250 -- -- 250
---------- ---------- --------- -----------
Total held-to-maturity 60,357 -- -- 60,357
---------- ---------- --------- -----------
$1,080,234 $ 30,348 $ (285) $ 1,110,297
========== ========== ========= ===========
Gross Gross
(In thousands) Unrealized Unrealized Fair
At December 31, 2002 Cost Gains (Losses) Value
- -------------------- ---------- ---------- ---------- -----------
Available-for-sale:
U.S. Treasury securities $ 105,583 $ 615 $ (15) $ 106,183
Commercial paper 57,397 -- -- 57,397
Certificates of deposit 29,218 77 -- 29,295
Corporate debt securities 214,127 1,202 (388) 214,941
Other debt securities 9,702 150 -- 9,852
Institutional fixed income fund 510,574 16,312 -- 526,886
---------- ---------- --------- -----------
Total available-for-sale 926,601 18,356 (403) 944,554
---------- ---------- --------- -----------
Held-to-maturity:
Time/term deposits 30,002 -- -- 30,002
U.S. Treasury securities 1,996 -- -- 1,996
Commercial paper 10,473 -- -- 10,473
Certificates of deposit 15,251 -- -- 15,251
Other debt securities 999 -- -- 999
---------- ---------- --------- -----------
Total held-to-maturity 58,721 -- -- 58,721
---------- ---------- --------- -----------
$ 985,322 $ 18,356 $ (403) $ 1,003,275
========== ========== ========= ===========
38 Wyeth
The contractual maturities of debt securities classified as
available-for-sale at December 31, 2003 were as follows:
Fair
(In thousands) Cost Value
- -------------- ---- -----
Available-for-sale:
Due within one year $276,522 $276,578
Due after one year through five years 190,696 190,872
Due after five years through 10 years -- --
Due after 10 years 8,734 8,727
-------- --------
$475,952 $476,177
======== ========
All held-to-maturity debt securities are due within one year and had
aggregate fair values of $60.4 million at December 31, 2003.
5. Goodwill and Other Intangibles
In accordance with SFAS No. 142, goodwill is required to be tested for
impairment at the reporting unit level utilizing a two-step methodology. The
initial step requires the Company to determine the fair value of each reporting
unit and compare it with the carrying value, including goodwill, of such unit.
If the fair value exceeds the carrying value, no impairment loss would be
recognized. However, if the carrying value of this unit exceeds its fair value,
the goodwill of the unit may be impaired. The amount, if any, of the impairment
then would be measured in the second step.
Goodwill in each reporting unit was tested for impairment as of the
beginning of 2002, the fiscal year in which SFAS No. 142 was initially adopted
(transitional impairment test). Thereafter, goodwill must be tested for
impairment at least annually. The Company completed step one of the transitional
impairment test during the second quarter of 2002 and performed its annual
impairment test during the fourth quarter of 2003 and 2002. As a result, the
Company determined there was no impairment of the recorded goodwill for any of
its reporting units as of December 31, 2003 and 2002.
The Company's other intangibles, the majority of which are license
agreements having finite lives, are being amortized over their estimated useful
lives ranging from three to 10 years. As of December 31, 2003, there is one
trade name with a carrying value of approximately $16.9 million, which is deemed
to have an indefinite life because it is expected to generate cash flows
indefinitely.
The following table presents the transitional disclosures for net
income and basic and diluted earnings per share for the years ended December 31,
2003, 2002 and 2001 to reflect the adoption of SFAS No. 142 as of January 1,
2002. Such disclosures add back goodwill amortization to the 2001 results to be
comparable with the 2003 and 2002 results, which do not include goodwill
amortization in accordance with the adoption of SFAS No. 142:
(In thousands except per share amounts)
Year ended December 31, 2003 2002 2001
- ----------------------- ---------- ---------- ----------
Net income, as reported $2,051,192 $4,447,205 $2,285,294
Add back: Goodwill amortization -- -- 153,926
---------- ---------- ----------
Adjusted net income $2,051,192 $4,447,205 $2,439,220
========== ========== ==========
Basic earnings per share:
As reported $ 1.54 $ 3.35 $ 1.74
Add back: Goodwill amortization -- -- 0.12
---------- ---------- ----------
Adjusted $ 1.54 $ 3.35 $ 1.86
========== ========== ==========
Diluted earnings per share:
As reported $ 1.54 $ 3.33 $ 1.72
Add back: Goodwill amortization -- -- 0.12
---------- ---------- ----------
Adjusted $ 1.54 $ 3.33 $ 1.84
========== ========== ==========
The changes in the carrying value of goodwill by reportable segment for
the years ended December 31, 2003 and 2002 were as follows:
Consumer Animal
(In thousands) Pharmaceuticals Healthcare Health Total
- -------------- --------------- ---------- ---------- ------------
Balance at January 1, 2002 $ 2,604,694 $ 589,004 $ 531,849 $ 3,725,547
Goodwill write-off* (10,035) -- -- (10,035)
Currency translation adjustments 28,290 1,342 605 30,237
------------ ---------- ---------- -----------
Balance at December 31, 2002 2,622,949 590,346 532,454 3,745,749
Currency translation adjustments 68,823 2,180 1,241 72,244
------------ ---------- ---------- -----------
Balance at December 31, 2003 $ 2,691,772 $ 592,526 $ 533,695 $ 3,817,993
============ ========== ========== ===========
* Write-off relates primarily to allocation of goodwill to the Company's generic
human injectables product line, which was sold in the 2002 fourth quarter (see
Note 2).
Wyeth 39
6. Debt and Financing Arrangements
The Company's debt at December 31 consisted of:
(In thousands) 2003 2002
- -------------- ---------- ----------
Commercial paper $ -- $3,787,145
Notes payable:
5.875% Notes due 2004 500,000 500,000
7.900% Notes due 2005 308,913 1,000,000
6.250% Notes due 2006* 1,000,000 1,000,000
4.125% Notes due 2008 300,000 --
6.700% Notes due 2011 1,500,000 1,500,000
5.250% Notes due 2013 1,500,000 --
5.500% Notes due 2014 1,750,000 --
7.250% Notes due 2023 250,000 250,000
6.450% Notes due 2024 500,000 --
6.500% Notes due 2034 750,000 --
Floating rate convertible debentures
due 2024 1,020,000 --
Pollution control and industrial
revenue bonds:
1.75% - 5.8% due 2006 - 2018 71,250 74,250
Other debt:
0.74% - 10.25% due 2004 - 2009 32,832 38,760
Fair value of debt attributable to
interest rate swaps 106,279 200,780
---------- ----------
9,589,274 8,350,935
Less current portion 1,512,845 804,894
---------- ----------
$8,076,429 $7,546,041
========== ==========
* At December 31, 2003, these Notes were classified as Loans payable due to the
exercise of a make-whole call option, which was completed in January 2004.
Other debt-related information at December 31 was as follows:
(Dollars in thousands) 2003 2002
- ---------------------- ----------- ----------
Fair value of outstanding debt $10,084,809 $8,471,800
Weighted average interest rate on outstanding
commercial paper -- 1.87%
Weighted average remaining maturity on
outstanding commercial paper -- 25 days
Revolving Credit Facilities
In March 2002, the Company renewed its $3,000.0 million, 364-day credit
facility (which supported borrowings under the commercial paper program) for an
additional 364-day term. The portion of commercial paper outstanding at December
31, 2002 supported by this credit facility was classified as Long-term debt
since the Company intended, and had the ability, to refinance these obligations
through either the issuance of additional commercial paper or the extension of
its credit facility for an additional year upon its termination in March 2003.
In March 2003, the Company replaced its $3,000.0 million, 364-day facility
with credit facilities totaling $2,700.0 million. These credit facilities are
composed of a $1,350.0 million, 364-day facility and a $1,350.0 million,
three-year facility. The credit facilities contain substantially identical
financial and other covenants, representations, warranties, conditions and
default provisions as the March 2002 credit facility. The Company had no
commercial paper outstanding as of December 31, 2003.
The proceeds from the credit facilities may be used to support
commercial paper and the Company's general corporate and working capital
requirements. At December 31, 2003 and 2002, there were no borrowings
outstanding under the facilities.
Notes and Debentures
During the past three years, the Company issued Senior Notes (Notes) and
Convertible Senior Debentures (Debentures) totaling $8,820.0 million. The
transactions were completed as follows:
- $3,000.0 million of Notes and $1,020.0 million of Debentures
issued in December 2003
- $1,800.0 million of Notes issued February 11, 2003
- $3,000.0 million of Notes issued March 30, 2001
December 2003 Issuance
On December 11, 2003, the Company issued $3,000.0 million of Notes through a
registered public offering. These Notes consisted of three tranches, which pay
interest semiannually on February 1 and August 1, as follows:
- $1,750.0 million 5.500% Notes due February 1, 2014
- $500.0 million 6.450% Notes due February 1, 2024
- $750.0 million 6.500% Notes due February 1, 2034
Concurrent with the above-noted issuance of Notes, on December 16,
2003, the Company completed the private placement of $1,020.0 million aggregate
principal amount of Debentures due January 15, 2024 through an offering to
qualified institutional buyers pursuant to Rule 144A under the Securities Act of
1933, as amended (the Securities Act). Interest on the Debentures will accrue at
the rate of six-month London Interbank Offering Rate (LIBOR) minus 0.50% (but in
no event less than 0%) and is payable semiannually on January 15 and July 15.
The Debentures contain a number of conversion features that include
substantive contingencies. The Debentures are convertible by the holders at an
initial conversion rate of 16.559 shares of the Company's common stock for each
$1,000 principal amount of the Debentures, which is equal to an initial
conversion price of $60.39 per share. The holders may convert their Debentures,
in whole or in part, into shares of the Company's common stock under any of the
following circumstances: (1) during any calendar quarter commencing after March
31, 2004 and prior to December 31, 2022 (and only during such calendar quarter)
if the price of the Company's common stock is greater than or equal to 130% of
the applicable conversion price for at least 20 trading days during a
30-consecutive trading day period; (2) at any time after December 31, 2022 and
prior to maturity if the price of the Company's common stock is greater than or
equal to 130% of the applicable conversion price on any day after December 31,
2022; (3) if the Company has called the Debentures for redemption; (4) upon the
occurrence of specified corporate transactions such as a consolidation, merger
or binding share exchange pursuant to which the Company's common stock would be
converted into cash, property or securities; and (5) if the credit rating
assigned to the Debentures by either Moody's or Standard & Poor's (S&P) is lower
than Baa3 or BBB - , respectively, or if the Debentures no longer are rated by
at least one of these agencies or their successors (the Credit Rating Clause).
Since the contingencies surrounding the conversion features of the Debentures
are considered substantive, the shares to be potentially issued upon the
occurrence of a conversion event will be excluded from the earnings per share
calculation
40 Wyeth
until such time as a contingency lapses and the effect of issuing
such shares is dilutive.
Upon conversion, the Company has the right to deliver, in lieu of
shares of its common stock, cash or a combination of cash and shares of its
common stock. The Company may redeem some or all of the Debentures at any time
on or after July 20, 2009 at a purchase price equal to 100% of the principal
amount of the Debentures plus any accrued interest. Upon a call for redemption
by the Company, the holder of each $1,000 Debenture may convert such note to
shares of the Company's common stock. The holders have the right to require the
Company to purchase their Debentures for cash at a purchase price equal to 100%
of the principal amount of the Debentures plus any accrued interest on July 15,
2009, January 15, 2014 and January 15, 2019 or upon a fundamental change as
described in the offering memorandum issued in conjunction with the private
placement of the Debentures.
The Credit Rating Clause described above has been determined to be an
embedded derivative as defined by SFAS No. 133. In accordance with SFAS No. 133,
embedded derivatives are required to be recorded at their fair value. Based upon
an external valuation, the Credit Rating Clause had a zero fair value at
December 31, 2003.
February 11, 2003 Issuance
On February 11, 2003, the Company issued $1,800.0 million of Notes through a
registered public offering. The issuance consisted of two tranches of Notes,
which pay interest semiannually, as follows:
- $300.0 million 4.125% Notes due March 1, 2008 with interest
payments due on March 1 and September 1
- $1,500.0 million 5.25% Notes due March 15, 2013 with interest
payments due on March 15 and September 15
March 30, 2001 Issuance
On March 30, 2001, the Company issued $3,000.0 million of Notes. These Notes
consisted of three tranches, which pay interest semiannually on March 15 and
September 15, in a transaction exempt from registration under the Securities
Act, pursuant to Rule 144A, as follows:
- $500.0 million 5.875% Notes due March 15, 2004
- $1,000.0 million 6.25% Notes due March 15, 2006 (subsequently
repurchased through the exercise of a make-whole call option
discussed below)
- $1,500.0 million 6.70% Notes due March 15, 2011
As of June 15, 2001, pursuant to an exchange offer made by the Company,
substantially all of the Notes had been exchanged for new Notes, which have
almost identical terms and which have been registered under the Securities Act.
Other
In addition to the $7,800.0 million of Notes described above and the $1,020.0
million of Debentures, the Company has outstanding the following non-callable,
unsecured and unsubordinated debt instruments at December 31, 2003:
- $308.9 million 7.90% Notes due February 2005 with interest
payments due on February 15 and August 15 (originally $1,000.0
million in principal issued of which $691.1 million was repurchased
through the December 2003 redemption discussed below)
- $250.0 million 7.25% Notes due March 2023 with interest payments due
on March 1 and September 1
At December 31, 2003, the aggregate maturities of debt during the next
five years and thereafter are as follows:
(In thousands)
- ---------------
2004 $1,512,845
2005 329,088
2006 12,553
2007 453
2008 312,546
Thereafter 7,421,789
----------
Total debt $9,589,274
==========
Interest Rate Swaps
The Company entered into the following interest rate swaps, whereby the Company
effectively converted the fixed rate of interest on its Notes to a floating
rate, which is based on LIBOR. See Note 9 for further discussion of the interest
rate swaps.
Notional Amount
(In thousands)
-------------------
Hedged Notes Payable Swap Rate 2003 2002
- -------------------- --------- -------- --------
$1,750.0 million, 5.500% due 2014 6-month LIBOR in arrears + 0.6110% $750,000 $ --
6-month LIBOR in arrears + 0.6085% 650,000 --
6-month LIBOR in arrears + 0.6085% 350,000 --
1,500.0 million, 6.700% due 2011 3-month LIBOR + 0.8392% 750,000 750,000
3-month LIBOR + 0.8267% 750,000 750,000
1,500.0 million, 5.250% due 2013 6-month LIBOR + 0.8210% 800,000 --
6-month LIBOR + 0.8210% 700,000 --
500.0 million, 6.450% due 2024 6-month LIBOR in arrears + 1.0370% 250,000 --
300.0 million, 4.125% due 2008 6-month LIBOR + 0.6430% 150,000 --
6-month LIBOR + 0.6430% 150,000 --
Wyeth 41
Credit Rating Trigger and Interest Expense Impact
The interest rate payable on each of the tranches of $7,800.0 million of Notes
is subject to a 0.25-percentage-point increase per level of downgrade in the
Company's credit rating by Moody's or S&P. There is no adjustment to the
interest rate payable on these Notes for the first single-level downgrade in the
Company's credit rating by S&P. If Moody's or S&P subsequently were to increase
the Company's credit rating, the interest rate payable on these Notes is subject
to a 0.25-percentage-point decrease for each level of credit rating increase.
The interest rate payable for these Notes cannot be reduced below the original
coupon rate of the Notes, and the interest rate in effect on March 15, 2006 for
these Notes, thereafter, will become the effective interest rate until maturity.
The following table summarizes, by respective Note, the maximum interest rate
adjustment and the additional annual interest expense for every
0.25-percentage-point increase in the interest rate as of December 31, 2003:
Maximum Incremental Annual
Interest Interest Expense per
Rate 0.25% Adjustment
Notes Payable Adjustment (In thousands)
- ------------- ---------- --------------------
$1,750.0 million, 5.500% 1.75% $ 4,375
1,500.0 million, 6.700%* 2.00% 3,750
1,500.0 million, 5.250%* 2.00% 3,750
1,000.0 million, 6.250%* 2.00% 2,500
750.0 million, 6.500% 1.75% 1,875
500.0 million, 6.450% 1.75% 1,250
500.0 million, 5.875%* 2.00% 1,250
300.0 million, 4.125%* 2.00% 750
---------
$ 19,500
=========
* As of December 31, 2003, interest rates on these Notes increased 0.25% due to
Moody's credit rating downgrade discussed below. As a result, the Company will
incur incremental annual interest expense of $9.5 million, which excludes
additional interest expense on the $1,000.0 million, 6.250% Notes due to the
exercise of a make-whole call option completed in January 2004, discussed
herein.
On October 22, 2003, Moody's placed the Company's A3 senior unsecured
credit rating (long-term rating) under review for possible downgrade pending
discussions with the Company; on the same day, Moody's confirmed the Company's
Prime-2 (P-2) short-term rating. In addition, on October 24, 2003, Fitch Ratings
(Fitch) downgraded the Company's senior unsecured credit rating (long-term
rating) to A- from A, its commercial paper credit rating (short-term rating) to
F-2 from F-1 and placed both ratings on "Rating Watch Negative" pending further
discussions with the Company. As a result of the short-term credit rating
downgrade by Fitch, the Company's commercial paper, which previously traded in
the Tier 1 commercial paper market, would trade in the Tier 2 commercial paper
market. Finally, on November 10, 2003, S&P placed the Company's A long-term and
A-1 short-term corporate credit ratings on "CreditWatch" with negative
implications pending discussions with the Company.
Subsequent to meeting with the Company, on December 4, 2003, Moody's
affirmed the Company's P-2 short-term rating and downgraded the Company's
long-term rating to Baa1. In addition, on December 4, 2003, Fitch affirmed the
Company's F-2 short-term and A- long-term ratings. Finally, on December 8, 2003,
S&P affirmed the Company's A-1 short-term and A long-term ratings. As a result
of Moody's long-term credit rating downgrade, the Company will incur incremental
annual interest expense of $9.5 million in 2004 and thereafter on $3,800.0
million of Notes.
Interest Expense, net
The components of Interest expense, net are as follows:
(In thousands)
Year Ended December 31, 2003 2002 2001
- ----------------------- ---------- ---------- ----------
Interest expense $ 298,303 $ 382,168 $ 395,402
Interest income (79,363) (92,108) (154,787)
Less: Amount capitalized for
capital projects (115,800) (88,008) (94,257)
--------- --------- ---------
Interest expense, net $ 103,140 $ 202,052 $ 146,358
========== ========= =========
Interest payments in connection with the Company's debt obligations for
the years ended December 31, 2003, 2002 and 2001 amounted to $299.7 million,
$375.8 million and $331.7 million, respectively.
Debt Extinguishment
In December 2003, the Company completed the redemption of $691.1 million of its
$1,000.0 million aggregate principal amount of 7.90% Notes due 2005, resulting
in $308.9 million in remaining Notes due 2005 outstanding at December 31, 2003,
which were classified as Long-term debt. In addition, the Company exercised a
make-whole call option on its $1,000.0 million aggregate principal amount of
6.25% Notes due 2006. The redemption period for the make-whole call option ended
on January 12, 2004, and as a result, as of December 31, 2003, the $1,000.0
million aggregate principal amount of 6.25% Notes due 2006 were classified as
Loans payable. On January 12, 2004, the $1,000.0 million 6.25% Notes due 2006
were redeemed in full.
In order to fund the Note repurchases, and for other general purposes,
the Company issued $3,000.0 million of Notes and $1,020.0 million of Debentures
in December 2003 as further discussed above. In connection with the Note
repurchases, the Company incurred early debt extinguishment costs of $152.0
million that primarily relate to the excess of prepayment premiums and principal
over the carrying value of the debt retired and the related write-off of debt
issuance costs. The Company recorded its debt extinguishment costs as a
component of results from continuing operations within Special charges on the
consolidated statement of operations for the year ended December 31, 2003. See
Note 3 for further discussion of special charges.
7. Other Noncurrent Liabilities
Other noncurrent liabilities includes reserves for the Redux and Pondimin diet
drug litigation (see Note 14), reserves relating to income taxes, environmental
matters, product liability and other litigation, pension and other employee
benefit liabilities, and minority interests.
The Company has responsibility for environmental, safety and cleanup
obligations under various local, state and federal laws, including the
Comprehensive Environmental Response, Compensation and Liability Act, commonly
known as Superfund. It is the Company's policy to accrue for environmental
cleanup
42 Wyeth
costs if it is probable that a liability has been incurred and the
amount can be reasonably estimated. In many cases, future environmental-related
expenditures cannot be quantified with a reasonable degree of accuracy.
Environmental expenditures that relate to an existing condition caused by past
operations that do not contribute to current or future results of operations are
expensed. As investigations and cleanups proceed, environmental-related
liabilities are reviewed and adjusted as additional information becomes
available. The aggregate environmental-related accruals were $325.8 million and
$379.7 million at December 31, 2003 and 2002, respectively.
Environmental-related accruals have been recorded without giving effect to any
possible future insurance proceeds. See Note 14 for discussion of contingencies.
The Company provides an incentive program to employees, the Performance
Incentive Award Program (PIA), which provides financial awards to employees
based on the Company's operating results and the individual employee's
performance. Substantially all U.S. and Puerto Rico exempt employees, who are
not subject to other incentive programs, and key international employees are
eligible to receive cash awards under PIA. The value of PIA awards for 2003,
2002 and 2001 was $150.7 million, $39.6 million and $117.3 million,
respectively. Through 1998, the Company provided incentive awards under the
Management Incentive Plan (MIP), which provided for cash and deferred contingent
common stock awards to key employees. Deferred contingent common stock awards
plus accrued dividends, related to the MIP program, totaling 651,287 and 798,304
shares were outstanding at December 31, 2003 and 2002, respectively.
8. Pensions and Other Postretirement Benefits
Plan Descriptions
Pensions
The Company sponsors various retirement plans for most full-time employees.
These defined benefit and defined contribution plans cover all U.S. and certain
international locations. Total pension expense for both defined benefit and
defined contribution plans for 2003, 2002 and 2001 was $302.4 million, $208.5
million and $141.9 million, respectively. Pension expense for defined
contribution plans for 2003, 2002 and 2001 totaled $73.4 million, $71.1 million
and $67.0 million, respectively.
Generally, contributions to defined contribution plans are based on a
percentage of the employee's compensation. The Company's 401(k) savings plans
have been established for substantially all U.S. employees. Certain employees
are eligible to enroll in the plan on their hire date and can contribute between
1% and 16% of their base pay. The Company provides a matching contribution to
eligible participants of 50% on the first 6% of base pay contributed to the
plan, or a maximum of 3% of base pay. Employees can direct their contributions
and the Company's matching contributions into any of the funds offered. These
funds provide participants with a cross section of investing options, including
the Company's common stock. All contributions to the Company's common stock,
whether by employee or employer, can be transferred to other fund choices daily.
Pension plan benefits for defined benefit plans are based primarily on
participants' compensation and years of credited service. Pension plan assets to
fund the Company's obligations are invested in accordance with certain asset
allocation criteria and investment guidelines established by the Company. The
Company's U.S. pension plan asset allocation, by broad asset class, was as
follows at December 31, 2003 and 2002, respectively:
Percentage of Plan Assets
as of December 31,
-------------------------
Asset Class 2003 2002
- ----------- ---- ----
U.S. Equity 49% 48%
Non-U.S. Equity 21% 20%
U.S. Fixed Income and Cash 30% 32%
U.S. pension plan (the Plan) assets totaled $3,261.6 million and
$2,916.8 million at December 31, 2003 and 2002, respectively. Investment
responsibility for these assets is assigned to outside investment managers, and
employees do not have the ability to direct these assets. Each of the Plan's
asset classes are broadly diversified by security type, market capitalization
(e.g., exposure to "large cap" and "small cap") and investment style (e.g.,
exposure to "growth" and "value"). Every attempt is made to maintain asset class
exposure closely in line with prevailing target asset allocation percentages -
U.S. Equity (50%), Non-U.S. Equity (20%) and U.S. Fixed Income (30%) - through
monthly rebalancing toward those targets.
Within U.S. Equity, the Company uses a combination of passive index,
enhanced index and active investment strategies. Investment vehicles utilized
within these classes include both separately managed accounts and diversified
funds. The Plan's enhanced index and active investment managers are prohibited
from investing in the Company's common stock.
The Company's Non-U.S. Equity composite is invested almost entirely in
mature or developed markets (i.e., minimal exposure to emerging markets) using a
combination of passive and active investment strategies. Investment vehicles
used include separately managed accounts and diversified funds.
The U.S. Fixed Income investment class is invested almost exclusively
in securities categorized as "investment grade" using active investment
strategies. Investment vehicles utilized for U.S. Fixed Income also include
separately managed accounts and diversified funds. The Plan's separate account
managers are prohibited from investing in debt securities issued by the Company.
The Plan's assets are managed with the objective of minimizing pension
expense and cash contributions over the long term. With the assistance of the
Company's outside pension consultant, asset-liability studies are performed
every three to five years, and the Plan's target asset allocation percentages
are adjusted accordingly. The investment managers of each separately managed
account in which the Plan invests are prohibited from investing in derivative
securities. With respect to the diversified funds in which the Plan invests, the
existing investment guidelines permit derivative securities in the portfolio,
but the use of leverage (i.e., margin borrowing) is strictly prohibited.
Investment performance by total Plan, asset class and individual
manager is reviewed on a monthly basis, relative to one or more appropriate
benchmarks. On a quarterly basis, the pension consultant performs a detailed
statistical analysis of both investment performance and portfolio holdings.
Formal meetings are held with each investment manager approximately twice per
year
Wyeth 43
to review investment performance and to ascertain whether any changes in
process or turnover in professional personnel have occurred at the management
firm.
Other Postretirement Benefits
The Company provides postretirement health care and life insurance benefits for
retired employees of most U.S. locations and Canada. Most full-time employees
become eligible for these benefits after attaining specified age and service
requirements.
Plan Obligations, Plan Assets, Funded Status and Periodic Cost
The Company uses a December 31 measurement date for the majority of its defined
benefit plans. The change in the projected benefit obligation for the Company's
defined benefit plans (principally U.S.) for 2003 and 2002 was as follows:
Pensions Other Postretirement Benefits
--------------------------- -----------------------------
Change in Projected Benefit Obligation (In thousands) 2003 2002 2003 2002
- ----------------------------------------------------- ------------ ------------ ------------ ------------
Projected benefit obligation at January 1 $ 3,894,769 $ 3,316,032 $ 1,433,126 $ 1,270,085
Service cost 119,446 95,695 38,093 31,764
Interest cost 249,031 233,169 94,281 87,681
Amendments and other adjustments (2,436) 95,537 (132,301) (38,331)
Net actuarial loss 338,845 418,212 213,722 170,301
Settlements (31,537) -- -- --
Benefits paid (433,072) (302,082) (97,370) (88,707)
Currency translation adjustment 76,270 38,206 3,241 333
----------- ----------- ----------- -----------
Projected benefit obligation at December 31 $ 4,211,316 $ 3,894,769 $ 1,552,792 $ 1,433,126
=========== =========== =========== ===========
Amendments to the other postretirement benefit plans, effective
December 31, 2003, consisted of an increase in prescription drug copayment
charges for all retirees and an increase in the medical plan deductible for
post-2002 retirees. The increase of $131.0 million in pension benefits paid
related to lump sum pension payments for employees whose positions were
eliminated in connection with the Company's restructuring programs. The increase
in the net actuarial loss for other postretirement benefits of $43.4 million
resulted primarily from a change in the assumption for future increases in per
capita cost of health care benefits and other changes in actuarial assumptions.
At December 31, 2003 and 2002, the accumulated benefit obligation (ABO)
for the Company's defined benefit pension plans was $3,670.0 million and
$3,449.3 million, respectively. Projected benefit obligation, ABO and fair value
of plan assets for defined benefit pension plans with an ABO in excess of plan
assets were as follows:
December 31,
---------------------
(In thousands) 2003 2002
- -------------- -------- --------
Projected benefit obligation $706,035 $614,736
Accumulated benefit obligation 624,972 548,724
Fair value of plan assets 239,362 218,904
======== ========
The change in plan assets for the Company's defined benefit plans
(principally U.S.) for 2003 and 2002 was as follows:
Pensions Other Postretirement Benefits
--------------------------- -----------------------------
Change in Plan Assets (In thousands) 2003 2002 2003 2002
- ------------------------------------ ------------ ------------ -------- --------
Fair value of plan assets at January 1 $ 3,215,028 $ 2,738,622 $ -- $ --
Actual return on plan assets 583,366 (215,402) -- --
Amendments and other adjustments -- 67,175 -- --
Settlements (31,537) -- -- --
Company contributions 230,787 909,602 97,370 88,707
Benefits paid (433,072) (302,082) (97,370) (88,707)
Currency translation adjustment 38,698 17,113 -- --
----------- ----------- ------- -------
Fair value of plan assets at December 31 $ 3,603,270 $ 3,215,028 $ -- $ --
=========== =========== ======= =======
In December 2003, the Company made a contribution to the U.S. qualified
defined benefit pension plans of $162.0 million. The 2003 contribution was made
to fund current pension expense for the U.S. qualified defined benefit pension
plans. The decline in the global equity markets that occurred during 2001 and
2002 contributed significantly to the decrease in the plan assets for those
years. As such, the Company made a contribution to the U.S. qualified defined
benefit pension plans of $875.0 million in 2002 in anticipation of future
statutory funding requirements. The contributions made during the last two years
fully funded the primary U.S. defined benefit pension plan on an ABO basis.
There were no plan assets for the Company's other postretirement
benefit plans at December 31, 2003 and 2002 as postretirement benefits are
funded by the Company when claims are paid. The current portion of the accrued
benefit liability for other postretirement benefits was approximately $96.0
million and $85.0 million at December 31, 2003 and 2002, respectively.
The Company expects to contribute approximately $135.0 million to the
U.S. qualified and non-qualified defined benefit pension plans and approximately
$96.0 million to its other postretirement benefit plans in 2004.
44 Wyeth
The reconciliation of funded status and the amounts recognized in the
consolidated balance sheets for the Company's defined benefit plans (principally
U.S.) for 2003 and 2002 were as follows:
Pensions Other Postretirement Benefits
--------------------------- -----------------------------
Reconciliation of Funded Status (In thousands) 2003 2002 2003 2002
- ---------------------------------------------- ------------ ------------ ------------- -------------
Funded status $ (608,046) $ (679,741) $ (1,552,792) $ (1,433,126)
Unrecognized net actuarial loss 1,383,581 1,459,416 603,346 406,684
Unrecognized prior service cost 38,834 55,283 (153,691) (23,639)
Unrecognized net transition obligation 4,269 4,717 -- --
----------- ----------- ------------ ------------
Net amount recognized $ 818,638 $ 839,675 $ (1,103,137) $ (1,050,081)
----------- ----------- ------------ ------------
----------- ----------- ------------ ------------
The unrecognized net actuarial loss for pensions was impacted by the
decline in the global equity markets discussed above and will be amortized
through the net periodic benefit cost over the remaining estimated service life
of employees to the extent the unrecognized net actuarial loss exceeds 10% of
the greater of the projected benefit obligation and the fair value of plan
assets.
Pensions
Amount Recognized in the ---------------------------
Consolidated Balance Sheets (In thousands) 2003 2002
- ------------------------------------------ ------------ ------------
Prepaid benefit cost $ 1,096,563 $ 1,084,072
Accrued benefit liability (390,385) (335,421)
Intangible asset 11,371 19,943
Accumulated other comprehensive loss 101,089 71,081
----------- -----------
Net amount recognized $ 818,638 $ 839,675
----------- -----------
----------- -----------
Net periodic benefit cost for the Company's defined benefit plans
(principally U.S.) for 2003, 2002 and 2001 was as follows:
Pensions Other Postretirement Benefits
Components of Net Periodic Benefit Cost ------------------------------------ ----------------------------------
(In thousands) 2003 2002 2001 2003 2002 2001
- --------------------------------------- ---------- ---------- ---------- ---------- --------- ---------
Service cost $ 119,446 $ 95,695 $ 78,634 $ 38,093 $ 31,764 $ 24,179
Interest cost 249,031 233,169 226,786 94,281 87,681 76,966
Expected return on plan assets (270,502) (236,490) (246,449) -- -- --
Amortization of prior service cost 8,399 7,146 11,720 (2,249) 2,003 2,003
Amortization of transition obligation 1,098 1,057 1,999 -- -- --
Recognized net actuarial loss 104,367 36,798 2,250 18,703 7,164 127
Settlement loss 17,155 -- -- -- -- --
--------- --------- --------- --------- --------- ---------
Net periodic benefit cost $ 228,994 $ 137,375 $ 74,940 $ 148,828 $ 128,612 $ 103,275
--------- --------- --------- --------- --------- ---------
--------- --------- --------- --------- --------- ---------
Net periodic pension benefit cost was higher in 2003 as compared with
2002 due primarily to increases in the service cost and the recognized net
actuarial loss. The increase in service cost arose primarily from changes in
assumptions used to estimate expected lump sum distributions as well as a
decrease in the discount rate associated with determining net periodic benefit
cost as described in the Plan Assumptions section herein. The recognized net
actuarial loss increased as a result of amortizing deferred actuarial losses
from prior periods as discussed above.
Plan Assumptions
Weighted average assumptions used in developing the benefit
obligations and net periodic benefit cost at December 31 were as follows:
Pensions Other Postretirement Benefits
--------------------- -----------------------------
Benefit Obligations 2003 2002 2001 2003 2002 2001
- ------------------- ----- ----- ----- ----- ----- -----
Discount rate 6.25% 6.75% 7.25% 6.25% 6.75% 7.25%
Rate of compensation increase 4.00% 4.00% 4.00% -- -- --
Pensions Other Postretirement Benefits
--------------------- -----------------------------
Net Periodic Benefit Cost 2003 2002 2001 2003 2002 2001
- ------------------------- ----- ----- ----- ----- ----- -----
Discount rate 6.75% 7.25% 7.50% 6.75% 7.25% 7.50%
Rate of compensation increase 4.00% 4.00% 4.00% -- -- --
Expected return on plan assets 9.00% 9.00% 9.25% -- -- --
Wyeth 45
The expected return on plan assets is determined on an annual basis,
with input from the Company as well as an outside pension consultant. Every
attempt is made to maintain a long-term investment horizon (e.g., 10 years or
more) in developing the expected rate of return assumption, and the impact of
current/short-term market factors is not permitted to exert a disproportionate
influence on the process. While long-term historical returns are a factor in
this process, consideration also is given to forward-looking factors, including,
but not limited to, the following:
- expected economic growth and inflation;
- the forecasted statistical relationship (i.e., degree of
correlation, or co-movement) between the various asset classes in
which the Plan invests;
- forecasted volatility for each of the component asset classes;
- current yields on debt securities; and
- the likelihood of price-earnings ratio expansion or contraction.
Finally, the expected return on plan assets does not represent the
forecasted return for the near term; rather, it represents a best estimate of
normalized capital market returns over the next decade or more, based on the
target asset allocation in effect.
The change in assumed health care cost trend for the Company's other
postretirement benefit plans for 2003, 2002 and 2001 was as follows:
Other Postretirement Benefits
-----------------------------
Assumed Health Care Cost Trend 2003 2002 2001
- ------------------------------ ------- ----- -----
Health care cost trend rate
assumed for next year 11.00% 9.50% 9.50%
Rate to which the cost trend rate is
assumed to decline (the ultimate
trend rate) 5.00% 5.00% 5.00%
Year that the rate reaches the
ultimate trend rate 2008 2006 2005
Assumed health care cost trend rates have a significant effect on the
amounts reported for the health care plans. A one-percentage-point change in
assumed health care cost trend rates would have the following effects:
1-Percentage- 1-Percentage-
(In thousands) Point Increase Point Decrease
- -------------- -------------- --------------
Effect on total service and interest cost $ 20,211 $ (16,218)
Effect on postretirement benefit obligation 201,413 (165,659)
9. Derivative Instruments and Foreign Currency Risk Management Programs
Derivative financial instruments are measured at fair value and are recognized
as assets or liabilities on the balance sheet with changes in the fair value of
the derivatives recognized in either net income (loss) or accumulated other
comprehensive income (loss), depending on the timing and designated purpose of
the derivative. The fair value of forward contracts and interest rate swaps
reflects the present value of the future potential gain or loss if settlement
were to take place on December 31, 2003. The fair value of option contracts
reflects the present value of future cash flows if the contracts were settled on
December 31, 2003.
The Company currently engages in two primary programs to manage its
exposure to intercompany and third-party foreign currency risk. The two programs
and the corresponding derivative contracts are as follows:
1. Short-term foreign exchange forward contracts and swap contracts are
used to neutralize month-end balance sheet exposures. These
contracts essentially take the opposite currency position of that
projected in the month-end balance sheet to counterbalance the
effect of any currency movement. These derivative instruments are
not designated as hedges and are recorded at fair value with any
gains or losses recognized in current period earnings. The Company
recorded net losses of $92.6 million and $88.1 million for 2003 and
2002, respectively, and a net gain of $28.7 million for 2001 in
Other income, net related to gains and losses on these foreign
exchange forward contracts and swap contracts. These amounts consist
of gains and losses from contracts settled during 2003, 2002 and
2001, as well as contracts outstanding at December 31, 2003, 2002
and 2001 that are recorded at fair value.
2. The Company uses foreign currency put options and foreign currency
forward contracts in its cash flow hedging program to partially
cover foreign currency risk related to international intercompany
inventory sales. These instruments are designated as cash flow
hedges; and, accordingly, any unrealized gains or losses are
included in Accumulated other comprehensive loss with the
corresponding asset or liability recorded on the balance sheet. The
Company recorded after-tax net losses of $47.2 million and $17.6
million for 2003 and 2002, respectively, and an after-tax net gain
of $4.4 million for 2001 in Accumulated other comprehensive loss
with the corresponding assets/liabilities recorded in Other current
assets including deferred taxes/Accrued expenses related to these
cash flow hedges. The unrealized net losses in Accumulated other
comprehensive loss will be reclassified into the consolidated
statement of operations when the inventory is sold to a third party.
As such, the Company anticipates recognizing these net losses during
the next 12 months. The Company recognized net losses of $41.2
million and $12.1 million for 2003 and 2002, respectively, and net
gains of $33.8 million for 2001 included in Other income, net
related to these cash flow hedges. Put option contracts outstanding
as of December 31, 2003 expire no later than September 2004.
Occasionally, the Company purchases foreign currency put options
outside of the cash flow hedging program to protect additional
intercompany inventory sales. These put options do not qualify as
cash flow hedges and were recorded at fair value with all gains or
losses, which were not significant for 2003, recognized in current
period earnings. The Company did not purchase any foreign currency
put options outside of the cash flow hedging program during 2002.
46 Wyeth
In addition to the programs identified above, the Company had entered
into a foreign exchange forward contract to hedge against foreign exchange
fluctuations on a yen-denominated long-term intercompany loan to the Company's
Japanese subsidiary. This forward contract had been designated as and qualified
for foreign currency cash flow hedge accounting treatment. As of December 31,
2002 and 2001, the Company had recorded after-tax gains of $3.3 million and $3.5
million, respectively, in Accumulated other comprehensive loss relating to the
unrealized gains on this foreign exchange forward contract. As of December 31,
2003, this foreign exchange forward contract had matured, resulting in a
realized gain of $6.4 million included in Other income, net.
The Company also has entered into the following effective fair value
interest rate swaps to manage interest rate exposures:
(In thousands) Fair Value
Hedged Notes Notional Assets (Liabilities)* Maturity
Payable Amount 2003 2002 Date
- ------------ -------- --------- --------- --------
$1,750,000, 5.500% $750,000 $ (4,776) $ -- 2014
650,000 (5,954) -- 2014
350,000 (2,224) -- 2014
1,500,000, 6.700% 750,000 79,077 100,938 2011
750,000 78,624 99,842 2011
1,500,000, 5.250% 800,000 (17,104) -- 2013
700,000 (16,360) -- 2013
500,000, 6.450% 250,000 (2,912) -- 2024
300,000, 4.125% 150,000 (1,452) -- 2008
150,000 (640) -- 2008
-------- ---------
$106,279 $ 200,780
======== =========
* Fair value amounts exclude accrued interest.
These interest rate swaps effectively convert the fixed rate of
interest on these Notes to a floating rate. Interest expense on these Notes is
adjusted to include the payments made or received under the interest rate swap
agreements. The fair value of these swaps has been recorded in Other assets
including deferred taxes with the corresponding adjustment recorded to the
respective underlying Notes in Long-term debt.
10. Income Taxes
The provision (benefit) for federal and foreign income taxes consisted of:
(In thousands)
Year Ended December 31, 2003 2002 2001
- ----------------------- ------------ ------------ ------------
Current:
Federal $ 239,006 $ 159,487 $ (96,805)
Foreign 488,419 381,018 412,438
----------- ----------- -----------
727,425 540,505 315,633
Deferred:
Federal (405,587) 1,126,839 270,144
Foreign (11,418) (17,304) (2,324)
----------- ----------- -----------
(417,005) 1,109,535 267,820
----------- ----------- -----------
$ 310,420 $ 1,650,040 $ 583,453
=========== =========== ===========
Net deferred tax assets inclusive of valuation allowances were
reflected on the consolidated balance sheets at December 31 as follows:
(In thousands) 2003 2002
- -------------- ------------ ------------
Net current deferred tax assets $ 1,474,664 $ 1,197,298
Net noncurrent deferred tax assets 1,304,593 840,377
Net current deferred tax liabilities (17,163) (9,847)
Net noncurrent deferred tax liabilities (31,036) (37,796)
----------- -----------
Net deferred tax assets $ 2,731,058 $ 1,990,032
=========== ===========
Deferred income taxes are provided for temporary differences between
the financial reporting basis and the tax basis of the Company's assets and
liabilities. Deferred tax assets result principally from the recording of
certain accruals and reserves, which currently are not deductible for tax
purposes. Deferred tax liabilities result principally from the use of
accelerated depreciation for tax purposes and contributions made to the
Company's pension plans.
Wyeth 47
The components of the Company's deferred tax assets and liabilities at
December 31 were as follows:
(In thousands) 2003 2002
- -------------- ------------ ------------
Deferred tax assets:
Diet drug product litigation accruals $ 1,230,779 $ 682,927
Product litigation and environmental
liabilities and other accruals 641,082 581,478
Postretirement, pension and other
employee benefits 651,357 579,547
Net operating loss and other tax
credit carryforwards 353,635 1,228,939
Goodwill impairment 44,853 48,836
Restructuring 39,630 74,551
Inventory reserves 241,968 163,936
Investments and advances 22,570 27,685
Property, plant and equipment 133,164 62,567
Research and development costs 431,294 493,303
Intangibles 76,383 63,288
Other 59,591 57,991
----------- -----------
Total deferred tax assets 3,926,306 4,065,048
----------- -----------
Deferred tax liabilities:
Tax on earnings which may be remitted
to the United States (205,530) (700,000)
Depreciation (419,923) (343,762)
Pension and other employee benefits (380,504) (345,606)
Investments (6,791) (478,441)
Other (151,293) (158,570)
----------- -----------
Total deferred tax liabilities (1,164,041) (2,026,379)
----------- -----------
Deferred tax asset valuation allowances (31,207) (48,637)
----------- -----------
Net deferred tax assets $ 2,731,058 $ 1,990,032
=========== ===========
Valuation allowances have been established for certain deferred tax
assets related to environmental liabilities and other operating accruals as the
Company determined that it was more likely than not that these benefits will not
be realized.
The Company had previously provided $700.0 million of income taxes on
unremitted earnings from its international subsidiaries that may be remitted to
the United States. In 2003, $494.5 million of that provision was utilized as the
Company repatriated foreign earnings leaving a $205.5 million balance of
deferred taxes related to foreign earnings, which may be remitted. As of
December 31, 2003, income taxes were not provided on unremitted earnings of
$6,435.3 million expected to be permanently reinvested internationally. If
income taxes were provided on those earnings, they would approximate $1,523.1
million.
Reconciliations between the Company's effective tax rate and the U.S.
statutory rate, excluding the diet drug litigation charges in 2003, 2002 and
2001 (see Note 14), gains relating to Immunex/Amgen common stock transactions
(see Note 2), and special charges in 2003 and 2002 (see Note 3), were as
follows:
Tax Rate
Year Ended December 31, 2003 2002 2001
- ----------------------- ------ ------ ------
U.S. statutory rate 35.0% 35.0% 35.0%
Effect of Puerto Rico and Ireland
manufacturing operations (11.0) (10.3) (9.1)
Research credits (1.7) (1.9) (2.1)
Goodwill amortization -- -- 1.2
Other, net (1.0) (1.7) (0.9)
----- ---- ----
Effective tax rate 21.3% 21.1% 24.1%
===== ==== ====
Including the effect of the 2003 diet drug litigation charge and
special charge (which had tax benefits of 35.0% and 27.1%, respectively) and
gains relating to Immunex/Amgen common stock transactions (which had a tax
provision of 35.1%), the overall effective tax rate in 2003 was 13.1%. Including
the effect of the 2002 diet drug litigation charge and special charge (which had
tax benefits of 35.0% and 31.5%, respectively) and gains relating to
Immunex/Amgen common stock transactions (which had a tax provision of 35.6%),
the overall effective tax rate in 2002 was 27.1%. Including the effect of the
2001 diet drug litigation charge (which had a 35.3% tax benefit), the overall
effective tax rate in 2001 was 20.3%.
Total income tax payments, net of tax refunds, in 2003, 2002 and 2001
amounted to $576.9 million, $535.8 million and $493.6 million, respectively.
The U.S. Internal Revenue Service (IRS) has completed its examination
of the Company's tax returns for all years through 1993, and there are no
material unresolved issues outstanding for those years. The IRS currently is
examining the Company's returns for the years 1994 through 1997.
There were no material revisions to prior year taxes in the years
presented.
11. Capital Stock
There were 2,400,000,000 shares of common stock and 5,000,000 shares of
preferred stock authorized at December 31, 2003 and 2002. Of the authorized
preferred shares, there is a series of shares (16,934 and 18,318 outstanding at
December 31, 2003 and 2002, respectively), which is designated as $2.00
convertible preferred stock. Each share of the $2.00 series is convertible at
the option of the holder into 36 shares of common stock. This series may be
called for redemption at $60.00 per share plus accrued dividends.
Changes in outstanding common shares during 2003, 2002 and 2001 were as
follows:
(In thousands except
shares of preferred stock) 2003 2002 2001
- -------------------------- --------- ---------- ---------
Balance at January 1 1,326,055 1,320,570 1,311,774
Issued for stock options 6,310 7,233 8,550
Purchases of common stock
for treasury -- (2,000) --
Conversions of preferred stock
(1,384, 2,168 and 1,462 shares in
2003, 2002 and 2001, respectively)
and other exchanges 87 252 246
--------- --------- ---------
Balance at December 31 1,332,452 1,326,055 1,320,570
========== ========= =========
The Company has a common stock repurchase program under which the
Company is authorized to repurchase common shares. The Company made no
repurchases during 2003 but did repurchase 2,000,000 shares in 2002. At December
31, 2003, the Company was authorized to repurchase 4,492,460 common shares in
the future.
Treasury stock is accounted for using the par value method. Shares of
common stock held in treasury at December 31, 2003 and 2002 were 89,930,211 and
96,276,705, respectively. The Company has not retired any shares held in
treasury during 2003 and 2002.
48 Wyeth
In 2003, the Board of Directors terminated the Company's Series A Junior
Participating Preferred Stock Shareholder Rights Plan effective December 15,
2003.
12. Stock Options
As of December 31, 2003, the Company has three Stock Incentive Plans, a Stock
Option Plan for Non-Employee Directors and a Restricted Stock Plan for
Non-Employee Directors. Under the Stock Incentive Plans, options may be granted
to purchase a maximum of 190,000,000 shares at prices not less than 100% of the
fair market value of the Company's common stock on the date the option is
granted. Restricted stock also may be granted under the plans. At December 31,
2003, there were 34,842,456 shares available for future grants under the Stock
Incentive Plans.
The plans provide for the granting of incentive stock options as
defined under the Internal Revenue Code. Under the plans, grants of
non-qualified stock options with a 10-year term or incentive stock options with
a term not exceeding 10 years may be made to selected officers and employees.
All stock option grants vest ratably over a three-year term. The plans also
provide for the granting of stock appreciation rights (SAR), which entitle the
holder to receive shares of the Company's common stock or cash equal to the
excess of the market price of the common stock over the exercise price when
exercised. At December 31, 2003, there were no outstanding SARs.
The Stock Incentive Plans allow for, among other things, the issuance
of up to 24,000,000 shares, in the aggregate, as restricted stock awards.
Restricted stock awards representing 978,990, 326,510 and 290,995 units were
granted in 2003, 2002 and 2001, respectively, to certain employees, including
key executives. The increase in 2003 awards was due to a substantial increase in
the number of executives receiving restricted stock awards and an increase in
the size of individual awards due to a reallocation of value to restricted stock
in total long-term incentive compensation. Most of these units are converted to
shares of restricted stock based on the achievement of certain performance
criteria related to performance years 2001 through 2005. The remaining units are
converted generally at the end of four years.
Under the Stock Option Plan for Non-Employee Directors, a maximum of
250,000 shares may be granted to non-employee directors at 100% of the fair
market value of the Company's common stock on the date of the grant. Under this
plan, each continuing director who is not a current or former employee receives
a grant of stock options (currently 4,000 options per year) on the day of each
annual meeting of stockholders, which generally become exercisable on the next
annual meeting date. During each of the years ended December 31, 2003, 2002 and
2001, 36,000 stock options were granted to non-employee directors. Shares
available for future grants at December 31, 2003 were 100,000.
Under the Restricted Stock Plan for Non-Employee Directors, a maximum
of 100,000 restricted shares may be granted to non-employee directors. The
restricted shares granted to each non-employee director are not delivered prior
to the end of a five-year restricted period. At December 31, 2003, 61,600 shares
were available for future grants.
Stock option information related to the plans was as follows:
Weighted Weighted Weighted
Average Average Average
Exercise Exercise Exercise
Stock Options 2003 Price 2002 Price 2001 Price
- ------------- ------------ -------- ------------ -------- ------------ --------
Outstanding at January 1 122,811,755 $50.47 100,003,072 $48.57 82,751,313 $43.74
Granted 22,903,370 41.08 32,907,776 52.29 28,360,196 56.89
Canceled/forfeited (6,263,646) 53.13 (2,866,185) 56.67 (2,558,655) 57.36
Exercised (2003 - $14.52 to
$46.81 per share) (6,309,540) 22.47 (7,232,908) 30.09 (8,549,782) 26.74
----------- ------ ----------- ------ ----------- ------
Outstanding at December 31 133,141,939 50.05 122,811,755 50.47 100,003,072 48.57
----------- ------ ----------- ------ ----------- ------
Exercisable at December 31 83,798,898 51.31 68,484,510 47.57 57,205,798 41.93
=========== ====== =========== ====== =========== ======
The following table summarizes information regarding stock options
outstanding at December 31, 2003:
Options Outstanding Options Exercisable
----------------------------------------------- ----------------------------
Weighted
Average Weighted Weighted
Range of Number Remaining Average Number Average
Exercise Prices Outstanding Contractual Life Exercise Price Exercisable Exercise Price
- --------------- ----------- ---------------- -------------- ----------- --------------
$14.52 to 19.99 4,609,722 1.3 years $ 18.85 4,609,722 $ 18.85
20.00 to 29.99 2,299,487 2.3 years 26.28 2,299,487 26.28
30.00 to 39.99 19,292,001 6.2 years 35.52 12,106,147 35.80
40.00 to 49.99 22,278,010 9.2 years 41.28 725,791 44.20
50.00 to 59.99 47,249,956 6.4 years 55.24 40,128,401 55.02
60.00 to 65.32 37,412,763 7.0 years 61.51 23,929,350 61.80
----------- ----------
133,141,939 83,798,898
=========== ==========
Wyeth 49
13. Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss consists of foreign currency translation
adjustments, net unrealized gains (losses) on derivative contracts, net
unrealized gains (losses) on marketable securities and minimum pension liability
adjustments. The following table sets forth the changes in each component of
Accumulated other comprehensive loss:
Foreign Net Unrealized Net Unrealized Minimum Accumulated
Currency Gains (Losses) Gains (Losses) Pension Other
Translation on Derivative on Marketable Liability Comprehensive
(In thousands) Adjustments (1) Contracts (2) Securities (2) Adjustments (2) Loss
- -------------- --------------- -------------- --------------- --------------- -------------
Balance January 1, 2001 $ (685,463) $ -- $ 12,904 $ -- $ (672,559)
Period change (166,200) 7,865 (2,134) -- (160,469)
---------- ---------- ----------- ---------- ----------
Balance December 31, 2001 (851,663) 7,865 10,770 -- (833,028)
Period change 226,797 (22,132) 520,483 (47,691) 677,457
---------- ---------- ----------- ---------- ----------
Balance December 31, 2002 (624,866) (14,267) 531,253 (47,691) (155,571)
Period change(3) 691,362 (32,887) (507,334) (22,057) 129,084
---------- ---------- ----------- ---------- ----------
Balance December 31, 2003 $ 66,496 $ (47,154) $ 23,919 $ (69,748) $ (26,487)
========== ========== =========== =========== ==========
(1) Income taxes are generally not provided for foreign currency translation
adjustments, as such adjustments relate to permanent investments in
international subsidiaries.
(2) Deferred income tax assets (liabilities) provided for net unrealized
(losses) gains on derivative contracts at December 31, 2003, 2002 and 2001
were $24,300, $9,500 and $(1,000), respectively; for net unrealized gains
on marketable securities at December 31, 2003 and 2002 were $(6,144) and
$(279,200), respectively; and for minimum pension liability adjustments at
December 31, 2003 and 2002 were $31,341 and $23,390, respectively.
(3) 2003 period change for net unrealized gains (losses) on marketable
securities includes a realized gain on the sales of Amgen common stock
reclassified to net income of $515,114.
14. Contingencies and Commitments
Contingencies
The Company is involved in various legal proceedings, including product
liability and environmental matters of a nature considered normal to its
business (see Note 7 for discussion of environmental matters). It is the
Company's policy to accrue for amounts related to these legal matters if it is
probable that a liability has been incurred and an amount is reasonably
estimable.
Prior to November 2003, the Company was self-insured for product
liability risks with excess coverage on a claims-made basis from various
insurance carriers in excess of the self-insured amounts and subject to certain
policy limits. Effective November 2003, the Company became completely
self-insured for product liability risks.
In the opinion of the Company, although the outcome of any legal
proceedings cannot be predicted with certainty, the ultimate liability of the
Company in connection with its legal proceedings (other than the diet drug
litigation discussed immediately below) will not have a material adverse effect
on the Company's financial position but could be material to the results of
operations or cash flows in any one accounting period.
The Company has been named as a defendant in numerous legal actions
relating to the diet drugs Pondimin (which in combination with phentermine, a
product that was not manufactured, distributed or sold by the Company, was
commonly referred to as "fen-phen") or Redux, which the Company estimated were
used in the United States, prior to their 1997 voluntary market withdrawal, by
approximately 5.8 million people. These actions allege, among other things, that
the use of Redux and/or Pondimin, independently or in combination with
phentermine, caused certain serious conditions, including valvular heart
disease.
On October 7, 1999, the Company announced a nationwide class action
settlement (the settlement) to resolve litigation brought against the Company
regarding the use of the diet drugs Redux or Pondimin. The settlement covered
all claims arising out of the use of Redux or Pondimin, except for claims of
primary pulmonary hypertension (PPH), and was open to all Redux or Pondimin
users in the United States.
On November 23, 1999, U.S. District Judge Louis C. Bechtle granted
preliminary approval of the settlement and directed that notice of the
settlement terms be provided to class members. The notice program began in
December 1999. In early May 2000, the district court held a hearing on the
fairness of the terms of the settlement, with an additional one-day hearing on
August 10, 2000. On August 28, 2000, Judge Bechtle issued an order approving the
settlement. Several appeals were taken from that order to the U.S. Court of
Appeals for the Third Circuit. All but one of those appeals were withdrawn
during 2001, and, on August 15, 2001, the Third Circuit affirmed the approval of
the settlement. When no petitions to the U.S. Supreme Court for certiorari were
filed by January 2, 2002, the settlement was deemed to have received final
judicial approval on January 3, 2002.
As originally designed, the settlement was comprised of two settlement
funds. Fund A (with a value at the time of settlement of $1,000.0 million plus
$200.0 million for legal fees) was created to cover refunds, medical screening
costs, additional medical services and cash payments, education and research
costs, and administration costs. Fund A has been fully funded by contributions
by the Company. Fund B (which was to be funded by the Company on an as-needed
basis up to a total of $2,550.0 million) would compensate claimants with
significant heart valve disease. Any funds remaining in Fund A after all Fund A
obligations were met were to be added to Fund B to be available to pay Fund B
injury claims.
In December 2002, following a joint motion by the Company and
plaintiffs' counsel, the Court approved an amendment to the settlement agreement
which provided for the merger of Funds A and B into a combined fund which now
will cover all expenses and injury claims in connection with the settlement. The
effect of the merger is to accelerate the spillover of the expected remainder in
Fund A, which now is available to pay Fund B claims. The merger of the two funds
took place in January 2003.
50 Wyeth
Payments into the settlement fund were $822.7 million and $936.7
million in 2002 and 2001, respectively. There were no payments made in 2003.
Payments into the fund may continue, if necessary, until 2018.
Diet drug users choosing to opt out of the settlement class were
required to do so by March 30, 2000. The settlement agreement also gave class
members who participate in the settlement the opportunity to opt out of the
settlement at two later stages, although they remain members of the class and
there are restrictions on the nature of claims they can pursue outside of the
settlement. Class members who were diagnosed with certain levels of valvular
regurgitation within a specified time frame could opt out following their
diagnosis and prior to receiving any further benefits under the settlement
(Intermediate opt outs). Class members who were diagnosed with certain levels of
regurgitation and who elect to remain in the settlement, but who later develop a
more severe valvular condition, may opt out at the time the more serious
condition develops (Back-End opt outs). Under either of these latter two opt out
alternatives, class members may not seek or recover punitive damages, may sue
only for the condition giving rise to the opt out right, and may not rely on
verdicts, judgments or factual findings made in other lawsuits. The Sixth
Amendment to the settlement agreement also gave certain class members an
additional opt out right, which is discussed below.
On January 18, 2002, as collateral for the Company's financial
obligations under the settlement, the Company established a security fund in the
amount of $370.0 million. In April 2002, pursuant to an agreement among the
Company, class counsel and representatives of the settlement trust, an
additional $45.0 million (later reduced to $35.0 million) was added to the
security fund. In February 2003, as required by the amendment to the settlement
agreement merging the two settlement funds discussed above, an additional $535.2
million was added by the Company to the security fund, bringing the total amount
in the security fund to $940.2 million, which is primarily included in Other
current assets including deferred taxes, at December 31, 2003. The amounts in
the security fund are owned by the Company and will earn interest income for the
Company while residing in the security fund. The Company will be required to
deposit an additional $180.0 million in the security fund if the Company's
credit rating, as reported by both Moody's and S&P, falls below investment
grade.
The Company recorded an initial litigation charge of $4,750.0 million
($3,287.5 million after-tax or $2.51 per share) in connection with the Redux and
Pondimin litigation in 1999, an additional charge of $7,500.0 million ($5,375.0
million after-tax or $4.11 per share) in 2000, a third litigation charge of
$950.0 million ($615.0 million after-tax or $0.46 per share) in 2001, a fourth
charge of $1,400.0 million ($910.0 million after-tax or $0.68 per share) in 2002
and a fifth litigation charge of $2,000.0 million ($1,300.0 million after-tax or
$0.97 per share) in the 2003 third quarter.
Payments to the nationwide class action settlement funds, individual
settlement payments, legal fees and other items were $434.2 million, $1,307.0
million and $7,257.9 million for 2003, 2002 and 2001, respectively.
The remaining litigation accrual is classified as follows at
December 31:
(In thousands) 2003 2002
- -------------- ---------- ----------
Accrued expenses $2,000,000 $ 925,000
Other noncurrent liabilities 1,516,500 1,025,700
---------- ----------
Total litigation accrual $3,516,500 $1,950,700
========== ==========
The number of individuals who have filed claims within the settlement
that allege significant heart valve disease (known as matrix claims) has been
higher than had been anticipated. The settlement agreement grants the Company
access to claims data maintained by the settlement trust (the Trust). Based on
its review of those data, the Company understands that, as of December 31, 2003,
the Trust had recorded approximately 111,700 matrix-level claim forms.
Approximately 27,200 of these forms were so deficient, incomplete or duplicative
of other forms filed by the same claimant that they are, in the Company's view,
unlikely to result in a significant number of matrix claims to be processed
further.
The Company's understanding of the status of the approximately 84,500
forms, remaining at December 31, 2003, based on its analysis of data received
from the Trust, is as follows. Approximately 11,200 of the matrix claims had
been processed to completion, with those claims either paid (approximately 3,000
claims, with payments of $1,105.5 million), denied (approximately 7,600) or
withdrawn. Approximately 3,000 claims had begun the 100% audit process ordered
in late 2002 by the federal court overseeing the national settlement.
Approximately 21,000 claims alleged conditions that, if true, would entitle the
claimant to receive a matrix award; these claims had not yet entered the audit
process. Another approximately 20,000 claims with similar allegations have been
purportedly substantiated by physicians whose claims now are subject to the
outcome of the Trust's Integrity Program, discussed below. Approximately 29,100
claim forms did not contain sufficient information even to assert a matrix
claim, although some of those claim forms could be made complete by the
submission of additional information and therefore could become eligible to
proceed to audit in the future. The remaining approximately 200 claims were in
the data entry process and could not be assessed.
In addition to the approximately 111,700 matrix claims filed as of
December 31, 2003, additional matrix claims may be filed through 2015 by class
members who develop a matrix condition in the future if they have registered
with the Trust by May 3, 2003 and have demonstrated FDA+ regurgitation (i.e.,
mild or greater aortic regurgitation, or moderate or greater mitral
regurgitation) or mild mitral regurgitation on an echocardiogram conducted after
diet drug use and obtained either outside of the Trust by January 3, 2003 or
within the Trust's screening program.
The Company's understanding, based on data received from the Trust, is
that as of December 31, 2003, audits had been completed on 1,963 of the
approximately 3,000 claims that had begun the 100% audit process. Of these, 697
were found to be payable at the amount claimed, and 38 were found to be payable
at a lower amount than had been claimed. The remaining claims were found
ineligible for a matrix payment, although the
Wyeth 51
claimants may appeal that determination to the federal court overseeing the
settlement. Because it remains unclear whether the claims audited to date are a
representative sample of the claims that might proceed to audit, the Company
cannot predict the ultimate outcome of the audit process.
Both the volume and types of claims seeking matrix benefits received by
the Trust to date differ materially from the epidemiological projections on
which the court's approval of the settlement agreement was predicated. Based
upon data received from the Trust, approximately 94% of the 21,000 matrix
claimants who allege conditions that, if true, would entitle them to an award
(and approximately 99% of the approximately 20,000 claims certified by
physicians currently subject to the Trust's Integrity Program) seek an award
under Level II of the five-level settlement matrix. (Level II covers claims for
moderate or severe mitral or aortic valve regurgitation with complicating
factors; depending upon the claimant's age at the time of diagnosis, and
assuming no factors are present that would place the claim on one of the
settlement's reduced payment matrices, awards under Level II ranged from
$192,111 to $643,500 on the settlement agreement's payment matrix.)
An ongoing investigation which the Company understands is being
conducted by counsel for the Trust and discovery conducted to date by the
Company in connection with certain Intermediate and Back-End opt out cases
(brought by some of the same lawyers who have filed these Level II claims and
supported by some of the same cardiologists who have certified the Level II
claims) cast substantial doubt on the merits of many of these matrix claims and
their eligibility for a matrix payment from the Trust. Therefore, in addition to
the 100% audit process, the Trust has embarked upon an Integrity Program, which
is designed to protect the Trust from paying illegitimate or fraudulent claims.
Pursuant to the Integrity Program, the Trust has required additional
information concerning matrix claims purportedly substantiated by 17 identified
physicians in order to determine whether to permit those claims to proceed to
audit. Based upon data obtained from the Trust, the Company believes that
approximately 20,000 matrix claims were purportedly substantiated by the 17
physicians covered by the Integrity Program as of December 31, 2003. It is the
Company's understanding that additional claims substantiated by additional
physicians might be subjected to the same requirements of the Integrity Program
in the future. As an initial step in the integrity review process, each of the
identified physicians has been asked to complete a comprehensive questionnaire
regarding each claim and the method by which the physician reached the
conclusion that it was valid. The ultimate disposition of any or all claims that
are subject to the Integrity Program is at this time uncertain. Counsel for
certain claimants affected by the program have challenged the Trust's authority
to implement the Integrity Program and to require completion of the
questionnaire before determining whether to permit those claims to proceed to
audit. While that motion was denied by the court, additional challenges to the
Integrity Program are possible.
The Trust also has adopted a program to prioritize the handling of
those matrix claims that it believes are least likely to be illegitimate. Under
the plan, claims under Levels III, IV and V will be processed and audited on an
expedited basis. (Level III covers claims for heart valve disease requiring
surgery to repair or replace the valve or conditions of equal severity. Levels
IV and V cover complications from, or more serious conditions than, heart valve
surgery.) The policy will also prioritize the auditing of, inter alia, Level I
claims, all claims filed by a claimant without counsel (i.e., on a pro se basis)
and Level II claims substantiated by physicians who have attested to fewer than
20 matrix claims.
The Trust has indicated that one of the goals of the Integrity Program
is to recoup funds from those entities that caused the Trust to pay illegitimate
claims, and the Trust has filed several lawsuits to that end. The Trust has
filed a suit alleging violations of the Racketeer Influenced and Corrupt
Organizations (RICO) Act against a Kansas City cardiologist who attested under
oath to the validity of over 2,500 matrix claims. The suit alleges that the
cardiologist intentionally engaged in a pattern of racketeering activity to
defraud the Trust. The Trust also has filed a lawsuit against a New York
cardiologist who attested under oath to the validity of 83 matrix claims,
alleging that the cardiologist engaged in, among other things,
misrepresentation, fraud, conspiracy to commit fraud and gross negligence.
Finally, the Trust has filed a number of motions directed at the
conduct of the companies that performed the echocardiograms on which many matrix
claims are based. In a pair of motions related to the activities of a company
known as EchoMotion, the Trust has asked the court to stay payment of claims
already audited and found payable in whole or in part if the echocardiogram was
performed by EchoMotion and to disqualify all echocardiograms by EchoMotion that
have been used to support matrix claims that have not yet been audited. In
addition, the Trust has filed a motion seeking discovery of 14 specific
companies whose echocardiograms support a large number of claims to determine
whether their practices violate the settlement. The Trust also has sent letters
to matrix claimants' lawyers requesting information about additional
unidentified companies and has asked the Court's permission to subpoena the
claimants' lawyers for this information if necessary. The Company does not
currently have information about the number of matrix claims potentially
affected by these motions.
The Company continues to monitor the progress of the Trust's audit
process and its Integrity Program and has brought and will continue to bring to
the attention of the Trust and the court overseeing the settlement any
additional irregularities that it uncovers in the matrix claim process. Even if
substantial progress is made by the Trust, through its Integrity Program or
other means, in reducing the number of illegitimate matrix claims, a significant
number of the claims which proceed to audit might be interpreted as satisfying
the matrix eligibility criteria, notwithstanding the possibility that the
claimants may not, in fact, have serious heart valve disease. If so, matrix
claims found eligible for payment after audit may cause total payments to exceed
the $3,750.0 million cap of the settlement fund.
Should the settlement fund be exhausted, most of the matrix claimants
who filed their matrix claim on or before May 3, 2003 and who pass the audit
process at a time when there are insufficient funds to pay their claim may
pursue an additional opt out right created by the Sixth Amendment to the
settlement agreement unless the Company first elects, in its sole discretion, to
pay the matrix benefit after audit. Sixth Amendment opt out
52 Wyeth
claimants may then sue the Company in the tort system, subject to the
settlement's limitations on such claims. In addition to the limitations on all
Intermediate and Back-End opt outs (such as the prohibition on seeking punitive
damages and the requirement that the claimant sue only on the valve condition
that gave rise to the claim), a Sixth Amendment opt out may not sue any
defendant other than the Company and may not join his or her claim with the
claim of any other opt out. The Company cannot predict the ultimate number of
individuals who might be in a position to elect a Sixth Amendment opt out or who
may, in fact, elect to do so, but that number could be substantial.
If the settlement fund were to be exhausted, some individuals who
registered to participate in the settlement by May 3, 2003, who had demonstrated
either FDA+ level regurgitation or mild mitral regurgitation on an
echocardiogram completed after diet drug use and conducted either outside of the
settlement prior to January 3, 2003 or within the settlement's screening
program, and who subsequently develop (at any time before the end of 2015) a
valvular condition that would qualify for a matrix payment might elect to pursue
a Back-End opt out. Such individuals may pursue a Back-End opt out within 120
days of the date on which they first discover or should have discovered their
matrix condition. The Company cannot predict the ultimate number of individuals
who may be in a position to elect a Back-End opt out or who may, in fact, elect
to do so, but that number also could be substantial.
The Company's current understanding is that approximately 76,000
Intermediate opt out forms were submitted by May 3, 2003, the applicable
deadline for most class members (other than qualified class members receiving
echocardiograms through the Trust after January 3, 2003, who may exercise
Intermediate opt out rights within 120 days after the date of their
echocardiogram). The number of Back-End opt out forms received as of December
31, 2003 is estimated to be approximately 20,000, although certain additional
class members may elect to exercise Back-End opt out rights in the future (under
the same procedure as described above) even if the settlement fund is not
exhausted. After eliminating forms that are duplicative of other filings, forms
that are filed on behalf of individuals who already have either received
payments from the Trust or settlements from the Company, and forms that are
otherwise invalid on their face, it appears that approximately 78,000
individuals had filed Intermediate or Back-End opt out forms as of December 31,
2003.
Purported Intermediate or Back-End opt outs (as well as Sixth Amendment
opt outs) who meet the settlement's medical eligibility requirements may pursue
lawsuits against the Company but must prove all elements of their claims -
including liability, causation and damages - without relying on verdicts,
judgments or factual findings made in other lawsuits. They also may not seek or
recover punitive, exemplary or multiple damages and may sue only for the
valvular condition giving rise to their opt out right. To effectuate these
provisions of the settlement, the federal court overseeing the settlement has
issued orders limiting the evidence that may be used by plaintiffs in such
cases. Those orders, however, are being challenged on appeal. The appeal has
been fully briefed and was heard by a panel of the U.S. Court of Appeals for the
Third Circuit in December 2003. The panel has asked for supplemental briefing,
which also has been filed. The Company cannot predict the timing or outcome of
the appeal.
In addition to the specific matters discussed herein, the federal court
overseeing the national settlement has issued a number of rulings concerning the
processing of matrix claims and the rights of, and limitations placed on, class
members by the terms of the settlement. Several of those rulings are being
challenged on appeal. Certain class members also have filed a number of motions,
as well as a lawsuit, attacking both the binding effect of the settlement and
the administration of the Trust. The Company cannot predict the outcome of any
of these motions or of the lawsuit.
As of December 31, 2003, approximately 27,000 individuals who had filed
Intermediate or Back-End opt out forms had filed lawsuits. The claims of most of
these 27,000 plaintiffs now are pending in federal courts and have been or will
be transferred for pretrial proceedings to the federal court overseeing the
national settlement. The Company expects to challenge vigorously all
Intermediate and Back-End opt out claims of questionable validity or medical
eligibility, and the number of such claims that meet the settlement's opt out
criteria will not be known for some time. As a result, the Company cannot
predict the ultimate number of purported Intermediate or Back-End opt outs that
will satisfy the settlement's opt out requirements, but that number could be
substantial. As to those opt outs who are found eligible to pursue a lawsuit,
the Company also intends vigorously to defend these cases on their merits.
The Company has resolved the claims of all but a small percentage of
the "initial" opt outs (i.e., those individuals who exercised their right to opt
out of the settlement class) and continues to work toward resolving the rest. It
also continues to work toward resolving the claims of individuals who allege
that they have developed PPH as a result of their use of the diet drugs. The
Company intends vigorously to defend those initial opt out and PPH cases that
cannot be resolved prior to trial.
On February 7, 2003, a jury in Santa Fe, New Mexico, hearing the Redux
lawsuit of Garcia v. Wyeth-Ayerst Laboratories Division of American Home
Products Corporation, et al., No. D-0101-CV-2000-1387, 1st Jud. Dist. Ct., Santa
Fe Cty., New Mexico, an initial opt out case, rendered a verdict in favor of the
Company.
On November 6, 2003, a jury in the District Court of Texas, 60th
Judicial District, Jefferson County, returned a verdict in favor of the
plaintiff in the case of Hayes v. American Home Products, et al., No. B-165,374,
the first Intermediate opt out case to go to trial. The jury in the Hayes case
awarded the plaintiff $1.36 million in compensatory damages for injuries
allegedly sustained by the plaintiff due to her use of Redux and Pondimin. The
court subsequently entered judgment in the amount of $588,480, based upon a
filing by the plaintiff conceding there was insufficient evidence to support the
jury's award of future medical expenses. The Company has filed post-trial
motions for judgment notwithstanding the verdict or for a new trial and intends
to pursue an appeal, if necessary.
On November 26, 2003, a jury in Georgia Superior Court, Fulton County,
Atlanta Judicial Circuit, returned a verdict in favor of the Company in the case
of Eichmiller et al. v. American
Wyeth 53
Home Products, et al., Civ. A. No. 2002-CV-52077, the first Back-End opt out
case to go to trial.
As noted above, in 2003, the Company increased its reserves in
connection with the Redux and Pondimin diet drug matters by $2,000.0 million,
bringing the total of the charges taken to date to $16,600.0 million. The
$3,516.5 million reserve at December 31, 2003 represents management's best
estimate of the minimum aggregate amount anticipated to cover payments in
connection with the Trust, up to its cap, initial opt outs, PPH claims,
Intermediate, Back-End or Sixth Amendment opt outs (collectively, the
"downstream" opt outs), and the Company's legal fees related to the diet drug
litigation. Due to its inability to estimate the ultimate number of valid
downstream opt outs, and the merits and value of their claims, as well as the
inherent uncertainty surrounding any litigation, the Company is unable to
estimate the amount of any additional financial exposure represented by the
downstream opt out litigation. However, the amount of financial exposure beyond
that which has been recorded could be significant.
The Company intends to defend itself vigorously and believes it can
marshal significant resources and legal defenses to limit its ultimate liability
in the diet drug litigation. However, in light of the circumstances discussed
above, including the unknown number of valid matrix claims and the unknown
number and merits of valid downstream opt outs, it is not possible to predict
the ultimate liability of the Company in connection with its diet drug legal
proceedings. It is therefore not possible to predict whether, and if so when,
such proceedings will have a material adverse effect on the Company's financial
condition, results of operations and/or cash flows and whether cash flows from
operating activities and existing and prospective financing resources will be
adequate to fund the Company's operations, pay all liabilities related to the
diet drug litigation, pay dividends, maintain the ongoing programs of capital
expenditures, and repay both the principal and interest on its outstanding
obligations without the disposition of significant strategic core assets and/or
reductions in certain cash outflows.
Commitments
The Company leases certain property and equipment for varying periods under
operating leases. Future minimum rental payments under non-cancelable operating
leases with terms in excess of one year in effect at December 31, 2003 are as
follows:
(In thousands)
- -----------------
2004 $ 69,774
2005 64,794
2006 55,835
2007 47,540
2008 44,289
Thereafter 68,000
--------
Total rental commitments $350,232
========
Rental expense for all operating leases was $133.6 million, $156.0
million and $133.7 million in 2003, 2002 and 2001, respectively.
15. Company Data by Segment
The Company has four reportable segments: Pharmaceuticals, Consumer Healthcare,
Animal Health and Corporate. The Company's Pharmaceuticals, Consumer Healthcare
and Animal Health reportable segments are strategic business units that offer
different products and services. Beginning in the 2003 fourth quarter, the
Company changed its reporting structure to include the Animal Health business as
a separate reportable segment. The Animal Health business was previously
reported within the Pharmaceuticals segment. Prior period information presented
herein has been restated to be on a comparable basis. The reportable segments
are managed separately because they manufacture, distribute and sell distinct
products and provide services that require various technologies and marketing
strategies.
The Pharmaceuticals segment manufactures, distributes and sells branded
human ethical pharmaceuticals, biologicals and nutritionals. Principal products
include neuroscience therapies, cardiovascular products, nutritionals,
gastroenterology drugs, anti-infectives, vaccines, oncology therapies,
musculoskeletal therapies, hemophilia treatments, immunological products and
women's health care products.
The Consumer Healthcare segment manufactures, distributes and sells
over-the-counter health care products that include analgesics,
cough/cold/allergy remedies, nutritional supplements, and hemorrhoidal, asthma
and other relief items.
The Animal Health segment manufactures, distributes and sells animal
biological and pharmaceutical products that include vaccines, pharmaceuticals,
parasite control and growth implants.
Corporate is responsible for the treasury, tax and legal operations of
the Company's businesses and maintains and/or incurs certain assets,
liabilities, income, expenses, gains and losses related to the overall
management of the Company which are not allocated to the other reportable
segments.
The accounting policies of the segments described above are the same as
those described in "Summary of Significant Accounting Policies" in Note 1. The
Company evaluates the performance of the Pharmaceuticals, Consumer Healthcare
and Animal Health reportable segments based on income before taxes, which
includes gains on the sales of non-corporate assets and certain other items.
Corporate includes interest expense and interest income, gains on the sales of
investments and other corporate assets, gains relating to Immunex/Amgen common
stock transactions, certain litigation provisions, including the Redux and
Pondimin litigation charges, special charges and other miscellaneous items.
54 Wyeth
Company Data by Reportable Segment
(In millions)
Year Ended December 31, 2003 2002 2001
- ----------------------- ------------ ----------- ------------
Net Revenue from Customers
Pharmaceuticals $ 12,622.7 $ 11,733.3 $ 10,940.3
Consumer Healthcare 2,434.5 2,197.4 2,267.2
Animal Health 793.4 653.3 776.2
----------- ----------- -----------
Consolidated Total $ 15,850.6 $ 14,584.0 $ 13,983.7
=========== =========== ===========
Income before Taxes(1)
Pharmaceuticals $ 3,798.5 $ 3,441.4 $ 3,340.2
Consumer Healthcare 592.4 608.0 592.1
Animal Health 127.4 64.1 163.3
Corporate(2) (2,156.7) 1,983.7 (1,226.9)
----------- ----------- -----------
Consolidated Total $ 2,361.6 $ 6,097.2 $ 2,868.7
=========== =========== ===========
Depreciation and
Amortization Expense(1)
Pharmaceuticals $ 458.0 $ 409.6 $ 486.5
Consumer Healthcare 34.9 32.1 53.1
Animal Health 25.9 25.2 52.6
Corporate 19.1 17.8 15.5
----------- ----------- -----------
Consolidated Total $ 537.9 $ 484.7 $ 607.7
=========== =========== ===========
Expenditures for
Long-Lived Assets(4)(5)
Pharmaceuticals $ 1,742.1 $ 1,758.2 $ 1,796.2
Consumer Healthcare 53.8 40.1 67.8
Animal Health 28.4 31.2 31.5
Corporate 126.3 126.3 137.1
----------- ----------- -----------
Consolidated Total $ 1,950.6 $ 1,955.8 $ 2,032.6
=========== =========== ===========
Total Assets at December 31,
Pharmaceuticals(3) $ 14,513.7 $ 12,608.7 $ 12,348.0
Consumer Healthcare 1,742.8 1,709.8 1,736.3
Animal Health 1,328.4 1,293.1 1,472.3
Corporate 13,447.0 10,431.0 7,411.3
----------- ----------- -----------
Consolidated Total $ 31,031.9 $ 26,042.6 $ 22,967.9
=========== =========== ===========
Company Data by Geographic Segment
(In millions)
Year Ended December 31, 2003 2002 2001
- ----------------------- ----------- ----------- ------------
Net Revenue from Customers(4)
United States $ 9,581.0 $ 9,233.8 $ 8,903.2
United Kingdom 863.0 750.6 680.2
Other International 5,406.6 4,599.6 4,400.3
----------- ----------- ------------
Consolidated Total $ 15,850.6 $ 14,584.0 $ 13,983.7
=========== =========== ===========
</Table>
Long-Lived Assets at
December 31,(4)(5)
United States $ 7,256.1 $ 7,468.9 $ 7,087.3
Ireland 2,472.0 1,341.0 652.7
Other International 2,996.6 2,939.0 2,727.4
----------- ----------- -----------
Consolidated Total $ 12,724.7 $ 11,748.9 $ 10,467.4
=========== =========== ===========
(1) Income before taxes included goodwill amortization for 2001 as follows:
Pharmaceuticals - $105.5, Consumer Healthcare - $23.7 and Animal Health -
$31.3. The Company ceased amortizing goodwill in accordance with SFAS No.
142 effective January 1, 2002.
(2) 2003, 2002 and 2001 Corporate included litigation charges of $2,000.0,
$1,400.0 and $950.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drug products Redux or
Pondimin (see Note 14). The charges related to the Pharmaceuticals
reportable segment.
2003 Corporate also included:
- A gain of $860.6 relating to the sales of the Company's remaining
Amgen common stock holdings (see Note 2). The gain related to the
Pharmaceuticals reportable segment.
- A special charge of $639.9 for manufacturing restructurings and
related asset impairments and the cost of debt extinguishment (see
Note 3). The charge related to the reportable segments as follows:
Pharmaceuticals - $487.9 and Corporate - $152.0.
2002 Corporate also included:
- A gain of $2,627.6 relating to the acquisition of Immunex by Amgen.
The gain represents the excess of $1,005.2 in cash plus the fair
value of 98,286,358 Amgen shares received, $2,500.1, over the
Company's book basis of its investment in Immunex and certain
transaction costs (see Note 2). The gain related to the
Pharmaceuticals reportable segment.
- A gain of $1,454.6 on the sales of a portion of the Company's Amgen
common stock holdings. The gain was determined by comparing the basis
of the shares sold, $1,782.7, with the net proceeds received,
$3,250.8, reduced by certain related expenses (see Note 2). The gain
related to the Pharmaceuticals reportable segment.
- A special charge of $340.8 for restructuring and related asset
impairments (see Note 3). The charge related to the reportable
segments as follows: Pharmaceuticals - $291.5, Consumer Healthcare -
$17.1, Animal Health - $16.1 and Corporate - $16.1.
(3) 2001 included an equity method investment in Immunex of $845.4. The Company
did not retain an equity method investment in Immunex subsequent to July 15,
2002 (see Note 2).
(4) Other than the United States and the United Kingdom, no other country in
which the Company operates had net revenue of 5% or more of the respective
consolidated total. Other than the United States and Ireland, no country in
which the Company operates had long-lived assets of 5% or more of the
respective consolidated total. The basis for attributing net revenue to
geographic areas is the location of the customer.
(5) Long-lived assets consist primarily of property, plant and equipment,
goodwill, other intangibles and other assets, excluding deferred taxes, net
investments in equity companies and various financial assets.
16. Subsequent Event
New Credit Facility
In February 2004, the Company replaced its $1,350.0 million, 364-day credit
facility entered into in March 2003 with a $1,747.5 million, five-year facility.
The new facility contains substantially identical financial and other covenants,
representations, warranties, conditions and default provisions as the replaced
facility (see Note 6).
Wyeth 55
Report of Independent Auditors
To the Board of Directors and Stockholders of Wyeth:
In our opinion, the accompanying consolidated balance sheets and the
related consolidated statements of operations, of changes in stockholders'
equity and of cash flows present fairly, in all material respects, the financial
position of Wyeth and its subsidiaries at December 31, 2003 and 2002, and the
results of their operations and their cash flows for each of the three years in
the period ended December 31, 2003 in conformity with accounting principles
generally accepted in the United States of America. These financial statements
are the responsibility of the Company's management; our responsibility is to
express an opinion on these financial statements based on our audits. We
conducted our audits of these statements in accordance with auditing standards
generally accepted in the United States of America, which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
As discussed in Notes 1 and 5 to the financial statements, on January
1, 2002, the Company adopted Statement of Financial Accounting Standards No.
142, "Goodwill and Other Intangible Assets."
PricewaterhouseCoopers LLP
Florham Park, NJ
January 22, 2004
except for Note 16
which is as of February 11, 2004
56 Wyeth
Management Report on Consolidated Financial Statements
Management has prepared and is responsible for the Company's consolidated
financial statements and related notes to consolidated financial statements.
They have been prepared in accordance with accounting principles generally
accepted in the United States and necessarily include amounts based on judgments
and estimates made by management. All financial information in this Annual
Report is consistent with the consolidated financial statements.
The Company maintains internal accounting control systems and related
policies and procedures designed to provide reasonable assurance that assets are
safeguarded, that transactions are executed in accordance with management's
authorization and are properly recorded, and that accounting records may be
relied upon for the preparation of consolidated financial statements and other
financial information. The design, monitoring and revision of internal
accounting control systems involve, among other things, management's judgment
with respect to the relative cost and expected benefits of specific control
measures. The Company also maintains an internal auditing function, which
evaluates and formally reports on the adequacy and effectiveness of internal
accounting controls, policies and procedures.
The Company's consolidated financial statements have been audited by
independent auditors who have expressed their opinion with respect to the
fairness of these statements. In addition, we have personally executed all
certifications required to be filed with the Securities and Exchange Commission
pursuant to the Sarbanes-Oxley Act of 2002 and the regulations thereunder
regarding the accuracy and completeness of the consolidated financial
statements.
Our Audit Committee is composed of non-employee members of the Board of
Directors, all of whom are independent from our Company. The Committee charter,
which is published in the proxy statement and on our Internet website
(www.wyeth.com), outlines the members' roles and responsibilities and is
consistent with the newly enacted corporate reform laws, regulations and New
York Stock Exchange guidelines. It is the Audit Committee's responsibility to
appoint independent auditors subject to shareholder ratification, approve audit,
audit-related, tax and other services performed by the independent auditors, and
review the reports submitted by them. The Audit Committee meets several times
during the year with management, the internal auditors and the independent
auditors to discuss audit activities, internal controls and financial reporting
matters, including reviews of our externally published financial results. The
internal auditors and the independent auditors have full and free access to the
Committee.
We are dedicated to ensuring that we maintain the high standards of
financial accounting and reporting that we have established. We are committed to
providing financial information that is transparent, timely, complete, relevant
and accurate. Our culture demands integrity and an unyielding commitment to
strong internal practices and policies. Finally, we have the highest confidence
in our financial reporting, our underlying system of internal controls and our
people, who are expected to operate at the highest level of ethical standards
pursuant to our code of conduct.
Robert Essner Kenneth J. Martin
- ------------------------------- ----------------------------
Chairman, President and Executive Vice President and
Chief Executive Officer Chief Financial Officer
Wyeth 57
Quarterly Financial Data (Unaudited)
First Quarter Second Quarter Third Quarter Fourth Quarter
(In thousands except per share amounts) 2003 2003 2003 2003
- --------------------------------------- ------------- -------------- ------------- --------------
Net revenue $ 3,689,057 $ 3,746,556 $ 4,081,609 $ 4,333,410
Gross profit 2,760,753 2,726,661 2,955,253 3,030,879
Net income (loss)(1) 1,277,882 864,405 (426,358) 335,263
Diluted earnings (loss) per share(1) 0.96 0.65 (0.32) 0.25
----------- ------------ ----------- ------------
First Quarter Second Quarter Third Quarter Fourth Quarter
(In thousands except per share amounts) 2002 2002 2002 2002
- --------------------------------------- ------------- -------------- ------------- --------------
Net revenue $ 3,643,521 $ 3,502,848 $ 3,623,672 $ 3,813,994
Gross profit 2,841,342 2,615,633 2,565,550 2,643,123
Net income(2) 871,920 599,859 1,401,399 1,574,027
Diluted earnings per share(2) 0.65 0.45 1.05 1.18
----------- ------------ ----------- ------------
(1) First Quarter 2003 included a gain of $558,694 after-tax or $0.42 per share
on the sales of the remaining 31,235,958 shares of Amgen common stock.
Third Quarter 2003 included a charge of $1,300,000 after-tax or $0.98 per
share to increase the reserve relating to the litigation brought against the
Company regarding the use of the diet drugs Redux or Pondimin.
Fourth Quarter 2003 included a special charge of $466,441 after-tax or $0.35
per share for manufacturing restructurings, asset impairments and the cost
of debt extinguishment.
(2) Third Quarter 2002 included a gain of $1,684,723 after-tax or $1.26 per
share relating to the acquisition of Immunex by Amgen and a charge of
$910,000 after-tax or $0.68 per share to increase the reserve relating to
the litigation brought against the Company regarding the use of the diet
drugs Redux or Pondimin.
Fourth Quarter 2002 included a gain of $943,401 after-tax or $0.71 per share
on the sales of 67,050,400 shares of Amgen common stock and a special charge
of $233,500 after-tax or $0.18 per share for restructuring and related asset
impairments.
Market Prices of Common Stock and Dividends
2003 Range of Prices* 2002 Range of Prices*
----------------------------- -----------------------------
Dividends Dividends
Paid Paid
High Low per Share High Low per Share
------ ------ --------- ------ ------ ---------
First quarter $40.00 $32.75 $ 0.23 $66.51 $60.48 $ 0.23
Second quarter 49.95 34.46 0.23 66.49 49.00 0.23
Third quarter 49.29 41.32 0.23 52.24 28.25 0.23
Fourth quarter 48.32 36.81 0.23 39.39 31.25 0.23
* Prices are those of the New York Stock Exchange - Composite Transactions.
58 Wyeth
Management's Discussion and Analysis of
Financial Condition and Results of Operations
The following commentary should be read in conjunction with the consolidated
financial statements and notes to consolidated financial statements on pages 28
to 55.
Overview
Wyeth is one of the world's largest research-based pharmaceutical and health
care products companies. We are a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines, biopharmaceuticals,
non-prescription medicines and animal health care.
We have four reportable segments: Wyeth Pharmaceuticals (Pharmaceuticals),
Wyeth Consumer Healthcare (Consumer Healthcare), Fort Dodge Animal Health
(Animal Health) and Corporate, which are managed separately because they
manufacture, distribute and sell distinct products and provide services which
require various technologies and marketing strategies. These segments reflect
how senior management reviews the business, makes investing and resource
allocation decisions, and assesses operating performance.
Our Pharmaceuticals segment, which provided 80% of our consolidated net
revenue for both 2003 and 2002, manufactures, distributes and sells branded
human ethical pharmaceuticals, biologicals and nutritionals. Principal products
include neuroscience therapies, cardiovascular products, nutritionals,
gastroenterology drugs, anti-infectives, vaccines, oncology therapies,
musculoskeletal therapies, hemophilia treatments, immunological products and
women's health care products. These products are promoted and sold worldwide
primarily to wholesalers, pharmacies, hospitals, physicians, retailers and other
human health care institutions.
The Consumer Healthcare segment, which provided 15% of our consolidated net
revenue for both 2003 and 2002, manufactures, distributes and sells
over-the-counter health care products which include analgesics,
cough/cold/allergy remedies, nutritional supplements, and hemorrhoidal, asthma
and other relief items. These products generally are sold to wholesalers and
retailers and are promoted primarily to consumers worldwide through advertising.
Our Animal Health segment, which provided 5% of our consolidated net
revenue for both 2003 and 2002, manufactures, distributes, and sells animal
biological and pharmaceutical products, including vaccines, pharmaceuticals,
parasite control and growth implants. These products are sold to wholesalers,
retailers, veterinarians and other animal health care institutions.
The Corporate segment is responsible for the treasury, tax and legal
operations of the Company's businesses. It maintains and/or incurs certain
assets, liabilities, income, expenses, gains and losses related to the overall
management of the Company that are not allocated to the other reportable
segments.
All of Wyeth's divisions exhibited strong revenue growth in 2003 compared
with 2002. Pharmaceuticals had revenue growth of 8% to $12,622.7 million,
Consumer Healthcare rose 11% to $2,434.5 million and Animal Health had revenue
growth of 21% to $793.4 million.
Pharmaceuticals sales growth was spurred by the strong performance of
several key products:
- Effexor (neuroscience therapies)-up 31% compared with 2002 to $2,711.7
million
- Protonix (gastroenterology drugs)-up 39% to $1,493.3 million
- Prevnar (vaccines)- up 46% to $945.6 million
Other areas of growth for the Pharmaceuticals segment included the
Zosyn/Tazocin family of products, Rapamune and alliance revenue from sales of
Enbrel, Altace and the CYPHER Stent.
The gains from these products more than offset the loss of revenue from the
decline in sales of the Premarin family products, the 2002 sale of the Company's
generic human injectables product line and decreases in sales of Cordarone I.V.,
which lost its market exclusivity in October 2002.
Both Consumer Healthcare and Animal Health posted strong results in 2003
after disappointing results in 2002. The increase in Consumer Healthcare sales
resulted primarily from the introduction of Alavert late in 2002 and stronger
international performance as a result of product globalization strategies and
the favorable impact of foreign exchange. Strong sales of its West
Nile-Innovator vaccine helped boost Animal Health's growth.
During 2003, the Company worked to strengthen its capital structure by
reducing its reliance on short-term debt and controlling costs. The capital
structure improvements were advanced by the sales of Amgen Inc. (Amgen) stock,
the issuance of approximately $1,020.0 million of convertible debentures and
$4,800.0 million of long-term debt, the proceeds of which were used to pay down
commercial paper, reducing the Company's reliance on short-term debt, increasing
liquidity and taking advantage of lower interest rates. While we have been
reducing our short-term debt and focusing on cost controls, the Company has
continued to make substantial investments in research and development (R&D) and
in capital investments to expand manufacturing capacity for key Company
products.
Despite the successes of 2003, in order to continue to succeed, the Company
must overcome some significant challenges over the next few years. One of the
biggest challenges is to defend the Company in the ongoing diet drug litigation
(see Note 14 to the consolidated financial statements). In this regard, we
continue to support the appropriate handling of valid claims under the national
class action settlement. At the same time, we are committed to vigorously
defending the Company and aggressively eliminating fraud and abuse in the
settlement.
In order for us to sustain the growth of our core group of products, we
must continue to meet the global demand of our customers. Two of our important
core products are Prevnar and Enbrel, both biopharmaceutical products that are
extremely complicated and difficult to manufacture. While our Company
Wyeth 59
made significant improvements in the production capabilities of Prevnar in 2003,
we continue to seek to improve manufacturing processes and overcome production
issues. The Company will continue to experience temporary supply limitations of
Prevnar throughout the first half of 2004 due to strong demand and supply
constraints. In 2003, we supplied more than 18 million doses of Prevnar, an
increase of 33% over the previous year. Overall, despite our challenges, supply
in 2004 again is expected to exceed last year's supply.
The production capability of Enbrel nearly doubled in 2003 with the
December 2002 U.S. Food and Drug Administration (FDA) approval of the Amgen
manufacturing facility in Rhode Island. The construction of the Company's Grange
Castle facility in Ireland, which remains on schedule to begin production in
2005, is critical to further expand the production of Enbrel and enable this
important product to reach even more patients throughout the world.
In July 2002, the National Institutes of Health announced that it was
discontinuing a portion of its Women's Health Initiative (WHI) study assessing
the value of combination estrogen plus progestin therapy, and in early March
2004, the portion of the study addressing estrogen-only therapy also was
discontinued. Refer to "Certain Factors That May Affect Future Results" herein
for additional discussion. The Company remains committed to women's health care
and stands behind the Premarin family products as the standard of therapy to
help women address serious menopausal symptoms. We have continued our efforts to
inform physicians and patients of the appropriate role of hormone therapy (HT)
for the short-term treatment of menopausal symptoms and have introduced new,
low-dose versions of Premarin and Prempro in 2003. Despite these efforts, sales
of the Premarin family products have declined from approximately $2,073.5
million in 2001 to $1,275.3 million in 2003. While the launch of low-dose
Premarin and Prempro has helped to moderate the decrease, sales are expected to
decline again in 2004.
Another challenge facing the Company is a near-term shortage of significant
new product introductions. To meet this challenge, we are focusing on maximizing
the strong growth potential and patent protection of our core group of
innovative products that we have introduced in recent years as well as actively
pursuing in-licensing opportunities.
Generally, the Company faces the same difficult challenges that all
research-based pharmaceutical companies are confronting, including political
pressures in countries around the world to reduce prescription drug prices;
increasingly stringent regulatory requirements that are raising the cost of drug
development and manufacturing; and uncertainties about the out-come of key
political issues in the United States regarding drug importation.
The Company's principal strategy for success, notwithstanding these
challenges, is based on R&D innovations. The Company intends to leverage its
unique breadth of knowledge and resources across three development platforms to
produce first-in-class and best-in-class therapies for significant unmet medical
needs around the world.
Results of Operations
Net Revenue
Worldwide net revenue increased 9% to $15,850.6 million for 2003. U.S. and
international consolidated net revenue increased 4% and 17%, respectively, for
2003. Worldwide net revenue increased 4% to $14,584.0 million for 2002. U.S. and
international consolidated net revenue increased 4% and 5%, respectively, for
2002.
The following table sets forth 2003, 2002 and 2001 worldwide net revenue by
reportable segment together with the percentage changes in worldwide net revenue
from prior years:
(Dollar amounts in millions) Year Ended December 31, % Increase (Decrease)
- ---------------------------- --------------------------------------------- ------------------------------
Net Revenue 2003 2002 2001 2003 vs. 2002 2002 vs. 2001
- ----------- ---- ---- ---- ------------- -------------
Pharmaceuticals $ 12,622.7 $ 11,733.3 $ 10,940.3 8% 7 %
Consumer Healthcare 2,434.5 2,197.4 2,267.2 11% (3)%
Animal Health 793.4 653.3 776.2 21% (16)%
------------- ------------- ------------- ------ -----
Consolidated Net Revenue $ 15,850.6 $ 14,584.0 $ 13,983.7 9% 4 %
============= ============= ============= ====== =====
2003 vs. 2002
Worldwide Pharmaceuticals net revenue increased 8% for 2003. Excluding the
favorable impact of foreign exchange, worldwide Pharmaceuticals net revenue
increased 4% for 2003. U.S. Pharmaceuticals net revenue increased 2% for 2003
due primarily to higher sales of Effexor, Protonix, Prevnar and Zosyn and
increased alliance revenue offset, in part, by lower sales of the Premarin
family products and Cordarone I.V. (market exclusivity ended October 2002).
Refer to "Certain Factors That May Affect Future Results" herein for additional
discussion relating to the Premarin family products.
International Pharmaceuticals net revenue increased 17% for 2003 due
primarily to higher sales of Effexor, Prevnar, Enbrel (for which the Company has
exclusive marketing rights outside of North America) and Zosyn offset, in part,
by lower sales of the Premarin family products.
Worldwide Consumer Healthcare net revenue increased 11% for 2003. Excluding
the favorable impact of foreign exchange, worldwide Consumer Healthcare net
revenue increased 8% for 2003. U.S. Consumer Healthcare net revenue increased 5%
for 2003 due primarily to higher sales of Alavert, which was introduced in the
2002 fourth quarter, and cough/cold/allergy products partially offset by lower
sales of Centrum.
60 Wyeth
International Consumer Healthcare net revenue increased 22% for 2003 due
primarily to higher sales of Centrum, Advil, Caltrate and cough/cold/allergy
products.
Worldwide Animal Health net revenue increased 21% for 2003. Excluding the
favorable impact of foreign exchange, worldwide Animal Health net revenue
increased 16% for 2003. U.S. Animal Health net revenue increased 29% for 2003
due primarily to higher sales of ProHeart 6 compared with 2002, which was
impacted by significant ProHeart 6 product returns, as well as higher sales of
the Company's West Nile-Innovator biological vaccine for horses.
International Animal Health net revenue increased 15% for 2003 due to
higher sales of pharmaceutical and biological products.
2002 vs. 2001
Worldwide Pharmaceuticals net revenue increased 7% for 2002. There was no
foreign exchange impact on worldwide Pharmaceuticals net revenue for 2002. U.S.
Pharmaceuticals net revenue increased 7% for 2002 due primarily to higher sales
of Protonix, Effexor, Rapamune and ReFacto and increased alliance revenue
offset, in part, by lower sales of the Premarin family products, Prevnar and
generic products (due to the discontinuance of certain oral generics).
International Pharmaceuticals net revenue increased 8% for 2002 due
primarily to higher sales of Effexor, Prevnar, Enbrel (for which the Company has
exclusive marketing rights outside of North America), Rapamune and ReFacto
offset, in part, by lower sales of the Premarin family products.
Worldwide Consumer Healthcare net revenue decreased 3% for 2002. There was
no foreign exchange impact on worldwide Consumer Healthcare net revenue for
2002. U.S. Consumer Healthcare net revenue decreased 5% for 2002 as a result of
lower sales of cough/cold/allergy products, Advil and Denorex, which was
divested in February 2002, partially offset by higher sales of Centrum and
initial sales of Alavert, which was introduced in the 2002 fourth quarter.
International Consumer Healthcare net revenue was flat for 2002 as lower
sales of cough/cold/allergy products and Caltrate were offset by higher sales of
Advil.
Worldwide Animal Health net revenue decreased 16% for 2002. Excluding the
negative impact of foreign exchange, worldwide Animal Health net revenue
decreased 15% for 2002. U.S. Animal Health net revenue decreased 20% due
primarily to lower sales and higher-than-projected returns of ProHeart 6 offset,
in part, by higher sales of West Nile-Innovator, which was introduced in the
2001 third quarter.
International Animal Health net revenue decreased 12% for 2002 due
primarily to lower sales of companion animal products as a result of various
manufacturing issues.
The following table sets forth significant 2003, 2002 and 2001
Pharmaceuticals, Consumer Healthcare and Animal Health worldwide net revenue by
product:
Pharmaceuticals
(In millions) 2003 2002 2001
- ------------- ---- ---- ----
Effexor $ 2,711.7 $ 2,072.3 $ 1,542.0
Protonix 1,493.3 1,070.8 561.3
Premarin family 1,275.3 1,879.9 2,073.5
Prevnar 945.6 647.5 798.2
Nutritionals 857.6 834.7 823.5
Zosyn/Tazocin 638.7 406.1 439.8
Oral contraceptives 589.2 576.3 703.4
Zoton 363.2 309.4 284.1
Enbrel 298.9 158.8 93.9
BeneFIX 248.1 219.2 212.8
ReFacto 224.2 197.5 147.3
Synvisc 222.6 212.5 188.3
Ativan 211.5 217.2 232.7
Rapamune 169.8 129.7 70.2
Minocin 97.4 117.1 122.1
Meningitec 63.5 90.1 78.6
Ziac/Zebeta 44.1 64.1 70.0
Cordarone 15.0 283.2 269.6
Generics -- 187.4 309.8
Alliance revenue 654.4 418.8 322.4
Other 1,498.6 1,640.7 1,596.8
------------- ------------- -------------
Total Pharmaceuticals $ 12,622.7 $ 11,733.3 $ 10,940.3
============= ============= =============
Consumer Healthcare
(In millions) 2003 2002 2001
- ------------- ---- ---- ----
Centrum $ 545.6 $ 516.2 $ 503.3
Advil 450.9 442.7 453.7
Other cough/cold/allergy products 390.3 352.3 420.6
Caltrate 153.4 142.4 148.3
Advil Cold & Sinus 134.7 111.6 109.1
ChapStick 113.9 111.3 110.0
Solgar 105.1 100.1 100.3
Alavert 81.6 8.5 --
Other 459.0 412.3 421.9
------------- ------------- -----------
Total Consumer Healthcare $ 2,434.5 $ 2,197.4 $ 2,267.2
============= ============= ===========
Animal Health
(In millions) 2003 2002 2001
- ------------- ---- ---- ----
Livestock products $ 329.2 $ 293.7 $ 311.1
Companion animal products(1) 226.7 158.0 321.1
Equine products(2) 147.2 117.7 59.0
Poultry products 90.3 83.9 85.0
---------- ---------- ----------
Total Animal Health $ 793.4 $ 653.3 $ 776.2
========== ========== ==========
(1) Companion animal products include net revenue from ProHeart products of
$38.1, $(18.8) and $88.9 for 2003, 2002 and 2001, respectively. Negative net
revenue in 2002 resulted from significant ProHeart returns.
(2) Equine products include West Nile-Innovator net revenue of $64.3, $51.5 and
$8.4 for 2003, 2002 and 2001, respectively.
Wyeth 61
The following table sets forth the percentage changes in 2003 and 2002
worldwide net revenue by reportable segment and geographic area compared with
the prior year, including the effect volume, price and foreign exchange had on
these percentage changes:
% Increase (Decrease) % Increase (Decrease)
Year Ended December 31, 2003 Year Ended December 31, 2002
---------------------------------------- ----------------------------------------
Foreign Total Net Foreign Total Net
Volume Price Exchange Revenue Volume Price Exchange Revenue
------ ----- -------- --------- ------ ----- -------- ---------
Pharmaceuticals
United States (5)% 7% -- 2% (1)% 8% -- 7%
International 4% 2% 11% 17% 6% 2% -- 8%
----- ----- ----- ----- ----- ----- ----- -----
Total (1)% 5% 4% 8% 2% 5% -- 7%
Consumer Healthcare
United States 3% 2% -- 5% (6)% 1% -- (5)%
International 9% 3% 10% 22% (1)% 2% (1)% --
----- ----- ----- ----- ----- ----- ----- -----
Total 6% 2% 3% 11% (4)% 1% -- (3)%
Animal Health
United States 24% 5% -- 29% (22)% 2% -- (20)%
International 5% 1% 9% 15% (8)% (2)% (2)% (12)%
----- ----- ----- ----- ----- ----- ----- -----
Total 14% 2% 5% 21% (15)% -- (1)% (16)%
Total
United States (2)% 6% -- 4% (2)% 6% -- 4%
International 4% 2% 11% 17% 4% 1% -- 5%
----- ----- ----- ----- ----- ----- ----- -----
Total -- 5% 4% 9% -- 4% -- 4%
===== ===== ===== ===== ===== ===== ===== =====
Operating Expenses
2003 vs. 2002
Cost of goods sold, as a percentage of Net revenue, increased to 27.6% for 2003
compared with 26.9% for 2002. Excluding alliance revenue, cost of goods sold, as
a percentage of net sales, for 2003 was 28.8%, a 1.1% increase from 27.7% in
2002. The decline in margin was due primarily to a less profitable product mix
as a result of lower sales of higher margin products (e.g., Premarin family and
Cordarone I.V.) and higher sales of lower margin products (e.g., Protonix, Zosyn
and Enbrel) offset, in part, by increased sales of higher margin Effexor and
Prevnar in the Pharmaceuticals segment. Gross margin also was negatively
impacted by higher royalty costs associated with the launch of Alavert in the
Consumer Healthcare segment and inventory write-offs related to ReFacto, the
Premarin family products and FluMist in the Pharmaceuticals segment, combined
with increased costs associated with addressing various manufacturing issues.
The Animal Health segment margin improved due primarily to a more profitable
product mix as a result of higher domestic sales of West Nile-Innovator combined
with the non-recurrence of significant ProHeart 6 product returns which occurred
during 2002.
Selling, general and administrative expenses, as a percentage of Net
revenue, increased to 34.5% for 2003 compared with 34.4% for 2002. The slightly
higher ratio of selling, general and administrative expenses resulted from
higher marketing expenses in the Pharmaceuticals and Consumer Healthcare
segments and higher expenses associated with increased general insurance and
employee benefit costs.
Research and development expenses increased 1% for 2003. The increase was
partially due to higher clinical grant spending, primarily in the field of
women's health care and infectious diseases, and higher cost-sharing
expenditures relating to pharmaceutical collaborations offset, in part, by lower
other research operating expenses (including lower chemical and material costs).
Pharmaceuticals research and development expenditures accounted for 93% of total
research and development expenditures in both 2003 and 2002. Pharmaceuticals
research and development expenses, as a percentage of worldwide Pharmaceuticals
net revenue, exclusive of nutritional sales and alliance revenue, were 17% and
19% in 2003 and 2002, respectively. The increase in research and development
expenses also was due to higher expenditures relating to Animal Health line
extensions and combination product projects.
2002 vs. 2001
Cost of goods sold, as a percentage of Net revenue, increased to 26.9% for 2002
compared with 24.2% for 2001. Excluding alliance revenue, cost of goods sold, as
a percentage of net sales, for 2002 was 27.7%, a 2.9% increase from 24.8% in
2001. The decline in margin was due primarily to a less profitable product mix
as a result of lower sales of higher margin products (e.g., Premarin family and
Prevnar) and higher sales of lower margin products (e.g., Protonix, ReFacto and
Centrum products) in both the Pharmaceuticals and Consumer Healthcare segments,
combined with increased costs associated with addressing various manufacturing
issues, as well as significant product returns in the Animal Health segment
related to ProHeart 6.
Selling, general and administrative expenses, as a percentage of Net
revenue, decreased to 34.4% for 2002 compared with 34.9% for 2001 (excluding the
effect of goodwill amortization from 2001). The slightly lower ratio of selling,
general and administrative expenses resulted from significant cost-containment
efforts directed specifically at marketing expenses in the Pharmaceuticals,
Consumer Healthcare and Animal Health segments offset, in part, by higher
selling expenses related to an expansion in the global sales force.
62 Wyeth
Research and development expenses increased 11% for 2002 due primarily to
increased headcount, clinical grant spending, cost-sharing expenditures relating
to pharmaceutical collaborations and other research operating expenses
(including higher chemical and material costs) offset, in part, by lower
payments under licensing agreements. Pharmaceuticals research and development
expenditures accounted for 93% and 94% of total research and development
expenditures in 2002 and 2001, respectively. Pharmaceuticals research and
development expenses, as a percentage of worldwide Pharmaceuticals net revenue,
exclusive of nutritional sales and alliance revenue, were 19% and 18% in 2002
and 2001, respectively.
Interest Expense and Other Income
2003 vs. 2002
Interest expense, net decreased 49% for 2003 due primarily to lower weighted
average debt outstanding compared with 2002 levels. Weighted average debt
outstanding during 2003 and 2002 was $7,346.7 million and $10,155.2 million,
respectively. The decrease in interest expense, net also was affected by higher
capitalized interest resulting from spending for long-term capital projects in
process. These projects include a new biopharmaceutical and vaccine
manufacturing facility in Ireland, as well as the expansion of an existing
manufacturing facility in Ireland.
Other income, net decreased 13% for 2003 due primarily to the
non-recurrence of income received in 2002 in connection with the sale of certain
assets relating to the generic human injectables product line, which resulted in
a gain of $172.9 million; the non-recurrence of a 2002 settlement regarding
price fixing by certain vitamin suppliers; and higher foreign exchange losses
offset, in part, by higher gains on sales of other non-strategic Pharmaceuticals
and Consumer Healthcare product rights.
2002 vs. 2001
Interest expense, net increased 38% for 2002 due primarily to lower interest
income compared with 2001. Weighted average debt outstanding during 2002 and
2001 was $10,155.2 million and $7,283.7 million, respectively. However, the
impact of higher weighted average debt outstanding was offset by lower interest
rates on outstanding commercial paper and capitalized interest relating to
capital projects.
Other income, net increased 40% for 2002 primarily as a result of the
Company completing the sale of certain of its assets relating to the generic
human injectables product line, which resulted in a gain of $172.9 million. In
addition, the Company received proceeds from a settlement regarding price fixing
by certain vitamin suppliers offset, in part, by lower equity income and the
non-recurrence of income received in 2001 related to the divestiture of certain
product rights.
2003, 2002 and 2001 Significant Items
Gains Related to Immunex/Amgen Common Stock Transactions
During the first quarter of 2003, the Company completed the sales of the
remaining 31,235,958 shares of Amgen common stock held by the Company at
December 31, 2002. These remaining shares netted proceeds of $1,579.9 million
and resulted in a gain of $860.6 million ($558.7 million after-tax or $0.42 per
share-diluted).
In the 2002 fourth quarter, the Company recorded a gain of $1,454.6 million
($943.4 million after-tax or $0.71 per share-diluted) from the sales of
67,050,400 shares of Amgen common stock, received in connection with Amgen's
acquisition of Immunex Corporation (Immunex), which generated net proceeds of
$3,250.8 million.
In the 2002 third quarter, the Company recorded a gain of $2,627.6 million
($1,684.7 million after-tax or $1.26 per share-diluted) related to the initial
acquisition of Immunex by Amgen. The gain represented the excess of $1,005.2
million in cash plus the fair value of 98,286,358 Amgen shares received,
$2,500.1 million, over the Company's book basis of its investment in Immunex and
certain transaction costs. The gain on the shares exchanged was based on the
quoted market price of Amgen common stock on July 15, 2002 (the closing date)
reduced by an overall discount rate based on valuations provided by independent
valuation consultants (see Note 2 to the consolidated financial statements).
Diet Drug Litigation Charges
The Company recorded a charge of $2,000.0 million ($1,300.0 million after-tax or
$0.97 per share-diluted) in 2003, a charge of $1,400.0 million ($910.0 million
after-tax or $0.68 per share-diluted) in 2002 and a charge of $950.0 million
($615.0 million after-tax or $0.46 per share-diluted) in 2001 to increase the
reserve relating to the Pondimin (which in combination with phentermine, a
product that was not manufactured, distributed or sold by the Company, was
commonly referred to as "fen-phen") and Redux diet drug litigation, bringing the
total of the charges taken to date to $16,600.0 million. The $3,516.5 million
reserve at December 31, 2003 represents management's best estimate of the
minimum aggregate amount anticipated to cover payments in connection with the
settlement trust (the Trust), up to its cap, initial opt outs, primary pulmonary
hypertension (PPH) claims, Intermediate, Back-End or Sixth Amendment opt outs
(collectively, the "downstream" opt outs), and the Company's legal fees related
to the diet drug litigation. Due to its inability to estimate the ultimate
number of valid downstream opt outs, and the merits and value of their claims,
as well as the inherent uncertainty surrounding any litigation, the Company is
unable to estimate the amount of any additional financial exposure represented
by the downstream opt out litigation. However, the amount of financial exposure
beyond that which has been recorded could be significant (see Note 14 to the
consolidated financial statements and the "Liquidity, Financial Condition and
Capital Resources" section herein for further discussion relating to the
Company's additional financing requirements for future diet drug litigation
exposure).
Special Charges
2003 Restructuring and Related Asset Impairments
In December 2003, the Company recorded a special charge for manufacturing
restructurings and related asset impairments of $487.9 million ($367.6 million
after-tax or $0.28 per share-diluted). The restructuring and related asset
impairments impacted only the Pharmaceuticals segment and were recorded to
recognize the costs of closing certain manufacturing facilities, as well as the
elimination of certain positions at the Company's facilities. These
restructuring initiatives were designed to achieve
Wyeth 63
optimal efficiencies and reduce production costs in response to changes in
demand projections for certain products.
Specifically, the Company has decided to close its pharmaceutical plant in
Singapore and rationalize its network of collection sites for Premarin-related
raw materials as a result of lower volume in the Premarin family products.
Restructuring charges of $208.2 million were recorded to recognize the costs of
closing the Singapore manufacturing facility, the elimination of certain
positions at the facility and contract settlement costs related to purchase
commitments with suppliers. Approximately 190 positions were identified for
elimination at the Singapore facility. Substantially all of the employee
terminations are expected to be completed during the 2004 first quarter. Also in
December 2003, the Company recorded fixed and intangible asset impairment
charges of $108.6 million related to rhBMP-2 and FluMist as a result of reduced
demand projections and announced that manufacturing operations at its St. Louis,
Missouri biopharmaceutical facility would be discontinued due to a decline in
current and projected demand for ReFacto, the Company's treatment for hemophilia
A. Total charges of $171.1 million for restructuring and asset impairments
relate to the closure of the St. Louis facility (see Note 3 to the consolidated
financial statements).
Debt Extinguishment Costs
In December 2003, the Company recorded a special charge of $152.0 million ($98.8
million after-tax or $0.07 per share-diluted) related to the early
extinguishment of debt in connection with the repurchase of certain Senior
Notes. The costs relate primarily to the excess of prepayment premiums and
principal over the carrying value of the debt retired and the related write-off
of debt issuance costs (see Note 6 to the consolidated financial statements).
2002 Restructuring and Related Asset Impairments
In the 2002 fourth quarter, the Company recorded a special charge for
restructuring and related asset impairments of $340.8 million ($233.5 million
after-tax or $0.18 per share-diluted). The restructuring charge and related
asset impairments were recorded to recognize the costs of closing certain
manufacturing facilities and two research facilities, as well as the elimination
of certain positions at the Company's facilities. The closing of the
manufacturing and research facilities and reduction of sales and
administrative-related positions cover approximately 3,150 employees worldwide
(see Note 3 to the consolidated financial statements).
Income before Taxes
The following table sets forth 2003, 2002 and 2001 worldwide income before taxes
by reportable segment together with the percentage changes in worldwide income
before taxes from prior years:
(Dollar amounts in millions) Year Ended December 31, % Increase (Decrease)
- ---------------------------- -------------------------------------- -----------------------------
Income before Taxes(1) 2003 2002 2001 2003 vs. 2002 2002 vs. 2001
- --------------------------- ---- ---- ---- ------------- -------------
Pharmaceuticals $ 3,798.5 $ 3,441.4 $ 3,340.2 10% 3%
Consumer Healthcare 592.4 608.0 592.1 (3)% 3%
Animal Health 127.4 64.1 163.3 99% (61)%
Corporate(2) (2,156.7) 1,983.7 (1,226.9) -- --
---------- ----------- ----------- ---- ----
Total(3) $ 2,361.6 $ 6,097.2 $ 2,868.7 (61)% --
========== =========== =========== ==== ====
(1) Income before taxes included goodwill amortization for 2001 as follows:
Pharmaceuticals-$105.5, Consumer Healthcare-$23.7 and Animal Health-$31.3.
The Company ceased amortizing goodwill in accordance with SFAS No. 142
effective January 1, 2002. Excluding goodwill amortization from the 2001
results, Pharmaceuticals, Consumer Healthcare and Animal Health income
before taxes decreased less than 1%, 1% and 67%, respectively, for 2002.
(2) 2003, 2002 and 2001 Corporate included litigation charges of $2,000.0,
$1,400.0 and $950.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drugs Redux or Pondimin
(see Note 14 to the consolidated financial statements). The charges related
to the Pharmaceuticals reportable segment.
2003 Corporate also included:
- A gain of $860.6 relating to the sales of the Company's remaining Amgen
common stock holdings (see Note 2 to the consolidated financial
statements). The gain related to the Pharmaceuticals reportable segment.
- A special charge of $639.9 for manufacturing restructurings and related
asset impairments and the cost of debt extinguishment (see Note 3 to the
consolidated financial statements). The charge related to the reportable
segments as follows: Pharmaceuticals-$487.9 and Corporate-$152.0.
2002 Corporate also included:
- A gain of $2,627.6 relating to the acquisition of Immunex by Amgen. The
gain represents the excess of $1,005.2 in cash plus the fair value of
98,286,358 Amgen shares received, $2,500.1, over the Company's book basis
of its investment in Immunex and certain transaction costs (see Note 2 to
the consolidated financial statements). The gain related to the
Pharmaceuticals reportable segment.
- A gain of $1,454.6 from the sales of 67,050,400 shares of Amgen common
stock. The gain was determined by comparing the basis of the shares sold,
$1,782.7, with the net proceeds received, $3,250.8, reduced by certain
related expenses (see Note 2 to the consolidated financial statements).
The gain related to the Pharmaceuticals reportable segment.
- A special charge of $340.8 for restructuring and related asset
impairments (see Note 3 to the consolidated financial statements). The
charge related to the reportable segments as follows:
Pharmaceuticals-$291.5, Consumer Healthcare-$17.1, Animal Health-$16.1
and Corporate-$16.1.
Excluding the 2003, 2002 and 2001 litigation charges, 2003 and 2002 gains
relating to Immunex/Amgen common stock transactions and 2003 and 2002
special charges, Corporate expenses, net increased 6% and 29% for 2003 and
2002, respectively.
(3) Excluding the 2003, 2002 and 2001 litigation charges, 2003 and 2002 gains
relating to Immunex/Amgen common stock transactions and 2003 and 2002
special charges, total income before taxes increased 10% for 2003 and
decreased 2% for 2002.
64 Wyeth
The following explanations of changes in income before taxes, by reportable
segment, for 2003 compared with 2002 and 2002 compared with 2001, exclude items
listed in footnote (2) to the table above.
Pharmaceuticals
Worldwide Pharmaceuticals income before taxes increased 10% for 2003 due
primarily to higher worldwide net revenue offset, in part, by lower gross
margins earned on worldwide net revenue, slightly higher research and
development expenses, higher selling, general and administrative expenses and
lower other income, net. Lower gross margins were due primarily to a less
profitable product mix and inventory write-offs.
Worldwide Pharmaceuticals income before taxes decreased less than 1% for
2002, excluding goodwill amortization from the 2001 results, due to higher cost
of goods sold, as a percentage of net revenue, and higher research and
development expenses offset, in part, by higher worldwide net revenue.
Consumer Healthcare
Worldwide Consumer Healthcare income before taxes decreased 3% for 2003 due
primarily to lower gross profit margins earned on worldwide sales, lower other
income, net and higher selling, general and administrative expenses as a result
of increased marketing expenses associated with the launch of Alavert. Lower
other income, net was due primarily to the non-recurrence of income received in
2002 in connection with a class action settlement gain related to price fixing
by certain vitamin suppliers.
Worldwide Consumer Healthcare income before taxes decreased 1% for 2002,
excluding goodwill amortization from the 2001 results, due primarily to lower
U.S. sales and higher research and development expenses offset, in part, by
higher other income, net (primarily attributable to the proceeds received from a
settlement regarding price fixing by certain vitamin suppliers).
Animal Health
Worldwide Animal Health income before taxes increased 99% for 2003 due primarily
to higher worldwide sales and higher gross margins earned on worldwide sales
offset, in part, by higher selling, general and administrative expenses. Gross
margins improved during 2003 due primarily to a more profitable product mix as a
result of higher domestic sales of West Nile-Innovator combined with the
non-recurrence of significant ProHeart 6 product returns in 2002.
Worldwide Animal Health income before taxes decreased 67% for 2002,
excluding goodwill amortization from the 2001 results, due primarily to lower
worldwide sales, significant ProHeart 6 product returns, lower gross margins and
higher selling, general and administrative expenses. Lower gross margins were
due primarily to unfavorable product mix and unfavorable manufacturing variances
as a result of reduced sales volume worldwide.
Corporate
Corporate expenses, net increased 6% for 2003 due primarily to higher general
and administrative expenses offset, in part, by lower interest expense due
primarily to lower weighted average debt outstanding compared with 2002 levels.
Corporate expenses, net increased 29% for 2002 due primarily to higher general
and administrative expenses and interest expense, net resulting from lower
interest income during 2002.
Effective Tax Rate
The effective tax rates for 2003, 2002 and 2001 were 21.3%, 21.1% and 23.3%,
respectively (excluding the significant items identified above and the effect of
goodwill amortization in 2001). The downward trend in the effective tax rates
from 2001 compared with 2002 and 2003 was due primarily to an increased benefit
from manufacturing in lower tax jurisdictions.
Net Income and Diluted Earnings per Share
As Reported
Net income and diluted earnings per share in 2003 decreased to $2,051.2 million
and $1.54, respectively, compared with $4,447.2 million and $3.33 for 2002.
Before Certain Significant Items
Net income before certain significant items and diluted earnings per share
before certain significant items exclude from net income and diluted earnings
per share, respectively, the impact of additional charges recorded to increase
the reserve relating to the Pondimin (which in combination with phentermine, a
product that was not manufactured, distributed or sold by the Company, was
commonly referred to as "fen-phen") and Redux diet drug litigation, the gains
related to the receipt and subsequent liquidation of Amgen shares received in
connection with Amgen's acquisition of Immunex, restructuring and asset
impairment charges and debt extinguishment costs.
The Company's management uses both generally accepted accounting principles
(GAAP) and non-GAAP measures to manage and evaluate the Company's performance.
The Company's management believes it is appropriate to disclose these non-GAAP
measures to assist investors with analyzing business performance and trends.
However, these measures should not be considered in isolation or as a substitute
for the results of operations and diluted earnings per share prepared in
accordance with GAAP. The additional diet drug charges increase the reserve
balance for a continuing legal matter that first resulted in a charge in 1999
and have been excluded due to their nature and magnitude. The gains related to
the Immunex/Amgen common stock transactions have been excluded due to the fact
that the Company had not previously nor does it currently hold a position for
investment purposes in an entity that, if acquired by another entity, would
impact the Company's financial position or results of operations to the
significant extent of the Immunex/Amgen common stock transactions. The special
charges, which include costs related to restructurings, asset impairments and
debt extinguishment have been excluded as the Company's management does not
consider these charges to be indicative of continuing operating results.
Wyeth 65
A reconciliation of net income before certain significant items and diluted
earnings per share before certain significant items to net income and diluted
earnings per share as reported under GAAP is presented in the following table:
(Dollar amounts in millions except per share amounts) Net Income Diluted Earnings per Share
---------- --------------------------
Year Ended December 31, 2003 2002 2001 2003 2002 2001
- ----------------------------------------------------- ---- ---- ---- ---- ---- ----
Net income and diluted earnings per share before certain
significant items $ 3,258.9 $ 2,962.6 $ 2,900.3 $ 2.44 $ 2.22 $ 2.18
Gains related to Immunex/Amgen
common stock transactions 558.7 2,628.1 -- 0.42 1.97 --
Redux and Pondimin diet drug
litigation charges (1,300.0) (910.0) (615.0) (0.97) (0.68) (0.46)
Special charges:
Restructuring charges and related
asset impairments (367.6) (233.5) -- (0.28) (0.18) --
Debt extinguishment costs (98.8) -- -- (0.07) -- --
--------- --------- --------- ------ -------- -------
Net income and diluted earnings per share, as reported $ 2,051.2 $ 4,447.2 $ 2,285.3 $ 1.54 $ 3.33 $ 1.72
========= ========= ========= ====== ======== =======
Net income and diluted earnings per share, before certain significant items
presented above, each increased 10% in 2003 to $3,258.9 million and $2.44,
respectively, compared with $2,962.6 million and $2.22 in 2002. The increases
were due primarily to higher net revenue and lower interest expense offset, in
part, by higher cost of goods sold, as a percentage of net revenue, higher
selling, general and administrative expenses and lower other income, net.
The higher cost of goods sold, as a percentage of net revenue, was due to a
less profitable product mix and inventory write-offs related to ReFacto, the
Premarin family products and FluMist. The less profitable product mix was
primarily a result of lower sales of higher margin products, including the
Premarin family products and Cordarone I.V. and higher sales of lower margin
products such as Protonix, Zosyn and Enbrel. The higher selling, general and
administrative expenses were due primarily to higher marketing expenses, higher
expenses associated with increased general insurance and employee benefit costs.
Lower other income, net was primarily due to the non-recurrence of income
received in 2002 in connection with the sale of certain assets related to the
generic human injectables product line, which resulted in a gain of $172.9
million ($108.9 million after-tax or $0.08 per share-diluted) and the
non-recurrence of proceeds received from a 2002 settlement regarding price
fixing by certain vitamin suppliers.
On January 1, 2002, the Company adopted SFAS No. 142, which eliminated the
amortization of goodwill. Excluding the after-tax goodwill amortization of
$153.9 million or $0.12 per share-diluted from the 2001 results, as well as the
2002 and 2001 certain significant items listed in the table above, net income
and diluted earnings per share in 2002 each decreased 3% to $2,962.6 million and
$2.22, respectively, compared with $3,054.2 million and $2.30 in 2001. The
decreases were due primarily to higher cost of goods sold, as a percentage of
net revenue, and higher research and development expenses offset by lower
selling, general and administrative expenses and higher other income, net.
For further details related to the items listed in the table above, refer
to the discussion of "2003, 2002 and 2001 Significant Items" herein.
Critical Accounting Policies and Estimates
The consolidated financial statements are presented in accordance with
accounting principles that are generally accepted in the United States. All
professional accounting standards effective as of December 31, 2003 have been
taken into consideration in preparing the consolidated financial statements. The
preparation of the consolidated financial statements requires estimates and
assumptions that affect the reported amounts of assets, liabilities, revenues,
expenses and related disclosures. Some of those estimates are subjective and
complex, and, therefore, actual results could differ from those estimates. An
accounting policy is deemed to be critical if it requires an accounting estimate
to be made based on assumptions about matters that are highly uncertain at the
time the estimate is made, and if different estimates that reasonably could have
been used, or changes in the accounting estimates that are reasonably likely to
occur periodically, could materially impact the financial statements. Management
believes the following critical accounting policies reflect its more significant
estimates and assumptions used in the preparation of the Company's consolidated
financial statements:
- Rebates and sales incentives, which are deducted to arrive at Net
revenue, are offered to customers based upon volume purchases, the
attainment of market share levels, government mandates, coupons and
consumer discounts. Rebates and sales incentives accruals, included in
Accrued expenses, are established at the later of a) the date at which
the related revenue is recorded or b) the date at which the incentives
are offered. The Company continually monitors the adequacy
66 Wyeth
of the accruals by comparing the actual payments to the estimates used
in establishing the accrual.
- The Company is involved in various legal proceedings, including product
liability and environmental matters that arise from time to time in the
ordinary course of business. These include allegations of injuries
caused by drugs and other over-the-counter products, including Pondimin,
Redux, Robitussin, Dimetapp and Prempro, among others. The estimated
costs the Company expects to pay in these cases (excluding costs
associated with the Redux and Pondimin diet drug litigation, see Note 14
to the consolidated financial statements) are accrued when the liability
is considered probable and the amount can be reasonably estimated. In
assessing the estimated costs, the Company considers many factors,
including past litigation experience, scientific evidence and the
specifics of each matter. Prior to November 2003, the Company was
self-insured for product liability risks with excess coverage on a
claims-made basis from various insurance carriers in excess of the
self-insured amounts and subject to certain policy limits. Effective
November 2003, the Company became completely self-insured for product
liability risks.
In addition, the Company has responsibility for environmental, safety
and cleanup obligations under various local, state and federal laws,
including the Comprehensive Environmental Response, Compensation and
Liability Act, commonly known as Superfund. In many cases, future
environmental-related expenditures cannot be quantified with a
reasonable degree of accuracy. As investigations and cleanups proceed,
environmental-related liabilities are reviewed and adjusted as
additional information becomes available.
- The Company applies an asset and liability approach to accounting for
income taxes. Deferred tax liabilities and assets are recognized for the
future tax consequences of temporary differences between the financial
statement and tax bases of assets and liabilities using enacted tax
rates in effect for the year in which the differences are expected to
reverse. The recoverability of deferred tax assets is dependent upon the
Company's assessment that it is more likely than not that sufficient
future taxable income will be generated in the relevant tax jurisdiction
to realize the deferred tax asset. In the event the Company determines
future taxable income will not be sufficient to utilize the deferred tax
asset, a valuation allowance is recorded. As of December 31, 2003,
valuation allowances have been established for certain environmental
liabilities and operating accruals in certain foreign jurisdictions with
little or no history of generating taxable income. In addition, the
Company records deferred income taxes on foreign subsidiaries' earnings
that are not considered to be permanently invested in those
subsidiaries.
- On an annual basis, the Company performs an internal study of actuarial
assumptions. Based on this study, the Company determines the appropriate
discount rate and expected long-term rate of return on plan assets for
its pension plans. In 2003, the discount rate used to determine the
Company's benefit obligation was decreased by 50 basis points to 6.25%,
while the expected rate of return on plan assets was maintained at
9.00%, consistent with the prior year. The net periodic benefit cost for
the Company's U.S. pension plans is expected to decrease by
approximately $30.0 million to $40.0 million in 2004 compared with 2003
due to positive returns on plan assets and contributions to the pension
trust partially offset by the increase in net periodic benefit cost
associated with the decrease in the discount rate.
The Company also reviews the principal actuarial assumptions relating to
its other postretirement benefit plans on an annual basis. In response
to the recent increase in health care costs in the United States, the
Company has increased the health care cost trend rate for 2003 to 11.0%
from 9.5% for 2002. This growth rate, ultimately, is expected to
decrease to 5% for 2008 and remain constant thereafter. In reviewing
postretirement claims data and other related assumptions, the Company
believes that this trend rate appropriately reflects the trend aspects
of the Company's other postretirement benefit plans as of December 31,
2003. Similar to the pension plans discussed above, in 2003, the
discount rate used to determine the Company's benefit obligation was
decreased by 50 basis points to 6.25%. 2004 net periodic benefit cost
for other postretirement benefit plans is expected to increase by
approximately $5.0 million to $10.0 million compared with 2003 primarily
due to the selection of the health care cost trend rate and the increase
in net periodic benefit cost associated with the decrease in the
discount rate offset, in part, by changes the Company has made to its
other postretirement benefit plans.
The Company has not participated in, nor has created, any off-balance
sheet financing or other off-balance sheet special purpose entities other than
operating leases. In addition, the Company has not entered into any derivative
financial instruments for trading purposes and uses derivative financial
instruments solely for managing its exposure to certain market risks from
changes in foreign currency exchange rates and interest rates.
Management has discussed the development and selection of these critical
accounting policies and estimates with the Audit Committee of the Board of
Directors, and the Audit Committee has reviewed the Company's disclosure
presented above.
Liquidity, Financial Condition and Capital Resources
Cash and cash equivalents increased $3,126.2 million, and total debt increased
by $1,238.3 million in 2003, including the fair value change of interest rate
swaps. The activity of these cash flows during 2003 related primarily to the
following items:
- Proceeds of $1,579.9 million related to the sales of the Company's
remaining 31,235,958 shares of Amgen common stock.
- Proceeds of $5,820.0 million related to the issuances of $1,800.0
million and $3,000.0 million of Senior Notes (Notes) during February and
December 2003, respectively,
Wyeth 67
and the issuance of $1,020.0 million of Convertible Senior Debentures
(Debentures) during December 2003.
- An increase in accounts payable and accrued expenses of $469.7 million
(excluding the 2003 diet drug provision and the effect of foreign
exchange) primarily related to timing of payments and increased employee
benefit accruals.
These proceeds were partially offset by the following cash uses:
- Payments of $434.2 million related to the Pondimin (which in combination
with phentermine, a product that was not manufactured, distributed or
sold by the Company, was commonly referred to as "fen-phen") and Redux
litigation. As discussed in Note 14 to the consolidated financial
statements, during 1999, the Company announced a nationwide class action
settlement to resolve litigation brought against the Company regarding
the use of the diet drugs Redux or Pondimin. Payments into the Trust may
continue, if necessary, until 2018. Additionally, payments of $535.2
million were added to the security fund in 2003, which was established
during 2002 as required by the settlement. Payments made to date and
future payments related to the diet drug litigation are anticipated to
be financed through existing cash resources, cash flows from operating
activities and commercial paper borrowings (if available), as well as
term debt financings and international earnings remitted back to the
United States, if necessary.
- Capital expenditures of $1,908.7 million due primarily to new production
capacity expansion worldwide, including biotechnology facilities,
research and development facilities, and the improvement of compliance
of U.S. technical operations and product supply processes. The Company
expects capital expenditures in 2004 to be slightly lower compared with
2003 spending levels.
- Repayments of $3,787.1 million of commercial paper and $691.1 million of
long-term debt related to the partial redemption of the Company's
$1,000.0 million aggregate principal amount of 7.90% Notes due 2005.
These repayments were made using a portion of the proceeds received in
connection with the above noted 2003 debt issuances.
- Dividends totaling $1,223.2 million consisting primarily of the
Company's annual common stock dividend of $0.92 per share.
- Contributions to fund the Company's defined benefit pension plans
totaling $230.8 million.
- An increase in inventories of $245.5 million (excluding the effect of
foreign exchange) primarily related to improved manufacturing output for
products, which had supply constraints throughout 2003.
Total debt: At December 31, 2003, the Company had outstanding $9,589.3 million
in total debt, which consisted of notes payable and other debt. The Company had
no commercial paper outstanding as of December 31, 2003. Current debt at
December 31, 2003, classified as Loans payable, consisted of $1,512.8 million of
notes payable and other debt that are due within one year. The Company was in
compliance with all debt covenants as of December 31, 2003.
As of December 31, 2003, the Company had net debt of $1,469.0 million that
was calculated as total debt of $9,589.3 million reduced by liquid assets
totaling $8,120.3 million, which consisted of cash and cash equivalents,
marketable securities and the security fund deposits primarily included in Other
current assets including deferred taxes.
On October 24, 2003, Fitch downgraded the Company's long-term rating to A-
from A and its short-term rating to F-2 from F-1. As a result of the short-term
credit rating downgrade by Fitch, the Company's commercial paper, which
previously traded in the Tier 1 commercial paper market, would trade in the Tier
2 commercial paper market. Subsequently, on December 4, 2003, Fitch affirmed the
Company's new ratings. In addition, on December 4, 2003, Moody's affirmed the
Company's P-2 short-term rating and downgraded the Company's long-term rating to
Baa1. Finally, on December 8, 2003, Standard & Poor's (S&P) affirmed the
Company's A-1 short-term and A long-term ratings. As a result of Moody's
long-term credit rating downgrade, the Company will incur incremental annual
interest expense of $9.5 million beginning in 2004 on $3,800.0 million of Notes.
The following represents the Company's credit ratings as of December 31, 2003:
Moody's S&P Fitch
------- --- -----
Short-term debt P-2 A-1 F-2
Long-term debt Baa1 A A-
Outlook Negative Negative Negative
Last rating update December 4,2003 December 8,2003 December 4, 2003
Additional Liquidity, Financial Condition and Capital Resource Information
At December 31, 2003, the carrying value of cash equivalents approximated fair
value due to the short-term, highly liquid nature of cash equivalents, which
have maturities of three months or less when purchased. Interest rate
fluctuations would not have a significant effect on the fair value of cash
equivalents held by the Company.
In March 2003, the Company's $3,000.0 million credit facility matured.
Concurrent with this maturity, the Company entered into new credit facilities
totaling $2,700.0 million. These facilities are composed of a $1,350.0 million,
364-day credit facility and a $1,350.0 million, three-year facility. The credit
facilities contain substantially identical financial and other covenants,
representations, warranties, conditions and default provisions as the matured
facility. In February 2004, the Company replaced its $1,350.0 million, 364-day
credit facility entered into in March 2003 with a $1,747.5 million, five-year
facility.
In December 2003, the Company completed the redemption of $691.1 million of
its $1,000.0 million aggregate principal amount of 7.90% Notes due 2005,
resulting in $308.9 million in remaining Notes due 2005 outstanding at December
31, 2003, which were classified as Long-term debt. In addition, the Company
exercised a make-whole call option on its $1,000.0 million aggregate principal
amount of 6.25% Notes due 2006. The redemption period for the make-whole call
option ended on January 12, 2004, and, as a result, as of December 31, 2003 the
$1,000.0 million aggregate principal amount of the 6.25% Notes due 2006 were
classified as Loans payable. On January 12, 2004,
68 Wyeth
the $1,000.0 million Notes due 2006 were redeemed in full. In connection with
the Note repurchases, the Company incurred early debt extinguishment costs of
$152.0 million, which primarily relate to the excess of prepayment premiums and
principal over the carrying value of the debt retired and the related write-off
of debt issuance costs.
In order to fund the Note repurchases, and for other general purposes, the
Company issued $3,000.0 million of Notes in December 2003 as follows:
- $1,750.0 million 5.500% Notes due February 1, 2014
- $500.0 million 6.450% Notes due February 1, 2024
- $750.0 million 6.500% Notes due February 1, 2034
Concurrent with the offering of Notes described above, on December 16,
2003, the Company completed the private placement of $1,020.0 million aggregate
principal amount of Debentures due January 15, 2024 through an offering to
qualified institutional buyers pursuant to Rule 144A under the Securities Act of
1933, as amended.
Also during February 2003, the Company issued $1,800.0 million of Notes.
The issuance consisted of two tranches of Notes, as follows:
- $300.0 million 4.125% Notes due March 1, 2008
- $1,500.0 million 5.25% Notes due March 15, 2013
The Company refinanced its debt to allow for greater financial flexibility
by obtaining lower interest rates and moving debt maturities out generally 10 or
more years. As such, the Company expects to be less reliant on the commercial
paper markets in the near term.
The interest rate payable on each series of Notes described above,
including the Notes issued in March 2001 (see Note 6 to the consolidated
financial statements) is subject to a 0.25-percentage-point increase per level
of downgrade in the Company's credit rating by Moody's or S&P. There is no
adjustment to the interest rate payable on each series of Notes for the first
single-level downgrade in the Company's credit rating by S&P. The Company would
incur a total of approximately $19.5 million of additional annual interest
expense for every 0.25-percentage-point increase in the interest rate. If
Moody's or S&P subsequently were to increase the Company's credit rating, the
interest rate payable on each series of Notes would be subject to a
0.25-percentage-point decrease for each level of credit rating increase. The
interest rate payable for these Notes cannot be reduced below the original
coupon rate of the Notes, and the interest rate in effect on March 15, 2006 for
these Notes will, thereafter, become the effective interest rate until maturity.
The Company has a common stock repurchase program under which the Company
is authorized, at December 31, 2003, to repurchase 4,492,460 additional shares
in the future. Depending upon market conditions, among other things, the Company
may make limited repurchases of its common stock to offset stock issuances in
connection with exercises of stock options during 2004.
In light of the circumstances discussed in Note 14 to the consolidated
financial statements, including the unknown number of valid matrix claims and
the unknown number and merits of valid downstream opt outs, it is not possible
to predict the ultimate liability of the Company in connection with its diet
drug legal proceedings. It is therefore not possible to predict whether, and if
so when, such proceedings will have a material adverse effect on the Company's
financial condition, results of operations and/or cash flows and whether cash
flows from operating activities and existing and prospective financing resources
will be adequate to fund the Company's operations, pay all liabilities related
to the diet drug litigation, pay dividends, maintain the ongoing programs of
capital expenditures, and repay both the principal and interest on its
outstanding obligations without the disposition of significant strategic core
assets and/or reductions in certain cash outflows.
The following chart discloses contractual obligations at December 31, 2003:
Payments Due by Period
(In millions) 2005 2007
Contractual Obligations Total 2004 and 2006 and 2008 Thereafter
- ----------------------- ----- ---- -------- -------- ----------
Total debt obligations $ 9,589.3 $ 1,512.9 $ 341.6 $ 313.0 $ 7,421.8
Purchase obligations(1) 1,359.4 791.6 390.2 157.5 20.1
Retirement-related obligations(2) 1,217.6 274.2 457.0 430.1 56.3
Capital commitments 1,108.7 736.5 372.2 -- --
Operating lease obligations 350.2 69.8 120.6 91.8 68.0
---------- --------- --------- --------- ----------
Total $ 13,625.2 $ 3,385.0 $ 1,681.6 $ 992.4 $ 7,566.2
========== ========= ========= ========= ==========
(1) Purchase obligations consist of agreements to purchase goods or services
that are enforceable and legally binding on the Company and that specify
all significant terms, including: fixed or minimum quantities to be
purchased; fixed, minimum or variable price provisions; and the approximate
timing of the transaction. These include obligations for minimum inventory
purchase contracts, clinical data management, research and development,
co-development and media/market research contracts.
(2) This category includes pension and postretirement benefit payments through
2008. The Company believes that external factors, including, but not
limited to, investment performance of pension plan assets, interest rates,
increases in medical care costs and Medicare subsidies preclude reasonable
estimates beyond 2008.
It also includes deferred compensation principal payments for retirees and
certain active employees who have elected payment before retirement as of
December 31, 2003 and guaranteed interest to be paid to those individuals
through December 2004. All other active employees as of December 31, 2003
are excluded for years subsequent to 2004 since the Company does not
believe it can predict factors such as employee retirement date and elected
payout period.
Wyeth 69
Quantitative and Qualitative Disclosures about Market Risk
The Company is exposed to market risk from changes in foreign currency exchange
rates and interest rates that could impact its financial position, results of
operations and cash flows. The Company manages its exposure to these market
risks through its regular operating and financing activities and, when deemed
appropriate, through the use of derivative financial instruments. The Company
uses derivative financial instruments as risk management tools and not for
trading purposes. In addition, derivative financial instruments are entered into
with a diversified group of major financial institutions in order to manage the
Company's exposure to non-performance on such instruments.
Foreign Currency Risk Management: The Company generates a portion of Net
revenue from sales to customers located outside the United States, principally
in Europe. International sales are generated mostly from international
subsidiaries in the local countries with the sales typically denominated in the
local currency of the respective country. These subsidiaries also incur most of
their expenses in the local currency. Accordingly, most international
subsidiaries use the local currency as their functional currency. International
business, by its nature, is subject to risks, including, but not limited to:
differing economic conditions, changes in political climate, differing tax
structures, other regulations and restrictions, and foreign exchange rate
volatility. Accordingly, future results could be adversely impacted by changes
in these or other factors.
The Company has established programs to protect against adverse changes in
exchange rates due to foreign currency volatility. The Company believes that the
foreign currency risks to which it is exposed are not reasonably likely to have
a material adverse effect on the Company's financial position, results of
operations or cash flows due to the high concentration of sales in the United
States. The Company currently operates in 11 of the member countries of the
European Union, which have adopted the Euro as their local currency.
Collectively, these countries accounted for 14% of 2003 and 11% of both 2002 and
2001 worldwide net revenue. Additionally, the British pound sterling accounted
for 5% of each 2003, 2002 and 2001 worldwide net revenue.
Interest Rate Risk Management: The fair value of the Company's fixed-rate
long-term debt is sensitive to changes in interest rates. Interest rate changes
result in gains/losses in the market value of this debt due to differences
between the market interest rates and rates at the inception of the debt
obligation. The Company manages a portion of this exposure to interest rate
changes primarily through the use of fair value interest rate swaps.
At December 31, 2003, the notional/contract amounts, carrying values and
fair values of the Company's financial instruments were as follows:
Carrying
Notional/ Value Fair Value
(In millions) Contract ---------------------------
Description Amount Assets (Liabilities)
----------- ------ ---------------------------
Forward contracts(1) $ 1,547.7 $ (6.1) $ (6.1)
Option contracts(1) 1,704.3 (44.8) (44.8)
Interest rate swaps 5,300.0 106.3 106.3
Outstanding debt(2) 10,182.0 (9,589.3) (10,084.8)
(1) If the value of the U.S. dollar were to strengthen or weaken by 10%, in
relation to all hedged foreign currencies, the net payable on the forward
and option contracts would decrease or increase by approximately $190.6.
(2) If the interest rates were to increase or decrease by one percentage point,
the fair value of the outstanding debt would decrease or increase by
approximately $597.0.
The estimated fair values approximate amounts at which these financial
instruments could be exchanged in a current transaction between willing parties.
Therefore, fair values are based on estimates using present value and other
valuation techniques that are significantly affected by the assumptions used
concerning the amount and timing of estimated future cash flows and discount
rates that reflect varying degrees of risk. Specifically, the fair value of
forward contracts and interest rate swaps reflects the present value of the
future potential gain or loss if settlement were to take place on December 31,
2003; the fair value of option contracts reflects the present value of future
cash flows if the contracts were settled on December 31, 2003; and the fair
value of outstanding debt instruments reflects a current yield valuation based
on observed market prices as of December 31, 2003.
Certain Factors That May Affect Future Results
Prempro/Premarin-HT Studies
In July 2002, the HT subset of the WHI study, involving women who received a
combination of conjugated estrogens and medroxyprogesterone acetate (Prempro),
was stopped early (after the patients were followed in the study for an average
of 5.2 years) because, according to the predefined stopping rule, certain
increased risks exceeded the specified long-term benefits. Additional analyses
of data from the HT subset of the WHI study have been released during 2003, and
further analyses of WHI data are expected to be released in the future.
In early March 2004, the National Institutes of Health (NIH) announced
preliminary findings from the estrogen-only arm of the WHI study and that it had
decided to stop the study. NIH concluded that estrogen alone does not appear to
affect (either increase or decrease) coronary heart disease and did not increase
the risk of breast cancer. In addition, NIH found an association with a decrease
in the risk of hip fracture and an increased risk of stroke similar to the
increase seen in the HT subset of the WHI study. NIH also stated that analysis
of preliminary data from the separate Women's Health Initiative Memory Study
(WHIMS) showed a trend toward increased risk of probable dementia and/or mild
cognitive impairment in women age 65 and older. The Company has not had the
opportunity to review final study data in order to analyze these preliminary
findings.
Sales of Prempro and other Premarin family products have been and will
continue to be adversely affected by the WHI results. Based on the most recent
available market data, average
70 Wyeth
weekly prescriptions written for Prempro and Premarin decreased approximately
76% and 47%, respectively, compared with the average weekly prescriptions
written during the eight-week period preceding the 2002 termination of the study
subset.
Set forth below are individual product operating results for
Prempro/Premphase and Premarin for the years ended December 31, 2003 and 2002:
Prempro/Premphase Premarin
----------------- --------
(In millions) 2003 2002 2003 2002
- ------------- ------ ------ ------ ------
Net revenue $ 291.6 $ 636.7 $ 983.7 $ 1,243.2
Gross profit* 203.2 546.3 850.8 1,132.1
* The Company recorded a $60.0 reserve in the 2003 second quarter for
anticipated returns in connection with a projected shift in prescriptions
toward the approved lower dosage forms of Prempro. This $60.0 reserve was
calculated by reviewing wholesalers' inventory levels as of June 30, 2003,
after deducting projected Prempro sales by wholesalers using the first-in,
first-out (FIFO) method and excluding "out of date" inventory (it is the
Company's policy to accept returns of product with expiration dates of six
months or less). The Company fully reserved for the value of this remaining
inventory, which approximated $60.0.
Competition
The Company operates in the highly competitive pharmaceutical and consumer
health care industries. Premarin, the Company's principal conjugated estrogens
product manufactured from pregnant mare's urine, and related products Prempro
and Premphase (which are single tablet combinations of the conjugated estrogens
in Premarin and the progestin medroxyprogesterone acetate) are the leaders in
their categories and contribute significantly to the Company's net revenue and
results of operations. Premarin's natural composition is not subject to patent
protection (although Prempro has patent protection). Premarin, Prempro and
Premphase are indicated for the treatment of certain menopausal symptoms. They
also are approved for the prevention of osteoporosis, a condition involving a
loss of bone mass in postmenopausal women. Their use for that purpose in women
without symptoms should be limited to cases where non-hormonal treatments have
been seriously considered and rejected. Estrogen-containing products
manufactured by other companies have been marketed for many years for the
treatment of menopausal symptoms. During the past several years, other
manufacturers have introduced products for the treatment and/or prevention of
osteoporosis. New products containing different estrogens and/or different
progestins than those found in Prempro and Premphase, utilizing various forms of
delivery and having one or more of the same indications, also have been
introduced. Some companies have attempted to obtain approval for generic
versions of Premarin. These products, if approved, would be routinely
substitutable for Premarin and related products under many state laws and
third-party insurance payer plans. In May 1997, the FDA announced that it would
not approve certain synthetic estrogen products as generic equivalents of
Premarin given known compositional differences between the active ingredient of
these products and Premarin. Although the FDA has not approved any generic
equivalent to Premarin to date, Premarin will continue to be subject to
competition from existing and new competing estrogen and other products for its
approved indications and may be subject to generic competition from either
synthetic or natural conjugated estrogens products in the future. One other
company has announced that it has applied for FDA approval of a generic version
of Premarin derived from the same natural source. Following a bench trial in
November 2002, a federal court found, in an order issued on October 2, 2003,
that the company which had developed the estrogens to be used in this product,
Natural Biologics, Inc., had misappropriated certain of the Company's trade
secrets relating to the manufacture of Premarin. The court has entered a
permanent injunction that, inter alia, bars Natural Biologics, Inc. from using
the misappropriated trade secrets and from engaging in the research,
development, production or manufacture of estrogens from urine. Wyeth v. Natural
Biologics, Inc., et al., No. 98-2469 (JNE/JGL), U.S.D.C., D. Minn. Natural
Biologics, Inc. has filed an appeal from the court's injunction. The Company
cannot predict the timing or outcome of the appeal or of any other effort by any
other company along these lines.
Product Supply
Prevnar Supply
Worldwide demand for Prevnar continues to grow. The manufacturing-related
constraints that led to backorders throughout 2002 were resolved early in 2003.
By April 2003, demand in the United States and other markets where Prevnar was
available was met, and this continued through October 2003. More than 20 million
doses of Prevnar were produced in 2003. However, a late 2003 shutdown of the
filling lines at the Pearl River, New York facility was extended by six weeks
beyond the original plan. As a result of this shutdown and other manufacturing
issues, delays in product availability are anticipated throughout the first half
of 2004 in all markets. As a result of delays in product availability, the
Centers for Disease Control and Prevention and the European Agency for the
Evaluation of Medicinal Products have issued interim dosing recommendations to
reduce usage during the supply-constrained period. Capacity should be enhanced
throughout 2004 due to internal improvements and third-party capacity. Although
production issues are not yet fully resolved, we believe 2004 production will
exceed the 2003 level.
Enbrel Supply
Market demand for Enbrel is strong; however, the sales growth had been
constrained by limits on the existing source of supply. In December 2002, the
retrofitted Rhode Island facility owned by Amgen was completed, and
manufacturing production was approved by the FDA. Consequently, manufacturing
capacity for Enbrel significantly increased in 2003. Market demand has continued
to grow, and additional manufacturing supply is projected to be required. In
April 2002, Immunex (prior to being acquired by Amgen) announced it entered into
a manufacturing agreement with Genentech, Inc. to produce Enbrel beginning in
2004, subject to FDA approval. The current plan for the longer term includes an
additional manufacturing facility, which is being constructed by the Company in
Ireland, and expansion of the Rhode Island facility, both of which are expected
to be completed during 2005.
Supply Chain
Management continually reviews the Company's supply chain structure with respect
to utilization of production capacities as well as manufacturing efficiencies.
Changes in product demand periodically create capacity imbalances within the
manufacturing network. When such imbalances result in overcapacity, which
Wyeth 71
management considers to be other than temporary, the network is restructured to
gain optimal efficiency and to reduce production costs. As a result, additional
restructuring charges may occur in future periods.
Litigation and Contingent Liabilities
The Company is involved in various legal proceedings, including product
liability and environmental matters that arise from time to time in the ordinary
course of business, the most significant of which are described in the Company's
Annual Report on Form 10-K for the year ended December 31, 2002, Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2003, June 30, 2003 and
September 30, 2003, as well as in the 2003 Annual Report on Form 10-K, which
will be filed by March 15, 2004. These include allegations of injuries caused by
drugs, vaccines and over-the-counter products, including Pondimin (which in
combination with phentermine, a product that was not manufactured, distributed
or sold by the Company, was commonly referred to as "fen-phen"), Redux,
Dimetapp, Robitussin, Prempro and Premarin, among others. In addition, the
Company has responsibility for environmental, safety and cleanup obligations
under various local, state and federal laws, including the Comprehensive
Environmental Response, Compensation and Liability Act, commonly known as
Superfund.
The estimated costs that the Company expects to pay in these cases
(excluding costs associated with the Redux and Pondimin diet drug litigation,
see Note 14 to the consolidated financial statements) are accrued when the
liability is considered probable and the amount can be reasonably estimated. In
many cases, future environmental-related expenditures cannot be quantified with
a reasonable degree of accuracy. As investigations and cleanups proceed,
environmental-related liabilities are reviewed and adjusted as additional
information becomes available. Prior to November 2003, the Company was
self-insured for product liability risks with excess coverage on a claims-made
basis from various insurance carriers in excess of the self-insured amounts and
subject to certain policy limits. Effective November 2003, the Company became
completely self-insured for product liability risks. It is not possible to
predict whether any potential liability that might exceed amounts already
accrued will have a material adverse effect on the Company's financial
condition, results of operations and/or cash flows. This is discussed in greater
detail in Note 14 to the consolidated financial statements.
Cautionary Statements Regarding
Forward-Looking Information
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor"
for forward-looking statements. This Annual Report, including management's
discussion and analysis set forth herein, as well as our quarterly, current and
special reports, proxy statements and other information filed with the
Securities and Exchange Commission and other written or oral statements made by
us or on our behalf may include forward-looking statements reflecting our
current views at the time these statements were made with respect to future
events and financial performance. These forward-looking statements can be
identified by their use of words such as "anticipates," "expects," "is
confident," "plans," "could," "will," "believes," "estimates," "forecasts,"
"projects" and other words of similar meaning. These forward-looking statements
address various matters, including:
- our anticipated results of operations, liquidity position, financial
condition and capital resources;
- the benefits that we expect will result from our business activities and
certain transactions we announced or completed, such as increased
revenues, decreased expenses, and avoided expenses and expenditures;
- statements of our expectations, beliefs, future plans and strategies,
anticipated developments and other matters that are not historical
facts;
- the accuracy of our estimates and assumptions utilized in our critical
accounting policies;
- the timing and successfulness of research and development activities;
- trade buying patterns;
- the impact of competitive or generic products;
- economic conditions, including interest rate and foreign currency
exchange rate fluctuation;
- changes in generally accepted accounting principles;
- any changes in political or economic conditions due to the threat of
terrorist activity worldwide and related U.S. military action
internationally;
- costs related to product liability, patent protection, government
investigations and other legal proceedings;
- our ability to protect our intellectual property, including patents;
- the impact of legislation or regulation affecting pricing, reimbursement
or access, both in the United States and internationally;
- impact of managed care or health care cost-containment;
- governmental laws and regulations affecting our U.S. and international
businesses, including tax obligations;
- environmental liabilities;
- the future impact of presently known trends, including those with
respect to product performance and competition;
- changes in product mix;
- anticipated amounts of future contractual obligations;
- anticipated developments related to sales of Prempro/ Premarin family
products and Enbrel and Prevnar product supply; and
- expectations regarding the impact of potential litigation relating to
Prempro, Premarin, Robitussin and Dimetapp; the nationwide class action
settlement relating to Redux and Pondimin; and additional litigation
charges related to Redux and Pondimin, including those for opt outs from
the national settlement.
All forward-looking statements address matters involving numerous
assumptions, risks and uncertainties, which may cause actual results to differ
materially from those expressed or implied by us in those statements.
Accordingly, we caution you not to place undue reliance on these forward-looking
statements, which speak only as of the date on which they were made. From time
to time, we also may provide oral or written forward-looking statements in other
materials we release to the public. Additionally, we undertake no obligation to
publicly update or revise any forward-looking statements, whether as a result of
new information, future developments or otherwise.
72 Wyeth
Directors and Officers
Board of Directors
Robert Essner 1
Chairman, President and
Chief Executive Officer
Clifford L.
Alexander, Jr. 2,4
President, Alexander & Associates, Inc.
Frank A.
Bennack, Jr. 1,3,5
Vice Chairman
The Hearst Corporation
Richard L. Carrion 2,3
Chairman, President and
Chief Executive Officer,
Popular, Inc. and
Banco Popular de Puerto Rico
John D. Feerick 2,4,5
Professor of Law,
Fordham University
School of Law
Robert Langer, Sc.D.
Kenneth J. Germeshausen
Professor of Chemical and
Biomedical Engineering,
Massachusetts Institute of Technology
John P. Mascotte 2,3,5,11
Retired President and
Chief Executive Officer,
Blue Cross and Blue Shield
of Kansas City, Inc.
Mary Lake Polan, M.D., Ph.D., M.P.H. 4,5
Professor and Chairman
Department of Obstetrics and Gynecology,
Stanford University School of Medicine
Ivan G. Seidenberg 1,3,4
Chairman and Chief Executive Officer,
Verizon Communications Inc.
Walter V. Shipley 2,3
Retired Chairman of the Board,
The Chase Manhattan Corporation
John R. Torell III 4,5
Partner
Core Capital Group
Director Emeritus
John W. Culligan
Retired - Former Chairman of the Board
Principal Corporate Officers
Robert Essner 6,7,8,9,10
Chairman, President and
Chief Executive Officer
Kenneth J. Martin 6,7,8,9,10
Executive Vice President and Chief Financial Officer
Bernard J. Poussot 6,7,8,9
Executive Vice President
Joseph M. Mahady 6,8
Senior Vice President
Robert R.
Ruffolo, Jr., Ph.D. 6,7,8,9
Senior Vice President
Lawrence V. Stein 6,7,8,9,10
Senior Vice President and General Counsel
Douglas A. Dworkin 7
Vice President and
Deputy General Counsel
Bruce Fadem
Vice President -
Corporate Information Services
and Chief Information Officer
Leo C. Jardot
Vice President -
Government Relations
Paul J. Jones 7,8
Vice President
and Controller
John C. Kelly
Vice President -
Finance Operations
Eileen M. Lach 7
Vice President,
Corporate Secretary and
Associate General Counsel
Rene R. Lewin 6,7,8,9,10
Vice President -
Human Resources
David A. Manspeizer 7
Vice President -
Intellectual Property and
Associate General Counsel
Jack M. O'Connor 9,10
Vice President
and Treasurer
Marily H. Rhudy 6,8
Vice President -
Public Affairs
Steven A. Tasher 7
Vice President -
Environmental Affairs and
Facilities Operations and
Associate General Counsel
Justin R. Victoria
Vice President -
Investor Relations
Mary Katherine Wold 9,10
Vice President - Taxes
Principal Division and Subsidiary Officers
Fort Dodge Animal Health Division
E. Thomas Corcoran 6,8,9
President
Wyeth Consumer Healthcare
Ulf Wiinberg 6,7,8,9
President
Wyeth Consumer Healthcare U.S.
Douglas A. Rogers 8
President
Wyeth Pharmaceuticals
Bernard J. Poussot 6,7,8,9
President
Wyeth
Pharmaceuticals -
Europe/Middle East/Africa
Mark M. Larsen 8
President
Wyeth
Pharmaceuticals -
International
Robert N. Power 6,8
President
Wyeth
Pharmaceuticals -
North America and Global Businesses
Joseph M. Mahady 6,8
President
Wyeth Research
Robert R. Ruffolo, Jr.,
Ph.D. 6,7,8,9
President
1 Executive Committee
2 Audit Committee
3 Compensation and Benefits Committee
4 Corporate Issues Committee
5 Nominating and Governance Committee
6 Management Committee
7 Law/Regulatory Review Committee
8 Operations Committee
9 Human Resources and Benefits Committee
10 Retirement Committee
11 Designated to be a "Financial Expert" as defined in applicable SEC rules
Wyeth 73
Corporate Data
Executive Offices
Wyeth
Five Giralda Farms
Madison, NJ 07940
(973) 660-5000
Stock Trading Information
Wyeth stock is listed on the
New York Stock Exchange (ticker symbol: WYE).
Independent Auditors
PricewaterhouseCoopers LLP
400 Campus Drive
Florham Park, NJ 07932
Annual Meeting
The Annual Meeting of Stockholders will be held on Thursday, April 22, 2004
at the Headquarters Plaza Hotel in Morristown, New Jersey.
Stockholder Account Information
The Bank of New York is the transfer agent, registrar, dividend disbursing
agent and dividend reinvestment agent for the Company. Stockholders of record
with questions about lost certificates, lost or missing dividend checks, or
notification of change of address should contact:
The Bank of New York
P.O. Box 11002
Church Street Station
New York, NY 10286
(800) 565-2067 (Inside the United States and Canada)
(610) 312-5238 (Outside the United States and Canada)
For the hearing impaired: (888) 269-5221 (TDD)
Via e-mail: shareowners@bankofny.com
Internet address: www.stockbny.com
BuyDIRECT Stock Purchase and Sale Plan
The BuyDIRECT plan provides stockholders of record and new investors with a
convenient way to make cash purchases of the Company's common stock and to
automatically reinvest dividends. Inquiries should be directed to The Bank of
New York.
Reports Available
A copy of the Company's Annual Report on Form 10-K may be obtained by any
stockholder without charge through The Bank of New York. Additionally, a copy
of this Annual Report and all Company filings with the Securities and
Exchange Commission can be accessed on our website at www.wyeth.com.
Equal Employment Opportunity
Our established affirmative action and equal employment programs demonstrate
our long-standing commitment to provide job and promotional opportunities for
all qualified persons regardless of age, color, disability, national origin,
race, religion, sex, sexual orientation, status as a Vietnam-era veteran or a
special disabled veteran, or any military uniformed services obligation.
Environmental Health and Safety Policy
Copies of the Company's "Environmental Health and Safety Policy" and "2002
Environmental and Safety Report" may be obtained upon written request to:
Wyeth
Department of Environment and Safety
Five Giralda Farms
Madison, NJ 07940
Wyeth on the Internet
Wyeth's Internet address is:
www.wyeth.com
Trademarks
Product designations appearing in differentiated type are trademarks.
Design: Arnold Saks Associates
Major Photography: Mark Tuschman
Text: Fulton Communications
74 Wyeth